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Preface  
 
Much has been learnt about transglutaminases and their involvement in 
physiological and more often pathological processes since they were first identified by 
Heinrich Waelsch almost half a century ago. Despite the long time there is still a long 
way to go; transglutaminases are everywhere and involved in many processes, from 
blood clotting to metastasizing, and including neurological and autoimmune diseases. 
The small heat shock proteins (sHsps) have a little shorter historical background; as a 
matter of fact our lab was one of the laboratories where their stories all began some 30 
years ago. In the three decades of small heat shock protein research, just in human, 
ten small chaperones have been identified and if transglutaminases are everywhere 
this holds even more for the small heat shock proteins, as they play a role in an 
astonishing array of biological activities from regulating muscle tonicity and contractility 
to contributing to cell division. Since 1992, when our lab and an American research 
group have independently described the enzyme-substrate relationship between 
transglutaminase and the small heat shock protein αB-crystallin for the first time, their 
story still continues as the question whether this interaction is relevant in physiological 
or even in pathological processes has not yet been answered with certainty. The 
experiments described in this thesis were mostly designed to find supporting clues and 
evidences that may help answering the question.  
 
The author 
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General Introduction 
IN MEDIAS RES : 
INTRODUCING TISSUE TRANSGLUTAMINASE AND THE SMALL HEAT SHOCK PROTEINS 
In medias res is Latin for "into the middle of things." It describes a narrative that begins, 
not at the beginning of a story, but somewhere in the middle — usually at some crucial 
point in the action. The term comes from the ancient Roman poet Horace, who advised 
the aspiring epic poet to go straight to the heart of the story instead of beginning at the 
beginning. 
 
 
Alzheimer’s disease, sporadic inclusion body myositis and cortical cataract 
formation – The most common Inclusion body diseases 
Alzheimer’s disease (AD), sporadic 
inclusion body myositis (sIBM) and cortical 
cataract formation (CCF) are the most 
common progressive degenerative 
disorders that affect the brain tissues, the 
skeletal musculature and eye lens of the 
elderly generations, respectively.  
Alzheimer’s disease is associated 
with specific lesions of brain regions and 
neural circuits. The tissue damage 
frequently occurs in brain regions such as 
the neocortex, the hippocampus or the 
nucleus amygdala, and the significant 
Diseases characterized by abnormal accumulation of misfolded and 
aggregated proteins in the form of inclusions and amyloid-like deposits are 
called inclusion body diseases. These diseases generally affect different 
types of muscles and parts of the neuro-sensory system, such as the brain 
or the eye. In many cases, such as Huntington’s disease and cerebellar 
ataxias, the damaged tissues often display elevated tissue 
transglutaminase activity, while in others like Alexander’s disease or most 
myopathies the function of small heat shock proteins is frequently 
impaired. A special group of inclusion body diseases, including the brain-
involving Alzheimer’s disease, the muscle-related sporadic inclusion body 
myositis and cortical cataract of the eye lens show an interesting 
pathological overlap as small heat shock proteins and transglutaminase are 
both believed to contribute to the onset of these diseases. However, the 
connection between these proteins is not yet understood, and therefore is 
the subject of this thesis. 
Figure 1. Macroscopic comparison of 
transversal cross sections of healthy 
(normal) and Alzheimer’s diseased brain. 
The obvious shrinkage in size is due to major 
neuronal loss in case of the diseased brain. The 
boxed areas indicate the impaired memory and 
language centers (picture taken from the 
Collection of the Department of Pathology, 
University of Debrecen. 
Chapter 1 
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neuronal loss results in dysfunctional 
neuronal circuits, and in turn, impaired 
cognitive ability, memory, thinking and 
behavior [1;2] (Figure 1).  
Sporadic inclusion body myositis 
describes patients with a chronic muscle 
inflammation, and progressively worsening 
weakness in the proximal and distal limbs 
gradually leading to severe disability [3;4]. 
Biopsy specimens show, in addition to the 
extensive lymphocyte infiltration [5], that the 
affected muscles contain abnormal muscle 
fibers and the tissues eventually become 
atrophic [3;4] (Figure 2). Patients are 
generally irresponsive to steroid therapy. In 
fact, there is no remarkably successful 
treatment available [4-6].  
Cortical cataract is a pathologic 
opacity of the eye lens interfering with its 
transparency (Figure 3). Incidence studies 
show that cortical cataract accounts for about 
30% of all cataracts [7]. With an aging 
European population this progressive age-
dependent disease is the leading cause of 
blindness [8]. The total incidence of age-
related cataract is about 45% for people 
between the age of 55 and 64, about 75% for 
people between age 65 and 74, and about 
88% for people older than 75. Generally, 
surgery is a good solution for cataract. The 
new implant technology promises to improve 
the image quality, and 85-90% of patients 
obtain vision sufficient to meet the 
requirements for driving. However, posterior 
capsule opacification 2-5 years after surgery is 
still a problem in many cases. 
 
Figure 2. Quadriceps atrophy in sporadic 
inclusion body myositis. sIBM is a 
progressive muscular disorder with a worsening 
muscle weakness in the extremities. In an 
advanced stage both thigh muscles and the left 
calf show an extensive loss of muscle mass 
that is characteristic for sIBM (Picture from 
personal collection). 
Figure 3. Cortical cataract of the eye lens. In 
this advanced state of cataract formation, due 
to the progressive nature of the disease, the 
lens becomes turbid and opaque because of 
the aggregation of the initially water-soluble 
proteins that provide the original lucidity of the 
lens (Figure taken from the Columbia 
University’s Collection). 
General Introduction 
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Other neurodegenerative disorders (Alexander’s disease, Parkinson’s disease, 
Huntington’s disease and other polyglutamine disorders) and the above mentioned 
three diseases are all described as folding diseases as they share the same 
histological feature, the abnormal, insoluble, aggregated accumulations of normal 
cellular proteins, in the form of either amyloid deposits or intracellular inclusion bodies 
[9-14]. In the damaged AD brain tissues, the precipitating extremely insoluble protein 
polymers form two types of aggregates, the extracellular amyloid-β containing senile 
plaques [11], and the intraneuronal neurofibrillary tangles, mainly composed of the 
hyper-phosphorylated tau protein [15;16]. Biopsy specimens from sIBM muscle fibers 
show that the abnormal muscle fibers also accumulate amyloid in the form of distinctive 
intracellular inclusions, so-called rimmed vacuoles, and cytoskeletal proteins in 
filamentous inclusions [17-19]. In the lens, aggregation and subsequent cataract 
formation is the result of the absence of protein turnover combined with the continuous 
posttranslational modifications such as oxidation, deamidation, or cleavage of the 
lenticular proteins such as abundant and water-soluble crystallins, resulting in 
undesirable and harmful protein–protein interactions and aggregation [20-22]. 
To what degree these various accumulations are the cause or a consequence 
of cellular dysfunction is still elusive. The similarities nevertheless point towards 
common mechanisms operating in the pathophysiology of diseases as diverse as AD, 
Parkinson's disease, Huntington’s disease, Creutzfeld-Jacob’s disease as well as sIBM 
or CCF, namely that the pathognomony of each disorder might be a consequence of 
abnormalities in protein conformation and consequent inappropriate protein-protein 
interactions and irreversible posttranslational modifications [23;24]. One of the possible 
underlying mechanisms was suggested to be the irreversible crosslinking of the 
damaged proteins by transglutaminases. However, malfunctioning of the chaperone 
machinery or disfunctioning of protein degradation and elimination are also considered 
to play a role in the pathobiology of the inclusion body diseases. 
 
 
TISSUE TRANSGLUTAMINASE 
 
Biochemical insight in transglutaminase  
Transglutaminases are a family of enzymes that catalyze the formation of a 
covalent isodipeptide linkage called crosslink between the γ-carboxamide group of 
protein-bound glutamine and the ε-amino group of protein-bound lysine residues [25-
27]. Eight genes encoding transglutaminases have been identified [28], namely TGase-
Chapter 1 
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1, TGase-3 and TGase-5, which are found mostly in epithelial cells, the prostate-
specific TGase-4, Factor-XIII-A that is responsible for blood clotting, TGase-5 and 
TGase-6 with unknown tissue distribution and function, Band-4.2, which is a 
component of the erythrocyte membrane and lost its enzyme activity, and finally the 
ubiquitously expressed tissue transglutaminase (tTG, also known as TGase2) 
[27;29], which is the primary interest of this thesis.  
The human ttg gene is 32.5 kb in 
size, contains 13 exons and 12 introns 
[30;31] and has been localized to 
chromosome 20q12 [32]. The full length 
product of the human ttg gene is 687 
amino acids in length with an 
approximately 77 kDa molecular mass. A 
partial crystal structure of tTG has been 
recently identified [33] and found to be 
similar to Factor-XIII-A, the first member of 
the TG family with known three-
dimensional structure [34]. As shown in 
Figure 4, tTG comprises four distinct 
domains [26]: an N-terminal β-sandwich 
(residues 1-138) carrying a fibronectin and 
integrin-binding site, the α/β-catalytic core 
(residues139-471) that contains the 
catalytic triad and the calcium-binding 
sites for the transglutaminase reaction 
[35], and finally, two β-barrel domains 
(residues 472-584 and residues 585-686) 
of which the second contains a phospholipase C binding sequence motif [36]. 
The enzymatic reaction characteristic for transglutaminases is the intrinsic 
transamidating activity. Therefore, the catalytic core and its special sites will be 
discussed first and the additional motifs and sites such as the integrin-binding site or 
the GTP-binding and hydrolyzing sites will be discussed later in combination with the 
relating cellular functions. 
Complete crystal structures are now available for three tTG related proteins: the 
A subunit of coagulation Factor-XIII [34], the sea bream liver TG [37] and the epidermal 
type transglutaminase (TG3) [38]. The three-dimensional structural analysis of tTG 
revealed a cysteine-proteinase-like active site comprising the catalytic triad of a 
Figure 4. Genomic organization, protein 
domains and tertiary structure of TGases. 
The TG1 and Factor-XIII-A genes comprise 15 
exons and 14 introns, whereas those for tTG, 
TG3-7 and band4.2 consist of 13 exons and 12 
introns. Broken lines indicate the exons 
encoding the four (d1-d4) domains (panel a). 
The partially solved three-dimensional crystal 
structure of tissue type transglutaminase 
(panel b). Figure taken from [27]. 
General Introduction 
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cysteine, a histidine and an aspartic acid at positions 277, 335 and 358, respectively. 
The active site cysteine is essential for the thiolester bond formation with the substrate-
bound glutamine, the aspartic acid is required for transamidation, but the function of the 
histidine is not yet fully understood. A unique tryptophan residue, part of the catalytic 
core but not the catalytic triad, also has been shown to be essential for the 
transamidating activity of tTG [33].  
Of all reactions catalyzed by tTG, protein crosslinking has attracted the 
greatest interest so far. The covalent isodipeptide crosslinks, which are generated in a 
two-step reaction, are highly resistant to proteolysis [39;40] (Figure 5). The first step is 
the rate limiting step that initiates with an acetylation reaction when a thiolester is 
formed between the active site cysteine and the acyl-donor target glutamine (Q-
substrate), and ammonia is released [39]. In the second transamidation step, the acyl 
group is transferred to the acyl acceptor amine (lysine or K-substrate) forming an 
isodipeptide bond (deacylation or crosslinking). Generally these bonds are developed 
between two proteins and thus called intermolecular crosslinks, although in some 
cases a protein can expose both the glutamine and lysine substrates to 
transglutaminase, and may become circularized by the formation of an internal, so 
called intramolecular crosslink. Amines with low molecular mass, especially 
polyamines, can replace the lysine residue in the transglutaminase reaction and result 
in the incorporation of a given amine by the formation of N-mono-(γ-glutamyl)-
polyamine [27;41]. Two proteins containing glutamine acceptor sites can also be 
coupled together by polyamines in the form of an N,N-bis(γ-glutamyl)polyamine bridge 
Figure 5. The transglutaminase reaction. Isodipeptide crosslinks are catalyzed in a two step reaction. 
First a thiolester is formed between the active site cysteine and the Q-substrate (in red) and ammonia is 
released. In the second step, if the K-substrate is present (in orange), the acyl group is transferred to the 
acyl acceptor ε-amino group of a peptide-bound lysine (Upper reaction). When suitable amines are 
absent, the enzyme-bound glutamines will undergo deamidation (Lower reaction).
tTG Ca 2+
(CH )2 2 NH2C
O (CH )2 42HN
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[42;43]. However, suitable amines or their substitutes may be absent, and glutamines 
already engaged by transglutaminase will in that case undergo deamidation [25;44] 
(Figure 5, lower reaction). This process is thought to take place at a much slower rate, 
and generates a glutamate through the loss of the γ-carboxamide group and 
concomitant gain of one negative charge. 
 
Calcium dependency of tTG 
In order to crosslink proteins calcium is required for transglutaminase to adopt 
the catalytically active conformation. Since one of the chapters speculates about a 
tentative activation of tTG by the small heat shock protein Hsp20, understanding the 
Ca2+-requirement of tTG is essential. Generally, residues such as aspartic acid and 
glutamic acid are necessary for calcium-binding [35]. The structure of tTG is still 
partially unsolved, but based on its sequence homology with Factor-XIII-A, these Ca2+-
binding sites were originally postulated between amino acids 427 and 455 [45]. In 
Factor-XIII-A, crystallization studies revealed that A457, D438, E485 and E490 are involved 
in the binding of Ca2+, and although these residues are conserved in other catalytically 
active transglutaminases, site-directed mutagenesis of these putative binding sites in 
tTG resulted in only decreased sensitivity to activation by calcium compared with wild 
type tTG [46]. In the epidermal type transglutaminase (TGase3), similar residues A393, 
E443 and E448 have been identified as calcium-binding sites [38], and the resolved three-
dimensional crystal structure has revealed that after binding calcium a channel opens 
to expose two critical tryptophan residues that control access of substrates to the active 
site [38]. As the domain structures of tTG and TGase3 are the same, similar 
conformational changes might be expected to trigger the activation of tTG. Divalent 
cations such as zinc are known to interfere with calcium-binding and in turn inhibit the 
activation of tTG [47].  
The calcium requirement for tTG activity in vitro and in vivo shows marked 
differences, as supraphysiologic free Ca2+-concentrations (thus, in the mM range) are 
required to activate tTG in vitro [47-49]. The Km for the activation of purified tTG by 
calcium has been earlier found to be approximately 3-4 µM but surprisingly, almost no 
activity could be detected for recombinant tTG, even at 100 µM calcium [49]. In 
permeabilized cells, generally 10-100 µM free calcium ion concentration is required for 
measurable transglutaminase activity [48]. As part of the cellular homeostasis, cells 
maintain a large free Ca2+ concentration gradient across the plasma membrane, 
approximately 2 mM outside the cell and approximately 80-100 nM inside the cell. This 
together with other findings have led to the central dogma of transglutaminase 
General Introduction 
 17
research, suggesting that transglutaminase in the normal cellular environment is a 
latent enzyme, its activation mainly occurring during extreme or terminal situations, 
such as apoptosis or necrosis [48]. In such cases, the internal Ca2+-storage capacity of 
the cell is exceeded or the outward-directed calcium pumps fail to keep up with the 
Ca2+ influx. 
In contrast to these earlier findings, later studies have convincingly 
demonstrated that activation of tTG can also take place at physiological increases in 
calcium concentration. Even though the normal physiological concentration of free Ca2+ 
in the cytoplasm is approximately 80-100 nM, neuroblastoma cells (SH-SY5Y) stably 
overexpressing tTG show a significant increase in the basal transglutaminase activity 
[50]. In cultured cells, the muscarinic receptor agonist carbachol transiently increases 
the intracellular Ca2+ concentration from approximately 100 nM to 450 nM, which in turn 
results in significant tTG activation [51]. Additionally, the egg envelope formation in the 
sea urchin requires a rapid activation of transglutaminase, which takes place within 
minutes following fertilization [52;53]. It is thus clear that transglutaminase can be 
activated by a variety of physiological conditions.  
 
Substrate requirements for transglutaminase – tTG is a fastidious enzyme 
Some chapters in this thesis (Chapters 2 and 4) deal with the substrate site 
requirements for tTG in small heat shock proteins, and therefore it is important to have 
a better insight the enzyme-substrate interaction of transglutaminase, as well as in its 
target sites and target proteins. Although it is clear that transglutaminase can deliver 
modifications only to lysine and glutamine residues, the exact mechanism governing 
the recognition of the target amino acids within the substrate proteins is still not entirely 
known. A generally accepted notion is that transglutaminase is highly selective toward 
its substrates, and this selectivity manifests itself at different levels. First of all, tTG is 
more selective toward glutamine than to lysine residues [27;54]. Concerning 
glutamines, the surrounding residues and the spacing between the target glutamine 
and adjacent side chains both seem to be crucial for target recognition and 
accessibility [55]. In unfolded proteins for instance, positively charged residues flanking 
the glutamine seem to discourage the transglutaminase reaction [54]. However, 
separated by two or four spacer residues, the targeted glutamine is much more 
reactive (i.e. QxxZ+ or QxxxxZ+ promotes the reaction, where Z is the basic residue) 
[54]. Glycines and asparagines in adjacent position may also favor the substrate 
accessibility of the glutamine [56;57]. Recent studies on gliadin peptides have clearly 
demonstrated the importance of proline residues in the substrate recognition of a given 
glutamine residue by tTG [55;58;59]. Depending on the presence of a spacer residue, 
Chapter 1 
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the adjacent proline promotes the reaction when the glutamine is part of a QxP motif, 
where x represents a variable spacer residue between the accessible glutamine and 
the neighboring proline [55]. Additional spacing (QxxP, QxxxP) however seems to 
hamper the transglutaminase reaction [55].  
 
 
Protein substrate Reactive site(s) Associated disease 
Cytoskeletal & cytoskeleton-
associated proteins 
  
Actin 
Spectrin 
Tau 
β-tubulin 
Vimentin 
Myosin 
 
Q41, Q167 
Q 
K163, K174, K180, K190, K225, K234, K240 & Q351, 
Q424 
Q 
K97, K102, K294, K439 & Q453, Q460  
 
 
 
Alzheimer’s disease 
Hormones / neurotransmitters   
VIP 
Glucagon 
β-endorphin 
Insulin α-chain 
Substance P 
 
K21 &Q16 
Q3, Q20 
K29, Q11 
Q5, Q15 
Q5, Q6 
 
Heat shock proteins   
Hsp60 
Hsp70 
Hsp90 
sHsps 
αB-crystallin 
Hsp27 
Hsp20 
HspB8 
HspB2 
cvHsp 
 
K 
K and Q 
K and Q 
 
K175 
K205 & Q31, Q80, Q90 
Q31, Q66, K152 
K/Q 
Q27, Q75 
K and Q 
 
 
 
 
Cataract 
Alzheimer’s disease (AD) 
Enzymes   
Aldolase 
GAPDH 
RhoA 
Rock-2 
PLA2 
 
K 
K191, K248, K251, K256, K257, K260, K268, K331 
Q52, Q63, Q136  
Q 
K10 &Q4 
 
Huntington’s disease 
Crystallins 
βA3-crystallin 
βB1-crystallin 
βB2-crystallin 
βB3-crystallin 
 
 
K17 & Q23 Q24 
Q 
Q9 
Q21 
Cortical cataract 
Others   
Parkin 
Amyloid 
Polyglutamine proteins (huntingtin) 
α-synuclein 
Q K 
Q15 & K16, K18 
 
Q79, K80 
Parkinsons’s disease (PD) 
AD, sporadic inclusion body 
myositis 
Huntington’s disease 
AD, PD 
Fibrinogen 
Collagen 
Nidogen 
Synapsin 
Q366, Q398, Q399, K148, K176, K183, K45 
Q14 ,K? 
Q726 
Q? 
 
 
Cytochrome-c 
F-box proteins 
Q42 
K 
 
Table 1. Tissue transglutaminase substrates in the cell. The substrate proteins and their exposed 
sites for tTG-catalyzed crosslinking have been identified by different methods, including mass 
spectrometry analysis, protein sequencing, mutagenesis and the use of differentially labeled substrate-
probes. Table is adapted from [54].  
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Transglutaminase is much less strict about its lysine substrates. For example, 
in the microtubule-associated tau protein at least 7 of the 64 lysines are available 
substrate residues for transglutaminase [60]. In fibrinogen, 6 out of 43 lysines are 
easily accessible for transglutaminase [61]. Vimentin, another structural element of the 
cytoskeleton, has at least four lysines that can serve as substrates for tTG [62]. Similar 
to the recognition of glutamine residues, the amino acids directly preceding a given 
lysine seem to greatly influence the substrate availability for tTG [63], as uncharged, 
basic and small aliphatic residues enhance, whereas aspartic acid, glycine, proline and 
histidine residues reduce the lysine’s reactivity with tTG [64]. In glyceraldehyde-3-
phosphate dehydrogenase (GAPDH), however, one of the eight lysine substrates is 
preceded by a glycine which adversely affects the crosslinking of this particular lysine 
residue [65;66]. Additionally, lysines located in sequence motifs that should enhance 
their reactivity seem to be masked, and remain hidden for crosslinking [65] 
The substrate property (i.e. the exposure of a potential site) of a protein is of 
course also greatly influenced by its folding, in other words the secondary and tertiary 
structure too can determine which side chains can be reactive. A residue protruding 
from compactly folded domain structures, such as the C-terminal lysine of certain small 
heat shock proteins [67-69], is more likely to become an available substrate than others 
deeply embedded in hidden pockets. However, glutamines in terminal positions (both 
N- and C termini) are not recognized by transglutaminase [70]. Conformational 
changes in the native protein induced by protein-protein interactions may also affect 
the availability of certain lysine residues to serve as tTG substrates. In GAPDH, 
different lysines are engaged when crosslinking takes place with Substance-P or polyQ 
[65;66]. 
Although a good number of proteins, including hormones, extracellular and 
intracellular structural proteins, enzymes or membrane proteins have been identified as 
potential substrates of tTG (Table 1), based on the previous findings one is allowed to 
say that crosslinking of two proteins by transglutaminase depends on multiple factors 
or in other words: TRANSGLUTAMINASE IS A PICKY ENZYME. 
 
Additional activities of tTG 
Nucleotide binding of tTG: In addition to its intrinsic transamidating activity, 
tTG has the exclusive ability in the TG family to bind and hydrolyze nucleotide 
triphosphates such as GTP and ATP [71-73]. A unique guanidine nucleotide-binding 
site, which has not been found in any signal transducing G-protein or other member of 
the transglutaminase family [74], is located in a cleft between the catalytic core and the 
first β-barrel [33]. Some other nucleotide-interacting residues are located in the N-
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terminal region of the catalytic core, together with those essential for GTP-hydrolysis 
[75;76]. But what is the relevance of such GTP-binding and hydrolyzing activity? The 
binding of GTP has multiple consequences for tTG: i) it induces a conformational 
change that results in a potent allosteric inhibition of the calcium-activated tTG activity 
and in decreased calcium-binding [71;73], ii) binding of GTP also protects against both 
tryptic proteolysis and cleavage by calcium-dependent calpain [50;77], iii) the GTP 
binding and hydrolysis enables tTG to also function as a signal transducing G-protein 
[78]. 
The function of tTG as a G-protein is still largely unknown. The role that tTG 
plays in mediating signal transduction is not directly comparable to the classical 
heterotrimeric G-proteins as it does not contain the conventional GTP-binding motif 
found in other G-proteins [74]. As a G-protein (Gαh) tTG has been shown to interact 
with the α1-adrenergic receptors (α1B and α1D) [78-80], and the oxytocin and 
thromboxane A2 receptors [81-83]. However, these receptors are likely to be coupled to 
phospholipase-Cδ1 (PLC-δ1), (and mediating inositol phosphate and diacylglycerol 
production) and not to the classical G-protein regulated PLC-β [80;82;84;85]. In 
addition, the second β-barrel in the N-terminal domain of tTG also contains a binding 
motif for PLC-δ1 [36]. Interestingly, cardiac-specific overexpression of tTG in transgenic 
mice brought no evidence for tTG acting as a signal transducing G-protein. Instead, the 
observed pathophysiologic changes have been shown to be due to the crosslinking 
activity of tTG [86;87]. 
Since the GTP concentration in the cell is higher than the concentration of GTP 
required to inhibit the activity of tTG, the transamidating activity of tTG is likely to be 
low under normal cellular conditions. Depleting the cellular GTP resulted in increased 
tTG activity, and an increase in the intracellular Ca2+-concentrations in combination 
with GTP depletion resulted in an almost additive increase in tTG activity [50]. These 
findings clearly indicate that nucleotides and calcium coordinate the activity of tTG in 
conjunction. Other factors, such as sphingosylphosphocholine, increase the sensitivity 
of tTG to calcium-mediated activation, and also reverse the inhibition of the crosslinking 
activity by GTP [49].  
Protein disulphide isomerase activity: Another novel function has been 
suggested recently for tTG since in vitro it can completely convert the reduced (thus 
denatured) inactive RNase A molecule to a native active enzyme [88]. This protein 
disulphide isomerase (PDI) activity of tTG is thought to be catalyzed by a different 
catalytic domain than the active center, as alkylation of the active site cysteine 
abolished only the transamidating but not the PDI activity of purifed quinea pig liver 
General Introduction 
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tTG. Moreover, the disulphide isomerase activity shows no Ca2+-dependency, nor can it 
be inhibited by GTP [88]. 
 
Expression and the regulation of tTG expression 
The molecular characteristics and the diverse biochemical activities suggest 
multifunctionality for transglutaminase in most tissues at different subcellular locations. 
So, what is the expression pattern of transglutaminase and what factors can regulate 
the activity? 
tTG is ubiquitously expressed throughout the human body [29;89]. It practically 
has been detected in every cell type including epidermal and endothelial cells, different 
cells of the connective tissue such as fibroblasts, osteoblast and chondrocytes, and 
several types of circulating white blood cells [26;27;29;89;90]. tTG has also been found 
in excitatory tissues such as the different types of muscle and neuronal cells, and in 
certain sensory cells [41;91]. Some of these cells constitutively express tTG, like 
smooth and heart muscle or neuronal cells, others like macrophages and lymphocytes 
have inducible tTG expression. Although tTG is generally considered as a cytosolic 
enzyme, localization studies have revealed that tTG can also be found in several other 
subcellular compartments. In 1:1 complex with integrins, tTG is present on the cell 
surface [92;93], but tTG associates as well with the intracellular side of the cell 
membrane, and under certain conditions large amounts of tTG can also translocate to 
the nucleus [94]. 
In various cells, many factors are known to regulate the expression of tTG 
including proinflammatory cytokines (interleukin-1β, interleukin-6, tumor necrosis 
factor-α and transforming growth factor-β1) [95-97], steroids (glucocorticoids) [98], 
cAMP [99] and NFκB [100;101]. However, the most generalized inducers of tTG 
expression are the retinoids [42;102-104]. Treatment of rats with retinoic acid increases 
both the expression and the crosslinking activity of tTG [42;102;103]. Additionally, 
retinoic acid induces tTG expression in numerous different types of cultured cells 
[42;105-107].  
 
The multifunctional tTG  
How do these diverse biochemical activities of tTG relate to cellular functions? 
The in vivo expression pattern, the subcellular locations, and also the identified 
substrates suggest multiple roles to the enzyme. Although tTG was the first 
transglutaminase to be discovered, and has been intensively investigated over half a 
century, the search for a physiological function of tTG is certainly not yet over.  
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Outside the cell, tTG is an important player in the extracellular matrix (ECM) 
biology. Despite the lack of a leader sequence, cells externalize tTG to the extracellular 
space, where independent from the crosslinking role, transglutaminase has a 
potentially important function in the promotion of cellular adhesion and spreading [92]; 
as a (fibronectin)-integrin-binding co-receptor it stabilizes the binding of fibronectin and 
integrin molecules [93]. However, the significance of tTG in the extracellular space 
goes beyond promoting adhesion and cell motility. tTG contributes directly to the 
assembly and remodeling of the ECM at various levels in many tissues by crosslinking 
the heteromeric assemblies of the often tissue-specific ECM protein components 
[25;29;108;109]. tTG also directly participates in wound healing, angiogenesis and the 
regulation and activation of TGF-β, a growth factor which promotes transcriptional 
regulation of ECM genes [110] and of tTG itself [111].  
tTG is also involved in a variety of processes intracellularly. Interestingly, tTG 
has been found to be essential in the receptor-mediated endocytosis of polypeptide 
hormones and α2-macroglobulin in various cellular systems [106]. Located at the cell 
membrane, as a unique non-conventional G-protein, tTG (Ghα) participates in 
transmitting signals from G-protein-coupled receptors to PLC [76] as the binding of 
GTP to tTG suspends the inhibition of PLC-δ1, and activation may take place [112]. 
However, tTG also mediates the activation of maxi-K channels and the inactivation of 
adenyl cyclase [113]. Its crosslinking activity enables tTG to participate in the 
cytoskeleton organization as well. Bound with Ca2+, tTG can interact with and modify 
most of the major components of the cytoskeleton [62;65;114-116]. Additionally, the 
transamidation (crosslinking) of the small G-protein RhoA augments its binding to 
ROCK-2 kinase, and through the autophosphorylation and phosphorylation of ROCK-2 
and vimentin, respectively, tTG promotes the formation of stress fibers [117].  
tTG has been speculated to have a direct role in chromatin modifications and 
gene expression regulation. Its interaction with the nuclear transport protein importin-α3 
allows tTG to translocate to the nucleus [118], where as a G-protein it may be part of 
the nuclear signaling [119] or covalently crosslink nuclear proteins like core histones 
[120;121] or the retinoblastoma proteins [122].  
By incorporating polyamines into acyl-donor substrates, tTG can prevent the 
proteolytic degradation of proteins such as the microtubule-associated protein tau 
[123], or the neurotransmitter substance-P [124].  
tTG also actively partakes in programmed cell death (apoptosis). However, in 
contrast with the early suggestion, namely the promotion of apoptosis, the enzyme 
shows Janus face properties since it not only has the capacity to facilitate but also to 
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prevent apoptosis. In several cell types, including thymocytes, neurons and red blood 
cells, tTG promotes apoptosis, whereas the overexpression of the enzyme primes 
cultured cells such as human U937 promyelocytic or SHS5Y neuroblastoma cells for 
suicide [89;90]. In the late phase of apoptosis, the decreasing cellular GTP 
concentration and the overall elevation of Ca2+ lead to extensive crosslinking in the 
apoptotic bodies [125]. The dying cells are stabilized by tTG prior to their clearance, 
which may prevent the inflammatory response against the leaking cellular components. 
On the contrary, the exogenous expression of tTG protects mouse fibroblasts against 
serum deprivation-mediated apoptosis [126]. 
Finally, it should also be mentioned that tTG can enhance the metastatic 
potential of tumor cells. EGF stimulation protects breast cancer cells from doxorubicin-
induced apoptosis by promoting tTG expression and activity [127]. Inhibition of tTG 
results in a nearly complete loss of EGF-mediated protection from doxorubicin-induced 
apoptosis, whereas ectopic expression of tTG confers resistance from the 
chemotherapeutic agent [127]. These findings suggest that tTG contributes to the 
oncogenic potential of cells by not only promoting cellular spreading and migration 
[92;93], but also by conferring chemoresistance.  
Although the above presented evidences of the cellular processes involving tTG 
or tTG activity are certainly not complete, they nevertheless clearly portray 
TRANSGLUTAMINASE AS A MULTIFUNCTIONAL PROTEIN. 
 
 
THE TRANSGLUTAMINASE-SUBSTRATE LENS β-CRYSTALLINS 
In relation to tTG, β-crystallins are of special interest because at least five of the 
six members of the β-crystallin protein family expose easily accessible lysine and 
glutamine residues for crosslinking [128-131], and therefore the β-crystallins will be 
discussed here in more detail.  
β-crystallins are the major structural proteins of the eye lens. The lens is a 
remarkable tissue with its unusually high protein content and two unique properties: 
transparency and refractivity, both critical to correctly focusing light on the retina. 
Responsible for both properties is the special architecture of lenticular cells and the 
short-range order between the highly concentrated abundant water-soluble crystallins 
contained within the fiber cells. This architecture is formed by the constant elongation 
and differentiation of the anterior epithelial cells into concentric layers of fiber cells, 
much like the layers of an onion. To reach the high degree of transparency and 
reduced light diffraction, the differentiating cells must gradually lose organelles such as 
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nuclei, mitochondria and ribosomes [132]. Lens proteins therefore have no turnover in 
terminally differentiated fiber cells, and thus must last a lifetime. 
In the vertebrate eye lens, the abundant soluble proteins are collectively known 
as crystallins and can be distinguished into two major groups: the ubiquitous crystallins 
with the three classes of α-, β-, and γ-crystallins, and the taxon specific crystallins, that 
are only found in specific groups of species such as the gecko or the platypus [133-
135]. 
 
Structural properties 
In human, seven β-crystallin gene products (of six genes) have been detected: 
the basic βB1-, βB2- and βB3-crystallins having N- and C-terminal sequence extensions, 
and the acidic βA1-, βA2-, βA3- and βA4-crystallins possessing only an N-terminal 
extension [129;136;137]. Encoded by the same gene, βA1-and βA3-crystallins are 
identical, except that the N-terminus of βA3-crystallin is longer. These two proteins are 
the result of a process called leaky ribosomal scanning [138]. β-crystallins share a 
common structure: the two globular domains are formed from two Greek key motif – a 
distinctive β-sheet folding – and connected to the N- and/or C-terminal extensions of 
various lengths [139;140]. These motifs enable crystallin molecules to associate and to 
form highly compact oligomers. 
 
β-crystallin associations  
β-crystallins can be relatively easily separated from α- and γ-crystallins by size 
exclusion chromatography (SEC), because α-crystallins tend to form large 800–1000 
kDa multimers, whereas γ-crystallins are monomers of 20 kDa. Three different 
oligomeric complexes of β-crystallin can be distinguished using gel permeation 
chromatography: the approximately 200 kDa hexamer and/or octamer containing βH-
complex, the intermediary βL1-complex and the dimeric 50 kDa βL2-complex [141-143]. 
However, obtaining detailed information about the exact composure of these 
assemblies has been difficult due to similarities in sequence, molecular mass and 
chromatographic behavior. Additionally, the actual composition of a complex depends 
also on the age of the lens and the various posttranslational modifications of the 
subunits. In newborn lenses, tetramers and oligomers of βB1-crystallin can be 
predominantly found in the βH-complex [144-147]. Both βA3- and βA4-crystallins tend to 
form larger assemblies when associated with βB1-crystallin, whereas in the absence of 
βB1-crystallin, βA3- and βA4-crystallins are the major components of the βL2-complex. 
The weakly expressed βA2-crystallin subunit has also been identified in the βL-complex 
in the human lens [148]. However, during aging βB1 is extensively truncated [144;145] 
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and increasing amounts of truncated βB1 are found in the intermediate βL1-complex and 
the βL2-complex [149]. Being versatile in its interactions with other acidic or basic 
subunits of β-crystallins, dimers and larger aggregates of βB2-crystallin are present 
both in the βL- and the βH-complexes, respectively [149;150]. Actually, the stability and 
solubility of both assemblies seems to depend on the presence of βB2-crystallin, 
because separated from βB2-crystallin, the other β-crystallins tend to precipitate 
[151;152]. 
 
Crosslinking and deamidation of β-crystallins 
Over a long lifetime, crystallins undergo a wide array of covalent, irreversible 
modifications, including deamidation, oxidation and proteolytic cleavage, among others 
[153;154]. When native crystallin structures begin to lose stability and/or solubility upon 
modification, a given modification can be critical for lens transparency, and with time 
may result in the formation of cortical cataract. Deamidation and covalent crosslinking 
are particularly interesting since both can be catalyzed by tTG [25;44]. The tTG-
catalyzed covalent crosslinking of β-crystallins is well established. The basic β-
crystallins βB2- and βB3-crystallin, but not the lysine-donor βB1-crystallin, are the major 
glutamine substrates for the enzyme [129;141;155]. Acidic crystallins, such as and βA4-
crystallin present accessible lysine residues to tTG [129;155;156], although βA3-
crystallin, with two additional glutamine residues available for crosslinking, is a multiple 
substrate for tTG [129]. 
Remarkably, all the reactive sites have been located in the N-terminal 
extensions, which is a crucial structural element in the β-crystallin complex assembly 
[149]. A captivating aspect of the tTG-catalyzed crosslinking of β-crystallins is that 
another posttranslational modification, namely oxidization, enhances the tTG-substrate 
capacity of already existing reactive residues [155]. Crosslinked β-crystallins in the 
form of different homo- and/or heteromers have been reported in a number of in vitro 
studies [131;157;158]. Nevertheless, it should be noted that the presence of isopeptide 
crosslinks in the lens has not yet been established in situ. 
Concerning tTG, the other exciting posttranslational modification of lens β-
crystallins is their deamidation. Numerous deamidating glutamine and asparagine sites, 
including some of the tTG-reactive Q residues have been identified in most β-
crystallins. However, the deamidation of lens crystallins has been speculated to occur 
spontaneously [137;144;159]. What is the importance of such deamidation? Depending 
on the location of the residues, deamidation may have stern consequences: i) the 
introduction of these negative charges into the crystallins can cause conformational 
changes [22;146;160], ii) the conversion of a single glutamine to glutamate may effect 
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the stability of the protein [161]. Consequently, through the above mentioned changes, 
deamidation is likely to affect non-covalent associations between β-crystallins.  
The limited number of direct and circumstantial evidences, such as the 
apparent presence of tTG in the lens [60;162;163], may nonetheless support a 
speculation: THE tTG-CATALYZED CROSSLINKING AND DEAMIDATION OF β-CRYSTALLINS 
COULD BE ASSOCIATED WITH THE AGING OF THE HUMAN LENS AND WITH SENILE CATARACT.  
 
 
SMALL HEAT SHOCK PROTEINS 
Two small heat shock proteins (sHsps), αB-crystallin and Hsp25 have been 
formerly established as lysine-donor substrates for tTG [67;68]. These findings formed 
an essential basis of the research described in this thesis. Since there is more about 
sHsps than being a tTG substrate, the following part gives an overall insight into the 
structural and functional characteristics of small heat shock proteins, although with an 
attempt to highlight those that are relevant in regard to tTG. 
Cells tend to preserve their intracellular milieu within a relatively narrow range 
of physiologic parameters – they maintain normal homeostasis. As active participants 
in their environment, cells constantly adjust structure and function to accommodate 
changing demands to extra- or intracellular stress stimuli. The palette is wide, stresses 
that can induce cell or bodily injury range from gross physical trauma of a car accident 
to a single gene defect that underlies many metabolic diseases. Of these, hypoxia, 
chemicals, drugs, microbiologic agents, genetic defects, nutritional imbalances and 
physical agents such as radiation, temperature or pH extremes are the most common 
causes of stress. Upon exposure to any of these factors the living organism – to 
maintain its structural and functional integrity – will respond with one of the most highly 
conserved biologic responses in evolution, the induction and synthesis of the heat 
shock proteins (Hsp). Hsps range in monomeric size between 110 and 16 kDa 
[164;165]; Hsps that typically range in size from 15 to 30 kDa form and show 
considerable sequence similarity in the so-called α-crystallin-domain comprise together 
the small heat shock protein (sHsp) family [166;167]. In human, there are ten 
different sHsps; the two α-crystallins (αA- and αB-crystallin), Hsp27, Hsp20, HspB2 
and HspB3 have been identified earlier [166], whereas cvHsp, HspB8, HspB9 and 
HspB10 have been found in recent genomic surveys [167-171].  
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The structural properties of sHsps 
sHsps exhibit a two domain structure; the N-terminal domain followed by the 
well conserved C-terminal region, including the “sHsp trademark” α-crystallin domain 
and often a short flexible tail at the C-terminus is generally characteristic to all small 
stress proteins  (Figure 6A and B) [166]. The N-terminal domain is poorly conserved 
and varies both in length and composition among the sHsps (Figure 6) [166;169]. The 
α-crystallin domain is an approximately 80-100 amino acid long region of the C-
terminal region, showing a high sequence similarity in all sHsps [166;169]. 
Figure 6. The ten human small  heat shock proteins (sHsp). Panel A shows the schematic structure of sHsps, 
the light grey bar indicates the N-terminal domain and the α-crystallin domain is denoted by the dark grey bar. The 
small triangles mark the location of the transglutaminase-reactive Q (black and grey triangles), and K (open triangle) 
sites. Panel B shows the multiple alignment of the ten human sHsps. The amino acids that are conserved at least in 
eight family members are black, while less conserved (in at least 5 to 7 sHsps) are depicted in grey. (The alignment 
is taken from [167]). 
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Crystal structures are currently available for three sHsps: Hsp16.5 from the 
archaebacterium Metanococcus jannaschii [172], Hsp16.9 from the wheat Triticum 
aestivum [165] and Tsp36 from the tapeworm Taenia saginata [173]. The three-
dimensional structural analysis revealed that in all three cases, the α-crystallin domain 
forms an immunoglobulin-like β-sandwich fold. The fact that the α-crystallin domain is 
highly conserved among all mammalians, but also in other vertebrates as well as 
invertebrates and plants, suggests a chief importance for this domain both in the 
structure and the functions of sHsps [174-177].  
Association into dynamic and often polydisperse oligomers is another 
emblematic characteristic of sHsps. Such a sHsp assembly shows great variations as 
several factors, including the composure, protein concentration, and most importantly, 
the number of different building subunits can determine the complex size [176;178]. For 
example, in the lens, where αA- and αB-crystallin are present in high concentrations, 
the α-crystallin complex is a heteromeric association of up to 40 sHsp subunits and 
ranging up to 800 kDa in size [178]. In muscle, small heat shock proteins are organized 
into two heteromeric non-covalent complexes, one comprising Hsp27, αB-crystallin and 
Hsp20, and the other HspB2 and HspB3 [179]. Apart from Hsp20, which can interact 
weakly with HspB2, members of one complex do not associate with those from the 
other complex [179].  
Although the α-crystallin domain has been considered to be more important for 
the multimerization of sHsps, and the N-terminal domain is less or not at all required in 
the oligomerization process, certain sHsps such as Hsp26 from the yeast 
Saccharomyces cerevisiae cannot assemble beyond the dimer level without its N-
terminal domain [180;181]. In addition, the most conserved part of the N-terminal 
domain in the mammalian αA-crystallin has been also recently reported as a crucial 
structural element for the higher order assembly, structural stability and for 
oligomerization [182], suggesting that the sHsps are likely to use different structural 
components in their diverse macromolecular assemblies.  
The phosphorylation of sHsps is an important factor in the regulation of the 
dynamics of the sHsp assemblies and also the functions of the small heat shock 
proteins. sHsps, including αA- and αB- crystallin, Hsp27, HspB8 and Hsp20 have 
phosphorylatable serine residues in both the N-and C-terminal domains [183-187]. The 
stress related kinases such as the MAP-kinase family member MAPKAP-2 and 
MAPKAP-3 kinases are commonly found to be responsible for the phosphorylation of 
sHsps (Hsp27, HspB8 and αB-crystallin) [186;188;189]. However, PKC isozymes and 
the cAMP-dependent PKA can also deliver phosphorylation to sHsps such as HspB8, 
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Hsp27 and Hsp20, respectively [170;190;191]. Phosphorylation of αB-crystallin clearly 
results in the dissociation of the large complex into smaller complexes [192], and 
similar to αB-crystallin, the phosphorylation of Hsp27 and Hsp20 also results in rapid 
dissociation of the sHsps-complex [183;192-194], which may be necessary for the 
chaperone function [195]. 
 
Chaperone-like activity of sHsps 
The ability of sHsps to bind and keep unfolding proteins from further 
aggregation in an energy-independent manner is called the chaperone-like activity. It 
probably is the most characteristic in vitro functional feature of sHsps. The surface 
exposure of hydrophobic sites and the increased subunit exchange allow sHsps to form 
transient, non-covalent interactions with their substrates [176]. Refolding of the 
substrate, notably, cannot take place without the ATP-dependent refoldase activity of 
the large Hsps [176;196;197]. Consequently, sHsps have been suggested to act as a 
standby reservoir for proteins that are prone to unfolding and aggregation, and keep 
them soluble in an intermediate so-called folding-competent state [176;197]. It is, 
however, important to note that sHsps are not all equally good chaperones, some 
sHsps, for example Hsp20 or HspB8 [198;199], exert poor chaperone-like activity in 
vitro, suggesting that the chaperone-like activity may not be an essential feature of 
each sHsp, and the weaker chaperones may have other functions in situ. 
 
sHsps in the cell – to serve and to protect 
Despite the fact that not all sHsps are good chaperones, the general opinion is 
that sHsps play a critical role in maintaining the cellular homeostasis under stressful 
conditions. So, where and how do sHsps play their part in the cellular safeguarding?  
sHsps exhibit a complex expression pattern as some like HspB9 and HspB10 or 
αA-crystallin, show a clear tissue specific expression restricted to the testis or the lens, 
respectively [169], whereas other sHsps have a broader, often ubiquitous tissue 
distribution. Levels of expression are particularly high in skeletal and heart muscle 
tissues; practically all sHsps, except αA-crystallin, HspB9 and Hsp10, have been 
detected in muscle cells [168;169;179]. sHsps like αB-crystallin, Hsp27 and Hsp20 are 
also present in the nervous system, gastrointestinal tract and kidney [168;169;200]. 
The highest level of sHsps is present in the eye lens, where α-crystallins (αA-crystallin 
and αB-crystallin) form a major part of the lenticular proteome. Some of the sHsps, like 
Hsp20, are expressed constitutively in for example muscle cells; others, like Hsp27 and 
αB-crystallin, can also have inducible expression under stressful, sometimes 
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pathological conditions. The cellular location of sHsps is generally considered to be 
cytosolic [201], although additional localization studies have also revealed the 
presumably transient presence of sHsps (Hsp27, Hsp20 or αB-crystallin) in other 
cellular compartments such as the nucleus and the mitochondrion [202-205]. 
The molecular characteristics and the widespread tissue distribution may 
suggest distinct and often specific functions for sHsps. In the cell, sHsps are attentive 
and compliant in their associations, as many different kinds of cellular proteins, 
including structural elements, housekeeping and signaling enzymes have been 
suggested to interact with sHsps [184;206-210]. So what are these cellular processes 
in which sHsps are known to be involved? 
Probably the best known “trademark” activity of sHsps is their ability to protect 
against cellular damage caused by different kinds of stress stimuli. Conferring 
thermoresistance has been suggested for both αA- and αB-crystallin, as well as for 
Hsp27, Hsp20 and HspB2 [211-215]. The mechanism by which sHsps can actually 
protect the cell against heat is not yet known, since no significant link can be 
demonstrated between the in situ chaperone-like activity and cell survival [215]. 
However, in incidental cases sHsps have been shown to be able to bind with lipid 
particles [204;216-218]. By modulating membrane fluidity (stability) the lipid-sHsp 
interaction has been speculated to be part of the protecting mechanism [219;220].  
sHsps can also protect against oxidative stress, which is probably the most 
common cellular trauma under certain (patho)-physiological conditions, such as 
ischemia reperfusion injury (I/R). In several experimental I/R models of the heart, 
Hsp27 and αB-crystallin protect cardiac cells from severe damage and increase their 
resistance [221-224]. The ectopic overexpression of these sHsps in other cultured cells 
particularly sensitive to oxidative stress also results in increased cellular resistance 
[225;226]. Moreover, Hsp20 has been recently suggested to play an important 
cardioprotective role during myocardial I/R in situ [227]. Hsp27 and αB-crystallin have 
been reported to decrease the reactive oxygen species levels in vitro by activating 
antioxidant proteins such as glucose-6-phosphate dehydrogenase, glutathione 
reductase and glutathione-S-transferase and subsequently maintain high levels of 
reduced glutathione [226]. In the case of Hsp20, however, other mechanisms such as 
preserving the mitochondrial integrity by binding to pro-apoptotic proteins, and 
maintaining the cytoskelatal integrity have been suggested [227-229].  
By binding to apoptotic molecules sHsps can also increase the rate of cellular 
survival in damaged tissues. In cardiac myocytes, isolated from transgenic Hsp20-
overexpressing mice, Hsp20 interacts with the Bcl-protein family member Bax, and 
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prevents its translocation to the mitochondria [227]. Phosphorylated Hsp20 can also 
bind to the apoptosis related 14-3-3 proteins [230] due to its PKA/PKG consensus 
phosphorylation site RRAS16 [190]. Immunoprecipitation studies have revealed that 
similar to Hsp20, both αA- and αB-crystallin can associate with Bax, arrest its 
translocation to the mitochondria and the subsequent cytochrome-c release-induced 
apoptosis [231]. However, when cytochrome-c is released from the mitochondria, 
Hsp27 can readily interact with it, and by doing so prevent the formation of the Apaf-1 
apoptosome [232]. In addition to these inhibitory effects of sHsps upstream of caspase 
activation, αB-crystallin also has been found to inhibit the maturation process of the 
apoptotic effector caspase-3 by binding to the partially cleaved pro-caspase 
intermediate [209]. 
An excellent example of the cooperation of sHsps is the well established 
interaction between the microfilamentous network of the cytoskeleton and sHsps. αB-
crystallin, Hsp27 and also Hsp20 can bind to actin, and this binding is strictly regulated 
by the phosphorylation state of the sHsps [206;207;233;234]. Each sHsp seems to act 
differently. The binding of Hsp27 to the actin filament (F-actin) on the barbed end 
terminates the polymerization by inhibiting the incorporation of a new actin monomer 
(G-actin) [235;236]. αB-crystallin, on the contrary, stabilizes the F-actin network and 
prevents its depolymerization induced by cytochalasin-D [233]. In respect to actin 
binding, Hsp20 is unique because it can also bind to G-actin [236;237]; moreover, 
binding of this sHsp with the myosin light chain results in vasorelaxation [183].  
Specific functions for a particular sHsp have been also described in the cell. For 
example no other sHsp but Hsp20 has been found to alter the cellular calcium 
homeostasis [229;238;239], whereas only HspB2 has been found to be able to 
associate with the myotonic dystrophy kinase [214]. Although sHsps can transiently 
translocate to the nucleus (Hsp27, αΒ, Hsp20), so far, αB-crystallin is the only sHsps to 
co-localize with the SC35 splicing factor containing nuclear speckles [240]. It is thus 
clear that sHsps can also exhibit distinct cellular functions, as is suggested by their 
widespread tissue distribution. Nevertheless, the earlier presented evidence is 
compelling: SHSPS GENERALLY POSSESS RATHER COMPLEMENTARY AND OFTEN 
OVERLAPPING FUNCTIONS IN THE LIVING CELL. 
 
THE LINK BETWEEN tTG AND sHSPS 
Alzheimer’s disease, sporadic inclusion myositis and cortical cataract formation 
in the eye lens are all described as protein unfolding diseases, because in the affected 
neuronal, muscle and lenticular tissues, respectively, normal cellular proteins tend to 
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unfold and accumulate into insoluble aggregates, so-called inclusions. Based on the 
unique molecular characteristics such as the ratio of hydrophobic and hydrophilic 
patches and the chaperone-like capacity, sHsps have been speculated to play a role in 
these diseases. Hsp27 immunoreactive neurons and αB-crystallin immunoreactive 
astrocytes are indeed frequent in AD brains [241;242]. In certain cases, the increased 
accumulation of αB-crystallin and Hsp27 appears to be part of a reactive process of 
glial and neuronal cells. Moreover, the expression of Hsp27 appears to increase with 
the severity of the AD-related morphological changes and with the duration of the 
associated dementia. More importantly, immunohistochemical studies have established 
the accumulation of both sHsps in the amyloid-β containing senile plaques and in the 
vicinity of the neurofibrillary tangles [241;243]. In addition, αB-crystallin can associate 
with amyloid-β (Aβ) in vitro [244], and increase its neurotoxic effect [243]. 
In vitro studies have also shown that components of senile plaques and tangles 
are substrates for tissue transglutaminase. The number of crosslinks in the insoluble 
materials from AD brains is 30 to 50 times greater than the number found in normal 
brain tissues [245]. Amyloid-β, with two accessible lysines and one glutamine residue, 
is an excellent substrate for tTG, and the enzyme can catalyze the formation of 
insoluble amyloid polymers [246]. Tau (τ), the major component of the paired helical 
filaments [247;248] that make up the neurofibrillary tangles is also a tTG substrate 
[60;248-251]. Remarkably, only the hyperphosporylated form of τ with the tendency to 
aggregate has TG-substrate properties. In addition, isoforms of transglutaminases co-
localize with both the tangles and plaques [41;252-254]. 
Histological analysis of tissue specimens from sporadic inclusion body myositis 
(sIBM) patients shows that diseased muscle fibers also accumulate both amyloid-β and 
hyperphosphorylated τ in the form of intracellular inclusions [3;19;255]. Similar to AD, 
αB-crystallin has been found to co-localize with these aggregates [17]. Additionally, the 
increased expression of this sHsp has also been observed in many other fibers from 
the affected tissue without showing any significant structural abnormalities [17], 
suggesting that the upregulated expression of αB-crystallin is likely an upstream event 
in the pathogenesis of sIBM.  
However, the augmented expression levels of both TG1 and tTG, and the 
accompanying 20-fold higher total transglutaminase activity in the diseased sIBM 
muscles suggest that the similarity between Alzheimer’s disease and sporadic inclusion 
body myositis goes beyond the increased sHsp expression and the accumulation of 
amyloid-β (and τ) containing inclusion bodies [256]. In accordance with the observed 
high transglutaminase activity, biochemical analysis has also revealed high 
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isodipeptide cross-link content in the high molecular weight protein insolubilities in 
sIBM [256]. 
Cataract formation in the eye lens is the consequence of undesired aggregation 
of lenticular proteins. As normal component of the eye lens proteome, α-crystallin has 
been suggested to keep other proteins from aggregating and maintain their proper 
protein-protein interactions [178;257]. However, due to the absence of protein turnover 
and the continuous posttranslational modifications such as oxidation, deamidation, 
cleavage and irreversible crosslinking, with time, structural and conformational changes 
occur, and cataract develops. It is also worth mentioning that Aβ-aggregates 
accumulate in the eye lenses of patients suffering from Alzheimer’s disease. Moreover, 
αB-crystallin has been found to co-localize with these inclusions [258].  
A number of compelling observations indicate a pivotal role for tTG in cataract 
development, as most of the β-crystallins (βB1-, βB2-, βB3-, βA3-crystallin) are 
substrates for tTG in vitro (for detailed information see above) [128-
131;141;155;156;259;260]. In addition, treatment of rabbit eye lens with the calcium 
ionophore ionomycin promotes the formation of β-crystallin dimers ex vivo, which 
resemble those produced in vitro [157;261]. More importantly, several studies have 
convincingly shown that αB-crystallin is a ready substrate for transglutaminases in vitro 
[67;130;262]. In lens homogenates, the lysine-donor substrate αB-crystallin has also 
been found to be readily crosslinked by tTG with other glutamine-donor substrate 
proteins [130]. 
Chronic oxidative stress has been suggested to play a role in the development 
of these diseases [263-266]. Free radicals and reactive oxygen species deliver serious 
damage to proteins, leading to aggregation, but they are also known to upregulate the 
expression of sHsps [226] and promote the translocation of sHsps from soluble to 
insoluble fractions [267]. In addition, these oxidizing molecules also influence the 
intracellular Ca2+-homeostasis which is frequently perturbed in inclusion body diseases. 
There is also evidence that reactive oxygen species can actually induce the activity of 
tTG [131;268]. Since tTG is a tightly regulated Ca2+-activated enzyme [25;39], a 
disrupting Ca2+-homeostasis induced by a stress stimulus is likely to result in its 
appropriate activation and may result in the unwanted covalent crosslinking of proteins. 
The exact mechanism underlying the pathogenesis of these three diseases is 
clearly not yet fully understood. The high transglutaminase activity observed in AD and 
sIBM, together with the evidence of the involvement of sHsps and their apparent TG-
substrate capacity in vitro and ex vivo, are probably only elements of a multifactorial 
process accountable for inclusion body diseases. Nevertheless, based on these 
Chapter 1 
 34
findings A DIRECT ENZYME-SUBSTRATE INTERACTION BETWEEN tTG AND SHSPS AND ITS 
CONTRIBUTION TO THESE DISORDERS MAY BE SUGGESTED. 
 
 
OUTLINE OF THIS THESIS 
Transglutaminase catalyzed protein crosslinking is an important physiological 
phenomenon. Yet, the molecular detail remains largely unexplored, mainly because of 
the lack of appropriate biochemical approaches. Much has been published about tTG 
and its possible contribution to neurodegenerative disorders in relation to the formation 
of inclusion bodies. On the other side of the coin there are the chaperones, including 
the small heat shock proteins, to combat the inclusion body formation by keeping the 
proteins from aggregation and/or trying to refold the non-native proteins.  
The separate involvement of sHsps and tTG in neurodegenerative disorders is 
well documented, but the question whether the actual interaction of these two proteins 
contributes to the pathology of the inclusion body diseases is still unanswered.  
The main goal of our experiments was to gain better insight into the functional 
relationship of sHsps and tTG. Earlier reports from this laboratory characterizing two of 
the sHsps, αB-crystallin and Hsp25, as lysine-donor substrates for transglutaminase 
set the agenda for much of the subsequent research [67;68]. To achieve this, the 
interaction between sHsps and tTG was investigated in vitro, in vivo and ex vivo. 
Chapter 2, characterizes the transglutaminase substrate properties of the most 
prominent members of the human sHsp family. In these in vitro experiments it is also 
found that tTG readily crosslinks certain sHsps in their multimeric associations. We 
also bring evidence that disease-related proteins with tTG-reactive sites, such as 
amyloid-β are capable of interacting with sHsps and can also become crosslinked to 
them.  
After identifying most members of the mammalian sHsps as lysine and/or 
glutamine substrates for tTG, in Chapter 3 we further characterize the substrate 
properties of the sHsps by localizing the reactive residues, and describe a mass 
spectrometry based technique to screen for TG-catalyzed modifications. Using this 
method, Chapter 4 deals with the thorough analysis of Hsp20, and portrays it as the 
most reactive sHsp, because the available crosslinking sites are engaged in a range of 
reactions, including common homodimer formation, but also the unique intramolecular 
crosslink formation. Next to these modifications, a conserved glutamine residue in the 
N-terminal domain of Hsp20 is found to be selectively and simultaneously 
deamidated.  
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The enzyme-substrate interaction between sHsps and tTG was further 
investigated in the cellular environment in Chapter 5, and identifies Hsp20 as the KEY 
TTG-SUBSTRATE among the sHsps, because it is a major endogenous substrate for tTG  
and in its mixed associations, Hsp20 can present other tTG-substrate sHsps for 
crosslinking. The importance of Hsp20 goes beyond its substrate behavior because it 
seems to have an effect on the activity of tTG. 
The serendipitous finding of the deamidating glutamine in Hsp20 prompted the 
experiments with lens-crystallins in Chapter 6. The capacity of tTG to deamidate lens 
proteins was examined ex vivo. We found that two of the six β-crystallins are targets for 
tTG-catalyzed deamidation, which in turn alters their functional properties and may 
contribute to the development of cortical cataract. 
HspB2 is an exceptional member of the sHsps, since it was thought to form 
exclusive complexes with HspB3. Interestingly, while HspB2 is a glutamine substrate 
for tTG, its partner, HspB3 has no accessible sites for the enzyme. Moreover, HspB2 
can be crosslinked by tTG to Hsp20 in their mixed associations. In Chapter 7 we 
investigated how the structural and functional properties of HspB2 are influenced by its 
interacting partner HspB3, and found that Hsp20 is the only sHsp that can compete 
with HspB3 for the association with HspB2. 
 
Although these studies may not give an exact answer to all the addressed 
research questions, the most important findings are discussed and concluded with 
implications for further perspectives and finally briefly summarized in Chapter 8. 
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Transglutaminase catalyzes differential crosslinking of small 
heat shock proteins and amyloid-β 
 
 
 
Introduction 
Transglutaminases (TGs) are calcium-dependent enzymes catalyzing the 
formation of isodipeptide bonds between the ε-amino group of polypeptide-bound 
lysines and the γ-carboxamide group of polypeptide-bound glutamines [1-3]. The 
ubiquitously expressed tissue TG (TGase2 or tTG) has been studied most extensively. 
Its substrate preference is not yet fully understood, but a common notion is that tTG is 
much less selective towards lysine residues than to glutamines. Both the adjacent 
residues in the primary structure and the exposure in the conformation of a protein 
determine whether glutamine and lysine residues can be reactive [2-5]. Tissue TG is 
involved in a wide array of biological activities, including differentiation and apoptosis 
as well as extracellular matrix remodeling [3;6;7]. As a result of increased tTG activity, 
large amounts of isopeptide crosslinks have been found in pathological deposits of 
aggregated proteins such as amyloid (Aβ) [1;8;9]. Accumulation of Aβ is one of the 
major pathologic hallmarks of neuromuscular disorders like Alzheimer’s disease (AD) 
and sporadic inclusion body myositis (sIBM), and Aβ is a well known substrate of tTG 
[10]. Whether tTG-catalyzed crosslinking is a cause or a consequence of the formation 
of aggregates is not clear. 
Two members of the small heat shock protein (sHsp) family, αB-crystallin and 
Hsp27, have been reported as lysine-donor substrates for tTG [11;12]. In human, eight 
additional sHsps have been identified [13;14]. sHsps generally form large and 
heteromeric complexes which readily exchange subunits [15;16]. Most sHsps are 
Crosslinking of proteins by tissue transglutaminase (tTG) is enhanced 
in amyloid (Aβ) deposits characteristic of Alzheimer’s disease and sporadic 
inclusion body myositis. Small heat shock proteins (sHsps) also occur in 
amyloid deposits. We here report the substrate characteristics for tTG of six 
sHsps, Hsp27, Hsp20 and HspB8 are both lysine- and glutamine-donors, αB-
crystallin only is a lysine-donor, HspB2 a glutamine-donor, and HspB3 no 
substrate at all. Close interaction of proteins stimulates crosslinking 
efficiency as crosslinking between different sHsps only takes place within the 
same heteromeric complex. We also observed that αB-crystallin, Hsp27 and 
Hsp20 associate with Aβ in vitro, and can be readily crosslinked by tTG. 
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abundantly expressed in contractile tissues and to a lesser extent in the nervous 
system, kidney and skin [13;17]. As components of the cellular chaperone machinery, 
sHsps may bind to unfolding or aggregating proteins to keep them from further 
aggregation. αB-crystallin has been found to be associated with the Aβ-containing 
senile plaques in AD brains [18], and with intracellular Aβ-aggregates in sIBM muscle 
fibers [19]. As a result of pathological overlap, the eye lenses of AD patients also show 
co-localization of αB-crystallin with Aβ-aggregates [20]. In addition, αB-crystallin can 
associate with Aβ in vitro [21], and increase its neurotoxic effect [22]. 
Since tTG, sHsps and Aβ colocalize at senile plaques in AD brains and 
inclusions in sIBM, we further explored the substrate characteristics of sHsps for tTG, 
and the tTG-mediated crosslinking of sHsps and Aβ. We here report that in addition to 
αB-crystallin and Hsp27, also Hsp20 (or HspB6), HspB8 (also known as Hsp22 or H11) 
and HspB2, but not HspB3, are substrates for tTG. We found evidence that tTG-
mediated crosslinking between different sHsps is more efficient when they can interact 
in the same mixed complex. In line with this result we show that sHsps when 
interacting with Aβ can also efficiently be crosslinked to this peptide by tTG.  
 
 
Materials and methods 
 
Expression and purification of recombinant proteins 
The following constructs were used: pET3b-human-αB-crystallin, pET3a-
human-Hsp27, pET8c-rat-Hsp20, pET16b-human-HspB8 and pET3a-rat-HspB2/B3 
(both B2 and B3 cloned into the same vector). Protein expression was induced in the 
BL21 rosetta strain by addition of 350 µM IPTG and subsequent incubation for 3 more 
hours at 37 °C. Cells were lysed by sonication in TEG buffer (25 mM Tris pH 8.0, 2 mM 
EDTA, 50 mM glucose) and then centrifuged at 16,000 g for 45 min at 4 °C. 
Supernatants containing Hsp27, αB-crystallin and HspB2/B3 were subjected to 0.12 % 
polyethylene-imine precipitation, and HspB8 to ammonium sulphate precipitation. All 
sHsps, except HspB8, were first fractionated on a DEAE Sepharose column, using a 
NaCl gradient from 0 to 1000 mM in 2 mM EDTA, 25 mM Tris HCl / bis-Tris HCl pH 
8.0-6.5 (depending on the pI of the sHsp), and subsequently purified on a Source 15Q 
HR 16/10 column. HspB8 was directly applied on Source 15Q. In each case, the last 
purification step was done on a Superose 6 gel permeation column using 25 mM bis-
Tris 2, mM EDTA, 150 mM NaCl pH 7.0. 
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tTG-mediated crosslinking of small heat shock proteins 
Two N-terminally biotinylated hexapeptides, biotin-GQDPVR (Q-donor) and 
biotin-GNDPVK (K-donor) (provided by Dr. J.W. Drijfhout, Leiden), were used as 
probes to detect tTG-catalyzed crosslinking. sHsps and tTG were first preincubated for 
15 minutes at 37 °C in crosslinking reaction buffer (50 mM Tris HCl pH 7.5, 150 mM 
NaCl, 15 mM DTT and 20 % glycerol). The crosslinking reaction was performed in a 
mixture with a final volume of 50 µL containing 20 µg sHsp, 1 µg probe or 5 µg Aβ(1-40) 
(Anaspec) and either no or 5 µg (2.5 × 10-4 U/µL) guinea pig liver tTG (Sigma), and 
incubated for 2 hours at 37 °C after adding CaCl2 to a final concentration of 5 mM. 
Samples were analyzed by SDS-PAGE followed by electro-blotting and stained with 
Extravidin-peroxidase conjugate (Sigma) or the appropriate antibodies (see below). 
 
sHsp-Aβ association assay 
Aβ(1-40) (5 µg) was incubated either in the absence or presence of each sHsp 
(20 µg) in 50 µL crosslinking buffer without DTT for six days at 37 °C. After SDS-
PAGE, samples were analyzed by Western blotting.  
 
Brain sample preparation 
Brain samples (obtained from the Department of Neurology, St. Radboud 
Hospital, Nijmegen) from autopsy material were homogenized and sonicated on ice in 
buffer (2% SDS, 150 mM NaCl, 100 mM Tris HCl, 1 mM EDTA, 1 mM PMSF, 
Boehringer protease cocktail, pH 7.4). Samples were cleared by centrifugation and the 
collected supernatant was analyzed by Western blotting. Protein concentration was 
determined by the BCA kit (Pierce) according to the manufacturer’s manual. 
 
SDS-PAGE and Western blotting of recombinant proteins and brain materials 
For the detection of proteins the following antibodies were used: anti-Aβ 
(Anaspec), anti-αB-crystallin (Riken Cell Bank), anti-Hsp27 (Stressgen), rabbit anti-
Hsp20 and anti-actin (Sigma). Samples containing 20 µg of brain proteins or 0.2-2 µg 
of sHsps present in crosslinking reaction mixture were subjected to SDS-PAGE and 
transferred to nitrocellulose membranes (Hybond). Membranes were then blocked with 
5% nonfat dry milk in TBST (15 mM Tris HCl pH 8.0, 150 mM NaCl, 0.1 % Tween-20) 
and probed with the appropriate primary and secondary antibodies. Immunoreactive 
bands were visualized by the enhanced chemiluminescence (ECL) Western blotting 
detection kit (Pierce) or alkaline phosphatase (Promega) reaction. 
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Results 
 
In vitro crosslinking of sHsps as substrates for transglutaminase 
We examined the six prominent members of the mammalian sHsp family which 
are expressed throughout the body. To determine the presence of glutamine and lysine 
donor sites for tTG in these sHsps, we assayed their capacity to be crosslinked to the 
peptides biotin-GNDPVK and biotin-GQDPVR, respectively. These peptide sequences 
are derived from the skin protein SKALP, which is known to be an excellent tTG 
substrate [23].  
In agreement with earlier findings [11;24], Fig. 1 shows that αB-crystallin is a 
potent K-donor and has no Q sites available for tTG. Also Hsp27 turns out to be an 
efficient K-donor (Fig. 1), as expected on basis of earlier findings with Hsp25, the 
mouse ortholog of human Hsp27 [12]. However, Hsp27 in addition shows some Q-
donor reactivity, which explains that Hsp27 in contrast to αB-crystallin can crosslink 
into a homodimer (open triangles, Fig. 1). The Hsp27-dimer could still be labeled with 
both probes (Fig. 1, Hsp27, upper panel), indicating that the available but unused K 
and Q sites are still accessible for tTG. 
Figure 1. Small heat shock proteins as substrates for tTG. Twenty µg of each recombinant sHsp 
was incubated with the biotin-GNDPVK and biotin-GQDPVR probes at 2 µM final concentration, in the 
absence or presence of 2.5× 10-4 U tTG/µL. Samples were then analyzed by SDS-PAGE followed by 
biotin blotting (upper panels) or staining with CBB (lower panels). Arrowheads (e) and open 
arrowheads (Y) indicate the monomeric and dimeric forms of sHsps crosslinked to the probes, 
respectively. 
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Similar to Hsp27, labeling of recombinant rat Hsp20 resulted in incorporation of 
both the K- and Q-probes. Hsp20 seems to be a very good substrate for tTG, since 
almost all Hsp20 underwent tTG-catalyzed modifications (Fig. 1, Hsp20, lower panel, 
2nd and 4th lanes). A considerable proportion of Hsp20 formed homodimers, especially 
in the presence of the K-donor probe. Non-labeled bands migrating faster than the 
unmodified monomer of Hsp20 were also found upon tTG incubation (Fig. 1, Hsp20, 
lower panel). This might be due to the formation of intramolecular isopeptide bonds, 
resulting in a circular polypeptide. 
HspB2 forms a stable complex with HspB3 [25] and for this reason they were 
expressed together in E. coli and purified as a complex. No incorporation of the K- or 
Q-donor probe was detected in HspB3, but we obtained a good labeling of HspB2 with 
the K-donor probe (Fig. 1, HspB2/B3 panel). In agreement with the absence of K-donor 
sites in HspB2, no dimers were observed. 
Finally, HspB8 underwent extensive modification upon tTG treatment, leaving 
hardly any unmodified protein (Fig. 1, HspB8, lower panel). Labeling with both the Q- 
and K-probes yielded several bands (upper panel), indicating the presence of multiple 
accessible Q- and K-donor sites. Bands at the expected position of the dimers were 
detected only faintly on both the biotin blot and the corresponding CBB-stained gel. 
 
Crosslinking of interacting subunits of sHsps 
Crosslinking catalyzed by tTG may occur between subunits within the same 
complex as well as between subunits present in different complexes, depending on 
localization and accessibility of K- and Q-donor residues. To distinguish between these 
possibilities, we made use of the observation that HspB2 and HspB3 are able to form 
mixed complexes with Hsp20, but not with Hsp27 or αB-crystallin [25]. How HspB8 
interacts with other sHsps is as yet not known, and HspB8 is therefore not included in 
these crosslinking studies. Hsp27, Hsp20 and αB-crystallin were first preincubated at 
37 °C, either alone or with other sHsps, to allow exchange of subunits and the 
formation of mixed complexes. Tissue TG was subsequently activated by the addition 
of calcium (Fig. 2). As already observed in Fig. 1, Hsp27 and Hsp20 alone, but not αB-
crystallin, could form homodimers. Crosslinking of premixed Hsp27 and Hsp20 yielded 
beside the homodimers also heterodimers (a in panels A and B, Fig. 2), indicating that 
Hsp27 and Hsp20 can crosslink to each other. Interestingly, αB-crystallin premixed with 
Hsp27 or Hsp20 could also form heterodimers (b in panels A and C, and d in panels B 
and C, respectively, Fig. 2), showing that the available K-donor site of αB-crystallin is 
sufficient for crosslinking with Hsp27 and Hsp20. However, HspB2 was only found to 
Chapter 2 
 58
Figure 3. Transglutaminase and sHsp expression in the temporal cortex of control and AD patients.
Extracts containing 20 µg of protein from cortical brain tissue of 3 healthy controls and 3 AD patients were 
separated by SDS-PAGE and subsequently analyzed by Western blotting with antibodies directed to tTG, 
Hsp27, αB-crystallin and Hsp20, as indicated. Actin was used as an internal control. 
be crosslinked to Hsp20 (c in panel B, Fig. 2), whereas no crosslinking was observed 
with Hsp27 or αB-crystallin. It thus appears that sHsp subunits can more readily be 
crosslinked when they are interacting in the same heteromeric complex than when they 
are present in different homomeric complexes.  
 
Crosslinking of sHsps to Aβ 
Several studies have demonstrated in 
various experimental systems the interaction 
between sHsps and Aβ [21;22;26;27]. Such 
interactions are physiologically only relevant 
if the particular sHsps are present in AD 
brains. We therefore identified the sHsps that 
are present in autopsy material from 
temporal cortices of three AD patients and 
three control individuals by Western-blotting. 
We found variable levels of Hsp27, αB-
Figure 2. Transglutaminase catalyzed crosslinking of interacting subunits of sHsps. Forty µg of 
sHsps (20 µg of each) were mixed with 2.5× 10-4 U tTG /µL. Subunit exchange was facilitated by 
preincubation at 37 °C, after which tTG was activated by the addition of 5 mM CaCl2. After crosslinking, the 
samples were separated by SDS-PAGE and immunoblotted with antisera against Hsp27 (panel A), Hsp20 
(panel B) αB-crystallin (panel C). Arrowheads indicate the homodimers and brackets with letters the 
heterodimers: a) Hsp20-Hsp27; b) Hsp27-αB; c) HspB2-Hsp20; d) Hsp20-αB. Since HspB3 is not a 
substrate for tTG no crosslinking of HspB3 was observed with other sHsps. 
actin
Hsp20
αB
Hsp27
tTG
Temporal cortex
control AD
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crystallin and Hsp20 in both control and AD brain samples, and no indication for 
increased expression in the latter (Fig. 3). No expression of HspB2, HspB3 and HspB8 
could be detected by immunoblotting (data not shown). In line with previous 
investigations [8], AD brains showed slightly higher expression of tTG as compared to 
controls.  
To analyze the possible association between Aβ and the three sHsps that are 
present in brain, Aβ was incubated for 6 days at 37 °C with the sHsps and 
subsequently separated on SDS-PAGE and identified by immunoblotting (Fig. 4). In the 
absence of sHsps, Aβ was mainly present as SDS-resistant aggregates in the form of a 
smear, and practically undetectable in its monomeric form. Co-incubation with αB-
crystallin, Hsp20 or Hsp27 drastically changed the polymerization properties of Aβ. In 
the presence of these sHsps, part of Aβ remained in the monomeric form, and part of it 
formed multimers with masses between 22-28 kDa. These multimer bands did not 
counterstain with anti-sHsps antibodies (data not shown). Thus, these sHsps appear to 
be able to inhibit the aggregation of Aβ by promoting the formation of smaller-sized 
SDS-resistant intermediates.  
Next we determined whether tTG could crosslink Aβ to Hsp27, αB-crystallin and 
Hsp20. The sHsps were incubated for 2 hours at 37 °C in the presence of calcium 
either with or without tTG and Aβ. Upon incubation with tTG, we found all three sHsps 
strongly decorated with Aβ-monomers (Fig. 5, last lane in each panel). On the blots 
probed with anti-Aβ-antibody a slower migrating band was detected above the main 
crosslinked products (Fig. 5, upper panels, top black arrowhead), indicating that more 
than one monomer of Aβ could be crosslinked to these three sHsps. In addition, 
crosslinking of Aβ to Hsp20 and Hsp27, but not αB-crystallin, also resulted in Aβ-
decorated sHsp dimers (Fig. 5, upper panels, open arrowheads). 
 
 
Figure 4. sHsps induce the formation of 
specific oligomers of Aβ1-40. Five µg of Aβ
was incubated either in the absence or 
presence of sHsp in crosslinking buffer without 
DTT, for six days at 37 °C. Samples then were 
subjected to immunoblotting and stained with a 
polyclonal antibody against Aβ. Lane 1 
represents 1% of the input, lanes 2-5 represent 
the samples after incubation of Aβ1-40 for 6 days 
without sHsp or with αB-crystallin, Hsp20 and 
Hsp27, respectively. The stacking gel has been 
removed prior to blotting; any fractions not 
penetrating the separating gel may thus have 
been missed.  
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Discussion  
 
Earlier studies have shown that both αB-crystallin and Hsp25 expose a lysine 
residue accessible for tTG [11;12;24]. Using biotinylated hexapeptide probes for K- or 
Q-donor sites, we screened for additional tTG substrates in the sHsp family (Fig. 1). 
These labeling experiments revealed that crosslinkable lysine residues were not 
restricted to αB-crystallin and Hsp27, but are also present in Hsp20 and HspB8. For 
both αB-crystallin and Hsp27 it has been shown that only the C-terminal lysine is 
available for tTG [12;24]. The C-terminal flexible tail of Hsp20 also exposes a terminal 
lysine and it is thus likely that this lysine is a glutamine acceptor. HspB8 clearly serves 
as a multiple lysine-donor for tTG although it lacks a C-terminal lysine. Therefore, the 
lysine substrates of this protein must be localized elsewhere.  
There are only few glutamine substrates known in intracellular proteins. 
Surprisingly, we found that Hsp27, Hsp20, HspB2 and HspB8, but not αB-crystallin, all 
exposed glutamines to tTG. Crosslinked Hsp27 has been identified very recently in 
neurofibrillary tangles which strongly corroborates our data about the glutamine site 
exposure in Hsp27 [28]. The absence of a glutamine-donor in αB-crystallin is in 
agreement with earlier studies [11;24], but not with the reported formation of 
homodimers by bovine lens αB-crystallin in the presence of tTG [29]. This discrepancy 
suggests that differences in the isolation or incubation 
procedures may affect the accessibility of substrate 
sites for tTG. The lower panel of Fig. 1 shows that 
Hsp20 and HspB8 are the most vulnerable to tTG 
modification, indicating that both sHsps expose 
multiple substrate sites for intra- and intermolecular 
crosslinking. In the case of HspB8 this nicely 
Figure 5. sHsps can readily 
crosslink to Aβ1-40. sHsps (0.1 
µg/µL) were incubated for 2 
hours at 37 °C alone (lanes 1), in 
the presence of tTG (50 ng/µL) 
(lanes 2), in the presence of Aβ1-
40 (0.1 µg/µL) (lanes 3), or 
together with tTG (50 ng/µL) and 
Aβ1-40 (0.1 µg/µL) (lanes 4). 
Samples were separated by 
SDS-PAGE and subjected to 
Western blotting with anti- Aβ1-40 
(top panels) and anti-sHsp 
antibodies (bottom panels). 
Panels A, B and C show the 
crosslinking of Aβ1-40 to αB-
crystallin, Hsp27 and Hsp20, 
respectively. Crosslinking 
products of Aβ1-40 with sHsp 
monomers are indicated by black 
arrowheads (e), with sHsp 
dimers by open arrowheads (Y), 
intermolecularly crosslinked 
Hsp27 and Hsp20 is marked by 
open diamonds (◊), and 
intramolecularly crosslinked 
Hsp20 by a filled diamond (♦). 
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correlates with the recent observation that HspB8 displays a randomly coiled and labile 
structure [30]. 
Two groups of heteromeric sHsp complexes have been distinguished in muscle 
extracts, one comprising Hsp27, αB-crystallin and Hsp20, and the other HspB2 and 
HspB3 [25]. Apart from Hsp20, members of one group do not form mixed complexes 
with those from the other group of sHsps. However, in yeast two-hybrid analyses 
Hsp20 seems to behave differently and can bind to HspB2 [25]. Thus, Hsp20 might 
provide cross-talk between the two systems by its ability to associate not only with 
Hsp27 and αB-crystallin, but also with HspB2. Our crosslinking experiments support 
this observation. While αB-crystallin, Hsp27 and Hsp20 can readily crosslink with each 
other (a, b and d in Fig. 2), Hsp20 is the only protein that can also crosslink to HspB2 
(c in Fig.2). The tTG-catalyzed crosslinking of different sHsps thus seems to be 
facilitated by their interaction. This might also implicate that the aggregating proteins 
present in pathological inclusions become prone to be fixed by tTG-catalyzed protein-
crosslinking. 
Hsp27 and αB-crystallin have been described in senile plaques in AD and in 
amyloid inclusions in sIBM [18;19]. The major component of the plaques is Aβ, and this 
peptide has been shown to expose both Q and K sites for tTG [31]. The aggregation of 
Aβ could possibly trigger its association with sHsps [22]. Our co-incubation 
experiments of Aβ with Hsp27, Hsp20 and αB-crystallin indeed suggest that sHsps can 
associate with Aβ and more importantly, they may interfere with the polymerization 
process of Aβ by fixing it in a defined oligomeric form (Fig. 4). This observation 
correlates well with the recent finding that αB-crystallin reduces the amount of 
physiologically stable amyloid deposits in favor of easily degradable aggregates [32]. In 
the presence of tTG, we find that Aβ can readily crosslink to sHsps in vitro. However, in 
the AD material we examined no sHsp was seen crosslinked to Aβ (Fig. 3), but this 
might be due to insolubility of such products. Based on our observation, it is not 
unlikely that the crosslinking efficiency between Aβ and sHsps is stimulated by their 
association. This might be an important aspect of the amyloid disease process, since 
the amount of isopeptide crosslinks in AD brain and sIBM muscle is strongly increased, 
up to 30- to 50-fold [8;9]. 
In conclusion, the human sHsps that we investigated are excellent in vitro 
substrates of tTG. By binding to Aβ, sHsps seem to have the potential to arrest its 
polymerization process. Moreover, larger complexes, such as formed when of sHsps 
associate with unfolding and aggregating proteins may become stabilized by their 
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crosslinking. This phenomenon could contribute to the formation of inclusion bodies in 
patients with Alzheimer’s disease and sporadic inclusion body myositis.  
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Screening for Transglutaminase-Catalyzed Modifications by 
Peptide Mass Finger-Printing using Multi-Point Recalibration on 
Recognized Peaks for High Mass Accuracy 
 
 
Introduction  
 
Mass spectrometry is widely used for large-scale protein identification in 
proteomics, based on peptide mass finger-printing or peptide fragmentation 
fingerprinting [1]. Mass spectrometry is also extremely useful to investigate post-
translational modifications (PTMs) in a protein [2-4]. These modifications may control 
the activity, subcellular localization and half-life of the proteins, and their interaction 
with other macromolecules, such as other proteins or DNA. Common modifications are 
phosphorylation, O-linked glycosylation, methylation, acetylation, farnesylation, 
ubiquitinylation, and, as seen below, deamidation and transpeptidation. Each protein 
may actually contain several different PTMs, for example, the transcription factor CREB 
is subject to regulation by phosphorylation, O-GlcNAc-glycosylation and acetylation [5]. 
Well over 300 different PTMs are listed and can be searched across the Internet (see 
Detection of post-translational modifications is expected to be one of 
the major future experimental challenges for proteomics. We here describe a 
mass spectrometric procedure to screen for protein modifications by peptide 
mass finger-printing, which is based on post-data acquisition improvement of 
the mass accuracy by exporting the peptide mass values into analytical 
software for multipoint recalibration on recognized peaks. Subsequently, the 
calibrated peak mass data set is used in searching for modified peptides, i.e. 
peptides possessing specific mass deviations. In order to identify the location 
of lysine- and glutamine-residues available for transglutaminase-catalyzed 
isopeptide bond formation, mammalian small heat shock proteins (sHsps) 
were screened for labeling with the two hexapeptide probes GQDPVR and 
GNDPVK in presence of transglutaminase. Peptide modification due to cross-
linking of the GQDPVR hexapeptide probe was detected for C-terminal lysine 
residues. Novel transglutaminase-susceptible glutamine sites were identified 
in two sHsps (Q31/Q27 in Hsp20 and HspB2, respectively), by cross-linking of 
the GNDPVK hexapeptide probe. Deamidation of specific glutamine residues 
was also detected, and an isopeptide derived from intramolecular glutamine-
lysine isopeptide bond formation. We conclude that peptide mass finger-
printing can be an efficient way of screening for various post-translational 
modifications. Basically any instrumentation for MALDI mass spectrometry 
can be used, provided that post-data acquisition recalibration is applied. 
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Delta Mass web page; http://www.abrf.org/index.cfm/dm.home). Post-translational 
modification of proteins occurs frequently, and is varying depending on cellular 
conditions. The picture is even emerging that differences between any two cellular 
states, such as in e.g. a tumor tissue versus a normal tissue, can be manifested in 
changes in the state of the PTMs rather than changes in expression of proteins [6]. 
Experimental detection of PTMs is expected to be one of the major experimental 
challenges for proteomics in this decade [7]. Clearly, there is a need for methods to 
rapidly screen for post-translational modifications in any sample set, by any 
investigator, using any MS instrumentation.  
Peptide mass finger-printing offers a possibility to rapidly screen for possible 
post-translational modifications, but only provided that the mass accuracy is sufficiently 
good. We here describe a rationale for routinely achieving data with sufficient mass 
accuracy, from any type of instrumentation for peptide mass finger-printing, by applying 
a procedure with user-designed data analysis following data acquisition. After recording 
mass spectra for peptide mass finger-printing, a subsequent three step data analysis is 
performed. First, observed peak mass values are used to search for recognized peaks, 
such as trypsin or keratin peaks. Such tryptic autodigest products and peptides from 
contaminating keratin are particularly prevalent when working with low amount of 
sample. If the identity of the protein is known, also peaks derived from the known 
protein can be recognized. A fairly large mass accuracy window can be used, since 
only a small data set is searched, namely the peptide mass values from theoretical 
digests of the sequences for trypsin, a limited number of keratins and the known 
protein. Secondly, the recognized peaks are used for a multi-point recalibration of the 
peak mass values, typically down to approximately 10 ppm. Thirdly, the recalibrated 
peak mass values are used to search for post-translational modifications by means of 
user-designed peak mass deviations.  
As an example it is here described how this approach was used to screen a 
number of small heat shock proteins (sHps) for modifications induced by tissue 
transglutaminase (TG) [8-10]. The TG catalyzes transamidation, i.e. the formation of a 
covalent isopeptide bond within or between polypeptide chains, between the ε-amino 
group of specific lysine residues, and the γ-carboxyamide group of specific glutamines. 
In a first step, the side chain of a glutamine residue forms a thioester with a cysteine in 
the active site of TG, and ammonia is released yielding an activated acyl group. 
Subsequently, a covalent isopeptide bond is formed between the activated acyl group 
and the amine group of a specific lysine. Alternatively, hydrolysis of the thioester bond 
leads to deamidation, converting the glutamine into a glutamic acid residue. Both 
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processes, transamidation and deamidation, are involved in celiac disease . 
Transamidation is also referred to as transpeptidation, or transglutamination [11].  
The small heat shock proteins (sHsps) are a family of ATP-independent 
chaperones which protect cellular proteins from irreversible aggregation by forming 
large, soluble complexes with the proteins that tend to unfold under stress conditions 
[12-14]. The sHsps are oligomeric proteins, which probably become activated by 
formation of dimers which expose hydrophobic surfaces for binding to unfolding 
proteins [12,15,16]. Mammalian sHsps often found in both extra- and intracellular 
protein aggregates in neurological disorders such as Alzheimer’s disease [17] or 
sporadic inclusion body myositis [18].  
Large amounts of isopeptide cross-links have been found in such pathological 
protein deposits [19-21]. Recently, cross-linking was demonstrated between Hsp27 and 
parkin and α-synuclein in neurofibrillar tangles [22]. To assess the capability for various 
sHsps to take part in such cross-linking, different mammalian sHsps were recently 
characterized in terms of their susceptibility to transglutaminase, using hexapeptides 
designed as probes for possible amine donor (lysine, K) and amine acceptor 
(glutamine, Q) sites [23]. Here we used the same hexapeptide probes to screen for the 
actual location of the lysine and glutamine modifications in these sHsps by mass 
spectrometry. Lysine modification by hexapeptide probe cross-linking was detected in 
the C-terminal lysine of αB-crystallin K175, Hsp27 K205 and Hsp20 K162. Glutamine 
modifications were detected by hexapeptide probe cross-linking, deamidation and 
cross-linking by intramolecular lysine-glutamine isopeptide bond formation. 
 
 
Materials and Methods  
 
Expression of sHsps and transglutaminase-catalyzed labeling of sHsps  
Several sHsps were recombinantly expressed and purified and treated by tTG 
and biotinylated hexapeptides as described previously [23]. Shortly, a glutamine amine-
acceptor hexapeptide (GQDPVR) was used for labeling of K residues, and a lysine 
amine-donor peptide (GNDPVK) for labeling of Q residues. After treatment with tTG 
(guinea pig liver transglutaminase from Sigma, 2.5 104 U/mL, 5 µg to 20 µg sHsp and 1 
µg hexapeptide probe in 50 mM Tris-HCl, pH 7.5), samples were separated by 1D 
SDS-PAGE, and samples were subjected to silver staining.  
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Mass spectrometry and acquisition of MALDI-TOF mass spectra  
Vacuum-dried gel pieces were trypsin digested according to the protocol 
described in [24], and mass spectra were recorded by matrix-assisted laser 
desorption/ionization time-of-flight mass spectrometry (MALDI-TOF-MS) on a Voyager 
Elite BioSpectrometry Workstation (Perseptive Biosystems, Framingham, 
Massachusetts), using α-cyano hydroxy cinnamic acid as matrix after micropurification 
on R2 columns according to [25]. 
 
Data analysis and multi-point recalibration on recognized peaks.  
Observed peak mass values were used to search, with a large mass accuracy 
window, for recognized peaks, such as trypsin peaks, keratin peaks, and peaks derived 
from the protein investigated. Then the recognized peaks were used for multi-point 
recalibration of the peak mass value data set, typically down to approximately 10 ppm. 
Trypsin and keratin peak mass values were then removed from the recalibrated peak 
mass value data set, which was used in searching for user-designed post-translational 
modifications.  
The software MoverZ (freeware available from Genomic Solutions, Ann Arbor, 
MI, http://65.219.84.5/moverzDL.html) was used to open mass spectrum files and 
export peak mass lists into the software GPMAW (General Protein Mass Analysis for 
Windows, available from Lighthouse data Ltd, Odense, Denmark, 
http://welcome.to/gpmaw/, demo-version freely available). The software includes the 
stand-alone module PeakErazor for recalibration of mass spectrum files on recognized 
peaks and removal of trypsin and keratin peaks (full version freely available). 
 
Detection of modified peptides using the recalibrated data set.  
Transglutaminase-catalyzed isopeptide bond formation between a lysine and a 
glutamine takes place under concomitant loss of NH3, or NH4+. Mass deviations 
following the isopeptide bond formation between the sHsp and the hexapeptide probes 
were calculated using the composition calculator in the software GPMAW, for both the 
probes including biotin (B) and a spacer arm (LC), by specifying names, formula and 
valid residues. For the hexapeptide GQDPVR, to label lysine residues, the mass 
deviations were calculated for the modification files, named B-LC-hexQ and B-LC-
hexQ+, to 992.475 Da (C43H68N12O13S1) and 991.467 Da (C43H67N12O13S1) for loss of 
NH3 or NH4+, respectively. For the hexapeptide GNDPVK, to label glutamine residues, 
mass deviations were calculated for the modification files, named B-LC-hexK and B-
LC-hexK+, to 950.453 Da (C42H66N10O13S1) and 949.445 Da (C42H65N10O13S1), 
respectively.  
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Figure 1. MALDI mass spectrum used to screen for TG-susceptible Lys and Gln residues. Mass 
spectrum showing a tryptic digest of human Hsp27 treated by TG in the presence of the hexapeptide 
probe GQDPVR for Lys labeling. After export of peak mass values for spectrum analysis, multipoint 
recalibration on recognized peaks was performed using the programs MoverZ, GPMAW, and 
PeakErazor as outlined in the protocol in Scheme 1 and Figures 2 and 3. After such spectrum analysis, 
two peaks were identified as peptides containing the C-terminal lysine, K205, modified by formation of a 
covalent isopeptide bond with the hexapeptide probe GQDPVR (arrows). That the C-terminal lysine is 
susceptible to tTG was previously documented using a similar hexa-peptide probe in combination with 
exoprotease treatment, both for αB-crystallin [25] and for Hsp27 [27].  
Results  
 
We recently proposed that several members of the human sHsp family contain 
lysine- and/or glutamine-residues which are substrates for tTG [23], based on biotin 
blotting after incubation of sHsps in the presence of biotinylated hexapeptide probes, 
containing either a substrate Q (hexapeptide GQDPVR) for cross-linking to sHsp lysine 
residues, or a substrate K (hexapeptide GNDPVK) for cross-linking to sHsp glutamine 
residues. Here the sHsps, incubated with tTG and hexapeptides, were analyzed by 
mass spectrometry to pinpoint the location of the tTG-susceptible lysine and glutamine 
residues. For all sHsps, MALDI mass spectra were recorded and analyzed as outlined 
in detail in the following, in order to identify peaks carrying covalent modifications. 
Figure 1 shows the mass spectrum obtained for Hsp27 labeled with the hexapeptide 
GQDPVR, arrows indicate peptides, which carry the probe covalently cross-linked to 
the C-terminal lysine K205. This is in agreement with existing data (Table 1). Hsp20 will 
be used in the following as an example to illustrate the strategy used for screening of 
new potential modifications induced by tTG. 
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Multi-point recalibration on recognized peaks.  
 Recorded mass spectra were subjected to multipoint recalibration on 
recognized peaks, using the programs GPMAW, PeakErazor and MoverZ as outlined 
in the protocol in Scheme 1. A peptide mass value list, obtained by in silico theoretical 
cleavage of the known sHsp sequence in GPMAW, is first pasted into PeakErazor. 
After data acquisition, the mass spectrum for each sHsp is opened in software like 
MoverZ, peak labeling is performed to assign peak mass values to the observed peaks. 
A peak mass value list is retrieved and imported into PeakErazor, yielding the situation 
illustrated with the PeakErazor screen-shots in Figure 2A. In contrast to a Mascot 
database search, only a small data set is being searched here, namely peptide mass 
values from the theoretical digests of the known protein, trypsin and keratin (trypsin 
and keratin peak lists are intrinsic in PeakErazor). Consequently, a large mass 
accuracy window (up to 800 ppm) can be used. In the left-hand peak list window, 
peptides from the observed mass spectrum match to six peptides from the in silico 
theoretical cleavage mass values (marked as <sHsp20> in Figure 2), five keratin peaks 
and one trypsin peak at 2211 Da. The matched peptides are automatically checked in 
the squares on the left-hand side, and the ones marked as <sHsp0> are hence 
recognized as peptides belonging to the sHsp. Although the mass deviations of the 
checked peptides are as large as 200-300 ppm in this step (Figure 2A, left), the mass 
values from the six recognized sHsp peaks and the keratin 1 and trypsin peaks all fall 
on a straight line, as seen in the PeakErazor graph (Figure 2A, right), hence forming a 
good basis for calibration. The keratin 8 peak (m/z value 2296.697) has a mass 
deviation of –228 and is clearly not a true contaminant and is removed from the 
calibration step. Using PeakErazor’s calibrate button, multipoint (linear) recalibration is 
thereafter performed on the peptides marked with a tick in the peak list in Figure 2A, to 
yield the situation illustrated in Figure 2B. Note how the mass deviations are now 
improved, as reflected by the way the peaks mass values are now centred around the 
horizontal line (Figure 2B, right). The mass deviations are now in the order of 10 pm for 
the <sHsp20> peaks (Figure 2B, left). The simple linear calibration algorithm in 
PeakErazor requires that the mass errors fall on a straight line. However, even if the 
mass error distribution curve is non-linear, the graphic tools in PeakErazor and 
GPMAW allows user to evaluate whether the mass deviation found on a potential 
modified peptide falls on the curve, i.e. has the expected calibration error.  
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The trypsin and keratins peaks that were utilized in the calibration procedure 
are now excluded from the peak mass list, before exporting the recalibrated peak mass 
list to GPMAW to search for post-translational modifications by identifying modified 
peaks. 
Figure 2 Multipoint recalibration on recognized peaks. Screen-shots of the program PeakErazor 
used for multipoint recalibration on recognized peaks as outlined in the protocol in Scheme 1. Peak 
mass value lists of peptides observed are imported from mass spectra into PeakErazor, and matched 
against peak lists derived from theoretical digests in silico of the sequence from the analyzed protein, 
annotated as <sHsp20>, and an Erazor list, intrinsic to PeakErazor, derived from theoretical digests in 
silico of the sequences for keratin and trypsin. Screen-shots illustrate appearance before (A) and after 
(B) the linear multipoint calibration, which is based on these matched and recognized peaks. Values 
presented in this figure are for Hsp20 (P97541 in Swiss-Prot). 
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Searching for modified peaks with user-defined modifications 
After multi-point calibration as 
described above, the recalibrated peak 
lists were next used with the Mass 
Search function in GPMAW, to search for 
peptides matching to the theoretical 
digest of the Hsp20 sequence, now using 
a mass accuracy of 10 ppm. Searching 
for modified peaks is simultaneously 
performed in the Mass Search function in 
GPMAW by loading modification files 
provided with the program, or by creating 
a new modification file and entering the 
desired modification. New user-defined 
modifications are added by specifying the 
name, its formula and valid residues (i.e. 
the residue that is able to incorporate the 
modification). A composition calculator 
provided with the program simplifies the 
task of calculations associated with 
entering the molecular formula of a new 
protein modification. Modifications can be 
defined globally (such as cysteine 
alkylation or methionine oxidation) for all 
amino acid residues of its kind, or locally 
by selecting an individual amino acid 
residue. To perform the search for 
peptides modified by the hexapeptide 
probes, masses were calculated for 
mass modification files named B-LC-
hexQ, B-LC-hexQ+, B-LC-hexK and B-
LC-hexK+, respectively, as described in 
Materials and Methods. 
Scheme 1. How to Make a Multipoint Calibration Against Theoretical Mass Values for Matched Peptide 
Peaks Using the Programs GPMAW, PeakErazor, and MoverZ.
PeakErazor 
4. Read from clipboard. Now all theoretical peak mass values are 
pasted into the Peak list window. 
5.  Right-click: Copy list to <blank>. Now the list with theoretical 
mass values are pasted into the Erazor list, which can be 
checked by looking in the Erazor list window. After the listed 
mass values for keratins, trypsin and contaminants of unknown 
origin now the theoretical mass values are listed as <blank>. 
The name can be changed to a more appropriate name, e.g., 
Hsp20.
PeakErazor 
7 Read from clipboard. Now your experimentally determined 
peak mass values are listed in the Peak list window 
8. To calibrate, first click the "Show graph" button beside 
"Calibrate button" to show a window in which your detected 
peak mass values are presented graphically to show how 
much they deviate (experimentally determined peak mass 
values from your spectrum that fit with the theoretical peak 
mass values, keratin peaks, trypsin peaks, and so called 
unknown peaks. Colours and names can be defined by the 
user). 
9. Then click on Calibrate button, and to the right of the Peak list 
window the appearance now changes to allow calibration. By 
moving the ruler in the mass accuracy window you can now 
chose how many dots you want to use for calibration. You can 
also remove single dots by Press Ctrl+click. 
10. When you have chosen the right conditions, press button 
Calibrate. Now the experimentally determined mass value list 
is calibrated, and you can see that the mass values in the 
Peak list window are adjusted after calibration, and that the 
deviations have become much smaller (now only a few ppm 
mass deviation from <blank> values). 
11. Copy to clipboard the calibrated list of experimentally 
determined peak mass values, after removing trypsin and 
keratin peaks, but not the sample peaks ("blanks")! 
GPMAW 
12. Finally, you can now paste the calibrated mass values into the 
Mass search in GPMAW using a very low ppm-setting (look 
what the ppm deviations were in the Peak list window after 
calibration). This will allow you to identify more peaks from 
your mass spectrum, such as peptides with missed cleavage 
sites or modifications. 
GPMAW 
1. Open relevant sequence. 
2. Make digest with scissor symbol, choosing trypsin or other 
relevant enzyme, with zero or 1 missed cleavages. Sort after 
MH+ column and remove low masses. 
3. Right-click: Copy special, Copy mass list (singly charged). 
MoverZ 
6. Copy peak mass values from your spectrum to clipboard.
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Table 1. Modifications of lysine and glutamine residues detected in four sHsps. Summary of 
results obtained by mass spectrometry as outlined in Figures 1-5 to screen four sHsps in order to locate 
and identify K and Q residues modified due to tTG-catalyzed hexapeptide probe crosslinking, 
intramolecular crosslinking or glutamine deamidation. Using the same biotinylated hexapaptide probes, 
sHsps were previously investigated by biotin blotting to elucidate differences between mammalian 
sHsps in terms of their possession of any K and Q residues avalaible for tTG-catalyzed crosslinking 
between sHsps and amyloid-β [23]. 
 A screen-shot of the output report from GPMAW for Hsp20 is presented in 
Figure 3, showing that Q31 in the peptide corresponding to amino acid 28-32, 
LFDQR, was labelled with the hexapeptide probe GNDPVK, as detected by the 
modification file B-LC-hexK. Furthermore, glutamine deamidation is also detected in 
another glutamine residue, Q66, in the peptide corresponding to amino acid 57-81 
(APSVAL…VLLDVK), as evident from the modification file searching for a 1Da mass 
increment (glutamine 146.07 Da, glutamic acid 147.05 Da). Such glutamine 
deamidation was never seen in any sample without prior TG treatment. Another 
sHsp, HspB2, was also found to display similar hexapeptide probe cross-linking on 
one glutamine (HspB2Q27), and deamidation of another glutamine (HspB2Q75), as 
summarized in Table I. 
After identifying the modified peptides using the Mass Search function in 
GPMAW, inspection of the peaks in the corresponding mass spectra showed that 
appearance of a certain modified peak occurred under concomitant disappearance of 
the corresponding unmodified peak. The hexapeptide probe labeling detected for 
glutamine Q31 corresponded to disappearance of the LFDQR peak at 677.35 Da and 
appearance of a peak at 1628.8 Da, i.e. with a 950.45 Da mass increment 
corresponding to B-LC-hexK (Figure. 4A). The hexapeptide probe labeling detected on 
the C-terminal lysine K162 corresponded the disappearance of peaks at 3763.7 Da and 
4083.2 Da (corresponding to aa 123-162 YRLPP….PAAK and 125-162 LPP….PAAK) 
and appearance of peaks at 4756.5 Da and 5075.7 Da, both with a 992.5 Da mass 
increment corresponding to B-LC-hexQ (Fig. 4B).  
 
 Contains tTG-modified residues tTG-modified residues identified by MS 
sHsp Lys (K) Gln (Q) Lys (K) Gln (Q) 
Hsp20 Yes Yes K162, crosslinked 
Q31, crosslinked 
Q66 deamidated 
Hsp27 Yes Yes K205, crosslinked Not detected 
αB-
crystallin 
Yes No K175, crosslinked Not detected 
HspB2 No Yes Not detected Q27 crosslinked 
Q75 deamidated 
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Since Hsp20 was found to possess both lysine (K162) and glutamine (Q31) residues 
susceptible to TG, we also checked if we could detect any signal that could represent 
an intramolecular glutamine-lysine isopeptide bond formation. The expected mass of 
an isopeptide from the peptides containing Q31 and K162 would be LPP…. PAAK 
(3763.0 Da) + LFDQR (677.35 Da), and with the loss of one NH3 (3763.0+677.35-
17.03) = 4423.32 Da. Such a peptide is indeed observed (Fig. 5), even in two variants - 
one without missed cleavage sites and one with a missed cleavage site, making the 
Figure 3. Searching for modified peaks using GPMAW with user-defined modifications.
Searching for modified peaks is performed in the program GPMAW using user-defined modifications as 
outlined in the protocol in Scheme 1. Screen-shot from the program GPMAW showing the report from a 
mass search in the Hsp20 sequence (P97541 in Swiss-Prot), with user-defined modifications for Hsp20 
incubated with TG and the hexapeptide probe GNDPVK. Upper part shows a graphic presentation of 
the sequence coverage (in this case 46%). Lower part shows the number of matched peptides (in this 
case 5) with mass deviations, 10 ppm, and the number of matched peptides with modifications (in this 
case 2), one peptide (aa 28–32) containing Hsp20 Q31 modified by Gln cross-linking to the hexapeptide 
probe GNDPVK, and one peptide (aa 57–81) containing Hsp20 Q66 with Gln deamidation to Hsp20 E66. 
Further below unmatched peptides are reported, and at the bottom also a list of all the user-defined 
modifications used in the GPMAW mass search. 
Screening for tTG-catalyzed modifications by mass spectrometry 
 77
assignment even more reliable. Detection of TG-modified lysine and glutamine 
residues in the four sHsps (Hsp20, Hsp27, αB-crystallin and HspB2) is summarized in 
Table 1. 
 
 
Discussion  
 
Screening sHsps for TG-susceptible lysine and glutamine residues  
We have described here how a number of small heat shock proteins (sHps) 
could be screened by peptide mass fingerprinting for modifications induced by tissue 
Figure 4. Hexapeptide probe cross-linking and appearance of modified peaks at the expense of 
unmodified peaks in Hsp20. Overview of MALDI mass spectra recorded for Hsp20 incubated with TG 
in presence of the hexapeptide probe GQDPVR for labeling of Lys residues (upper), or the hexapeptide 
probe GNDPVK for labeling of Gln residues (middle), and control Hsp20 without TG (lower). Mass 
spectra are magnified to show different mass ranges, m/z below 1700 Da (A) or m/z above 3800 Da 
(B). Filled and unfilled arrows mark the peptides, which increase and decrease in intensity, 
respectively. 
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TG. Evidence that such cross-linking involves lysine and glutamine residues in several 
different mammalian sHsps was previously suggested, using the same hexapeptides 
here used as probes to search for possible amine donor (lysine, K) and amine acceptor 
(glutamine, Q) sites [23]. By our peptide mass fingerprinting, lysine modification was 
confirmed for the previously known modification of the C-terminal lysine in αB-crystallin, 
K175 [26] and Hsp27 K205 [27], and it was here detected also on the C-terminal lysine 
also in Hsp20, K162.  
Glutamine residues susceptible to TG-catalyzed modification was identified for the first 
time, and located to Hsp20Q31 (incorporation of hexapeptide probe), and Hsp20Q66 
(deamidation of). A similar pattern for observed for another sHsp, HspB2, for which 
incorporation of the hexapeptide probe was detected at a corresponding glutamine, 
HspB2Q27, and deamidation for HspB2Q75.  
It is likely that the different sHsps in the mammalian sHsp family may play 
distinctly different roles in general, and in transglutamination events in particular. By 
our peptide mass finger-printing, Hsp20 was found to have both a TG-susceptible 
lysine (K162), and a TG-susceptible glutamine (Q31), whereas αB-crystallin has only a 
TG-susceptible lysine (K175) and HspB2 only a TG-susceptible glutamine (Q27). This fits 
the previous observations [23], with the exception of Hsp27, for which we could only 
detect unmodified Q31 (Table I). The different human sHsps have different capacities to 
intermix and cross-link with each other and with amyloid-β in brain autopsy material 
[23], and exact roles for the various sHsps remains to be elucidated. Present data call 
for further investigation on differences between sHsps in terms of their behaviour with 
TG under cellular conditions.  
 
The approach to screen proteins for various modifications using peptide mass 
finger-printing and recalibrated data sets  
Mass spectrometry has been used previously to suggest the location of 
glutamines susceptible to tTG crosslinking after incubation with 14C-labelled 
polyamines, such as Gln93 in vitronection [28] or the Gln83, Gln84 and Gln86 for 
plasminogen activator inhibitor type 2 [29]. We here describe a procedure to 
systematically screen for protein modifications by peptide mass fingerprinting (PMF), 
based on post-data acquisition improvement of the mass accuracy by multipoint 
recalibration on recognized peaks. This approach offers the possibility to screen for 
post-translational modifications in any sample set, by any investigator, using any MS 
instrumentation. In our case, the K and Q modifications discovered by this approach 
had already been indicated by other independent techniques, such as the streptavidin-
biotin blot analyses [23]. Otherwise, a sound strategy may be to first screen for PTMs 
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by PMF as done here, than to verify the most interesting discoveries by peptide 
fragmentation (MS/MS) and de novo sequencing, which however is more time-
consuming. In case of cross-linked peptides, MS/MS can also turn out very complex, 
since the two peptides will fragment simultaneously. To first screen for PTMs by PMF 
as done here is obviously useful in itself. In addition, it also gives an idea of what to 
expect from an MS/MS spectrum of crosslinked peptides, which otherwise would be 
very difficult to solve.  
 
Other types of software  
To use the recalibrated data set in searching for PTMs, other types of software 
than GPMAW, which we have used here, can also be applied. The new search-engine 
Aldente at ExPASy has, in contrast to Mascot, ProFound and MS-Fit, a function for 
editing user-defined modifications similar to what we here describe for the software 
GPMAW. Mascot can do the same on an “in-house” server. When the identity of the 
protein - whose PTM status is going to be investigated - is known, it is still an important 
advantage to restrict the search only to the amino acid-sequence of this protein as can 
be done in GPMAW, or in FindMod at ExPASy. Another advantage with using the 
GPMAW program locally on the user’s own computer is that the user can store and 
build small databases of often-used sequences of the proteins under investigation. 
Moreover, PeakErazor offers the opportunity to detect and filter away also specific 
Figure 5. Crosslinking by intramolecular peptide bond formation in Hsp20. MALDI mass spectra 
recorded for Hsp20 incubated with tTG (A) and control Hsp20 without TG (B). A band, detected below 
the hexapeptide probe labeled Hsp20 (see Figure 1, Hsp20 in [23]), was investigated for a presumed 
intramolecular crosslink. A crosslinked peptide representing an intramolecular Q31-K162 isopeptide bond 
formation was detected as two peaks (marked by green arrows) appearing at 3763.0 Da (LFDQ31R 
covalently cross-linked to LPP. . .PAAK162) and 4423.32 Da (LFDQ31R covalently cross-linked to LPP. . 
.PAAK162), respectively. The peaks representing corresponding unmodified peptides decreased 
correspondingly (marked by white arrows ). 
Chapter 3 
 80
contaminants, other than keratins and trypsin, which repeatedly occur in any given 
sample-set.  
The world of PTMs is extremely complex – one protein may have several 
potential PTMs, yet under some circumstances some will not appear at all, others will. 
Especially in the beginning of the “PTMomics”/”modificomics” challenge there will be a 
need for systematic and comprehensive analyses applying multiple time-points and 
experimental conditions. New functions are continuously added to GPMAW.  
We have detected sHsp lysine and glutamine residues which become modified 
by TG crosslinking. Several other lysine and glutamine residues were detected as 
unmodified, and some were not detected at all. We can conclude that some specific 
lysine and glutamine residues are indeed substrates for TG (αB-crystallin K175, Hsp27 
K205 and Hsp20 K162, and Hsp20Q31, HspB2Q27 (crosslinking), and Hsp20Q66, 
HspB2Q75 (deamidation), but not exclude the possibility that certain other lysine and 
glutamine residues in the sHsps may be substrates also. This is due to sequence 
coverage aspects, and due to quantitative aspects. For the best characterized PTMs so 
far, phosphorylation [30-32], it has become clear that a single modification of a protein 
can be a very small fraction of the total amount of protein. The actual amount of 
modified peptide may vary depending on the conditions assayed. That PTMs vary with 
cellular status further emphasizes the need for rapid screening approaches, which can 
cope with assessment of more than one time-point. 
In order to be really useful, PTM screening should have 100 % sequence 
coverage not to “miss” the PTM. There are various ways to improve sequence 
coverage (see Hjernoe and Roepstorff 2004, in web-based “Basic techniques”, website 
address to be included). One way to reduce the suppression effects is by separating 
the individual peptides before reaching the mass spectrometer by applying LC-MALDI-
MSMS to tryptic digests of the individual proteins, to use other proteolytic enzymes 
besides trypsin, by removing impurities by microcolumns [25,33], and by sample pre-
treatment to convert lysine residues to homoarginine by O-methylisourea to enhance 
signals from lysine containing peptides [34-36] or by using matrix mixtures compared to 
the use of a single matrix [37].  
Peptide mass finger-printing can be an efficient way of screening for various 
post-translational modifications, and basically any instrumentation for mass 
spectrometry can be used provided that post-data acquisition recalibration is applied.  
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Site-specific transamidation and deamidation of the small heat 
shock protein Hsp20 by tissue transglutaminase 
 
 
 
 
 
 
Introduction 
The ubiquitously expressed tissue transglutaminase (also known as TGase2 or 
tTG) (EC 2.3.2.13) is a multifunctional enzyme mediating cell signaling, protein 
crosslinking and deamidation [1-7]. The crosslinking activity of tTG has been implicated 
in a variety of cellular processes, including cell motility [8;9], wound healing, and 
extracellular matrix remodeling, as well as differentiation and apoptosis [1;6;10;11]. In a 
two-step reaction, tTG catalyzes crosslinking by isodipeptide bond formation between 
the ε-amino group of polypeptide-bound lysines and the γ-carboxamide group of 
polypeptide-bound glutamines in a Ca2+-dependent manner [2;3;5]. A thiolester 
formation between the active site cysteine and the target glutamine initiates the 
acylation step and ammonia is released [12]. In the second rate-limiting transamidation 
step, the acyl group is transferred to the acyl acceptor amine (lysine) forming an 
isopeptide bond (also known as deacylation or crosslinking). However, in the absence 
of the lysine, deamidation at a much slower rate can also take place [12;13]. The 
substrate preference of tTG is not yet fully understood but a common notion is that tTG 
is much less selective towards lysine than to glutamine residues, and both the primary 
structure and the exposure in the conformation of a protein appear to determine 
whether glutamine and lysine residues are reactive [3;7;12-15]. 
As a result of increased transglutaminase activity, crosslinks have been found 
in pathological deposits of aggregated proteins such as amyloid in Alzheimer’s disease 
and sporadic inclusion body myositis [2;16-18]. αB-crystallin and Hsp27, two of the ten 
Crosslinking of small heat shock proteins (sHsps) by tissue 
transglutaminase (tTG) is enhanced by stress and under pathological 
conditions. We here used hexapeptide probes to determine the amine donor 
(K) and acceptor (Q) sites for tTG in Hsp20. Mass spectrometric peptide mass 
fingerprinting and peptide fragmentation established that Q31 and the C-
terminal K162 are involved in inter- and intra-molecular crosslinking 
(transamidation). Q31 is a conserved glutamine in sHsps where the 
neighboring residue determines its reactivity. Moreover, we detected highly 
efficient simultaneous deamidation of Q66, which suggests that tTG-catalyzed 
transamidation and deamidation is specific for different glutamine residues. 
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known human small heat shock proteins (sHps) [19;20] also have been identified in 
these aggregates [21-23]. Generally, sHsps are abundantly expressed in contractile 
tissues and to a lesser extent in the nervous system [19;24], where by binding to 
unfolding and aggregating proteins sHsps keep those from further aggregation [25;26]. 
The C-terminal domain, an 80–100 amino acid long conserved stretch called the α-
crystallin domain, hallmarks the sHsps [19;20]. Furthermore, sHsps have a short 
flexible C-terminal tail [27], and a less homologous and more variable N-terminal 
domain [19;20]. sHsps are also well known substrates for tTG [18;28-31]. Hsp27 
crosslinked at glutamine sites has been recently found in neurofibrillary tangles [18]. 
Hsp20 is a lysine and glutamine substrate for tTG [30], and in culture cells 
overexpressed Hsp20 forms dimers likely by the crosslinking activity of endogenous 
tTG (S.B., unpublished result). 
In this study the transglutaminase reactivity of Hsp20 was investigated by mass 
spectrometry (MS and MS/MS). Our findings indicate that the evolutionarily conserved 
glutamine Q31 and C-terminal lysine K162 are the primary targets for crosslinking, and 
that the accessibility of Q31 is determined by the adjacent amino acid residue. We also 
observed for the first time in a cellular protein that tTG simultaneously deamidates 
Hsp20 with high efficiency exclusively on Q66. Moreover, among sHsps, the 
intramolecular crosslink formation found between K162 and Q31 appears to be unique for 
Hsp20. 
 
 
Materials and methods 
Expression and purification of recombinant proteins 
For protein expression in the BL21 rosetta strain of E. coli the following 
constructs were used: pET3b-humanαB-crystallin, pET3b-humanαB-crystallinF27R, 
pET3a-humanHsp27 pET8c-ratHsp20, pET8c-ratHsp20Q31E, and pET3a-ratHspB2/B3 
(both cloned into the same vector). Purification of sHsps were performed as described 
previously [30]. 
 
Crosslinking of small heat shock proteins by tTG 
Two N-terminally biotinylated hexapeptides, biotin-GQDPVR (Q-donor) and 
biotin-GNDPVK (K-donor) (provided by Dr. J.W. Drijfhout, Leiden), were used to label 
sHsps in tTG-catalyzed crosslinking reactions. sHsps and tTG were first preincubated 
for 15 minutes at 37 °C in crosslinking reaction buffer (50 mM Tris HCl pH 7.5, 150 mM 
NaCl, 15 mM DTT and 20% glycerol). The reaction was performed in a mixture with a 
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final volume of 50 µL containing 20 µg sHsp, 1 µg probe and either no or 5 µg (2.5 × 
10-4 U/µL) guinea pig liver tTG (Sigma), and incubated for 2 hours at 37°C after adding 
CaCl2 to a final concentration of 5 mM. 
 
Cell culture and transfections 
HeLa cells were cultured in Dulbecco's modified Eagle's medium (Invitrogen) 
with penicillin and streptomycin (Roche Applied Science) and supplemented with 10% 
fetal calf serum (PAA Laboratories). For transient transfections approximately 3×105 
HeLa cells were plated and after 24 h, cells were transfected with a total of 1 µg of DNA 
per well using FuGENE6TM (Roche Molecular Biochemicals) as described by the 
manufacturer. 
 
Site-directed mutagenesis 
Mutagenesis of sHsps was performed by using the Quikchange® Site-Directed 
Mutagenesis Kit (Stratagene). In αB-crystallin, the phenylalanine at position 27 was 
mutated to arginine (forward primer: 5’-
CTTTGACCAGCGTTTCGGAGAGCACCTGTTG-3’, reverse primer 5’-
GCTCTCCGAAACGC-TGGTCAAAGAGGCGGC-3’). In Hsp20, Q31 was substituted 
with glutamate (forward primer: 5’-CCTCTTTGACAACCGTTTCGGCGAAGGGC-3’, 
reverese primer: 5’-CTTCGCCGAAACGGTTGTCAAAGAGGCGTCCC-3’). All 
mutations were verified by DNA sequencing. 
 
SDS-PAGE and Western blotting 
For detecting proteins extravidin-HRP (Sigma) or the following antibodies were 
used: anti-αB-crystallin (Riken Cell Bank), rabbit anti-Hsp20 or anti-tTG (Neomarkers). 
Samples of crosslinked sHsps or cell lysates were subjected to SDS-PAGE, 
transferred to nitrocellulose membranes (Hybond) and probed with the appropriate 
primary and secondary antibodies. Immunoreactive bands were visualized by the 
enhanced chemiluminescence (ECL) Western blotting detection kit (Pierce) reaction. 
 
Sample preparation for mass spectrometry 
After treatment with tTG as described above, samples were either separated by 
SDS-PAGE, bands excised from gel and subjected to tryptic in-gel digestion as 
described [32]. Alternatively, samples were not run on SDS-PAGE but directly 
subjected to tryptic in-solution digestion (trypsin/protein 1:50). The tryptic peptide 
mixture was loaded onto POROS R2 microcolumns [33]. After washing the 
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microcolumn-bound peptides with 0.5% TFA, samples were eluted with matrix (5 mg/ml 
alfa-cyano hydroxy cinnamic dissolved in 70% acetonitrile and 0.5% TFA) onto target 
plate. Lysine-terminated peptides were modified by O-methylisourea [34] in the 
following way: 10 µL ammonium hydroxide was added to the tryptic digest and 
vortexed, O-methylisourea was then added to a final concentration of 1.5 M and 
incubated at 65°C for 12 minutes, followed by desalting using POROS R2 
microcolumns. 
 
Mass spectrometry  
Mass spectra were recorded by MALDI-TOF mass spectrometry on a Voyager Elite 
BioSpectrometry Workstation (Perseptive Biosystems), or an Applied Biosystems 4700 
Proteomics Analyzer with TOF/TOF™ optics (Applied Biosystems), in positive reflector 
mode. MS data acquisition was performed manually and laser intensity and number of 
laser shots were varied depending on the peptide analyzed, and for selected peaks it 
was performed in automated mode (collision gas on, laser intensity 3600). Mass 
spectrum evaluation was performed using the software GPMAW and PeakErazor as 
described[35]. After multi-point recalibration of the peak mass value data set, the mass 
deviations were typically down to 10 ppm. Screening for mass deviations was 
performed using the composition calculator in the software GPMAW, for the 
biotinylated hexapeptide GQDPVR, 992.475 Da (C43H68N12O13S1), for the biotinylated 
hexapeptide GNDPVK, 950.453 Da (C42H66N10O13S1), for deamidation, + 1 Da (NH 
replaced by O), and for internal crosslinking by using the X-link function in GPMAW.  
 
Results 
 
Transamidation of a conserved glutamine Q31 and the C-terminal lysine K162 
Purified recombinant Hsp20 was crosslinked to two biotinylated peptide probes, 
providing a Q-donor (biotin-GQDPVR) and a K-donor (biotin-GNDPVK) for tTG. After 
separation by SDS-PAGE, bands with the tTG-catalyzed modifications were excised, 
digested with trypsin and subjected to a procedure developed to screen for 
modifications by mass spectrometry [36]. Modified peaks were detected, containing 
either the Q-probe crosslinked to K162 (Fig. 1A), the K-probe labeled Q31 (Fig. 1B) or an 
intramolecular crosslink formed between Q31 and K162 (Fig. 1C). Although peaks were 
small, their identities were confirmed by peptide fragmentation, as is shown for the K-
probe labeled 1628.8-Da LFDQ31R peptide (Fig. 2). 
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Deamidation of glutamine Q66 occurs in parallel with transamidation of glutamine 
Q31  
Deamidation of glutamine residues in native proteins rarely occurs because of 
the general preference of tTG to crosslinking in the presence of any accessible lysine 
substrate [5;7;37;38]. Most remarkably therefore, in the tTG-treated Hsp20 samples 
shown above, deamidated glutamine (Q66) was reproducibly detected. To further 
investigate this phenomenon, and analyze if other glutamines can also become 
deamidated, Hsp20 samples were directly subjected to in-solution tryptic digestion to 
obtain a high (≥ 85%) sequence coverage. All peptides containing glutamines were 
detected (Table I). Out of the five glutamines (Q8, Q31, Q66, Q145 and Q152), only Q31 was 
found to be crosslinked by the K-probe, and Q66 was found to be deamidated (Table 1). 
Figure 1. Hsp20 has lysine and glutamine substrate sites for tTG-catalyzed crosslinking.
Recombinant Hsp20 (20 µg) was incubated with the biotin-GNDPVK and biotin-GQDPVR probes at 2 
µM final concentration, in the absence or presence of 2.5 × 10-4 U tTG/µL. Samples were then 
separated by SDS-PAGE followed by CBB staining. The boxed bands were excised from the gels and 
subjected to tryptic digestion and subsequent MALDI-TOF analysis. (A) CBB-stained gel of biotin-
GQDPVR-labeled Hsp20 (boxed band) and mass spectrum of the Q-probe labeled Hsp20 peptides. (B) 
CBB-stained biotin-GNDPVK-labeled Hsp20 (boxed band) and the corresponding mass spectrum. (C) 
Intramolecularly crosslinked Hsp20 (boxed band) and the respective mass spectrum. Note that the 
circularized form of Hsp20 has a lower apparent molecular mass (16 kDa) than the unmodified 
monomer due to its ability to move faster in the acrylamide gel. 
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The tryptic peptide A57PSVALPTAQ66VPTDPGYFSVLLDVK81 is terminated by 
lysine, which generally gives lower mass spectrometric signals. For improvement, 
lysines were converted to homo-arginine by O-methylisourea treatment [34]. Compared 
to the control, a 1-Da mass increase was detected in the two tTG-treated Hsp20 
samples (Fig. 3A middle and lower panels). This shift results from the deamidation of 
Q66 as the -NH (15 Da) is replaced by -O- (16 Da). No peptide with Q66 in unmodified 
form was detectable after tTG treatment, suggesting that tTG catalyzes the 
deamidation of Hsp20 very efficiently. The presence of the deamidated Q66 was verified 
by the fragmentation of the peptide (Fig. 3B). Remarkably, Q66 was deamidated even at 
a 10-fold excess of K-probe, and did not become crosslinked to the K-probe (Table 1). 
Tryptic peptides Mass Hsp20 control 
Hsp20 + 
tTG 
Hsp20 + 
tTG + K-
probe 
Trypsini
zed 
Hsp20 + 
tTG + K-
probe 
Modification 
M1EIR4 548.29 - + + -  
V5PVQ8PSWLR13 1081.62 + + + +  
V5PVQ8PSWLRR14 1237.72 - + + -  
M1EIRVPVQ8PSWLR13 1610.88 + + + -  
R14 175.12 - - - -  
A15SAPLPGFSTPGR27  1257.66 - + + +  
R14ASAPLPGFSTPGR27  1413.76 + + + +  
L28FDQ31R32  678.36 + + + +  
L28FDQ31R32 - PepK  1628.81 - - + + 
Crosslinking 
with the K-
probe 
F35GEGLLEAELASLCPAAIAPYYLR56  2567.32 - + + +  
A57PSVALPTAQ66VPTDPGYFSVLLDVK81  2585.39 + - - -  
A57PSVALPTAE66VPTDPGYFSVLLDVK81  2586.39 - + + + Deamidation 
H82FSPEEISVK91  1172.59 - + + +  
V92VGDHVEVHAR102  1217.64 + + + +  
H82FSPEEISVK VVGDHVEVHAR102  2371.23 + + + -  
H103EERPDEHGFIAR115  1592.76 + + + +  
E116FHR119  588.29 - - + -  
H103EERPDEHGFIAREFHR119  2162.04 + + + -  
R120  175.12 - - - -  
Y121R122  338.18 - - - -  
E116FHRRYR122  1063.55 - + - -  
L123PPGVDPAAVTSALSPEGVLSI 
Q145ATPASAQ152ASLPSPPAAK162 
3764.01 - - - +  
Y121RLPPGVDPAAVTSALSPEGVLSI 
Q145ATPASAQ152ASLPSPPAAK162 
4083.18 + + + +  
RYRLPPGVDPAAVTSALSPEGVLSI 
Q145ATPASAQ152ASLPSPPAAK 
4239.28 + - - -  
L28FDQ31R32 – 
L123PPGVDPAAVTSALSPEGVLSIQ145 
ATPASAQ152ASLPSPPAAK162 
4424.33 - + + - Internal crosslinking 
L28FDQ31R32 – 
Y121RLPPGVDPAAVTSALSPEGVLSI 
Q145ATPASAQ152ASLPSPPAAK162 
 
4743.49 - + + - Internal crosslinking 
Sequence coverage  85 100 99 97  
Table 1. Mass spectrometric detection of glutamine residues in Hsp20. Hsp20 (20 µg) was incubate
5 µg (2.5 × 10-4 U/µL) guinea pig liver tTG and with biotin-GNDPVK-probe (ratios probe/Hsp20 0:1, 2:
subjected to in-solution tryptic digestion and subsequent MALDI-TOF analysis. At high ≥ 85% seque
residues (Q8, Q31, Q66, Q145 and Q152) were detected in unmodified or modified (deamidated or crossli
terminal Lys152) form. Glutamines indicated with an asterisk are present in the same tryptic fragment. 
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Transamidation of corresponding glutamines in related sHsps 
HspB2 and Hsp27, two other members 
of the sHsp family, are also glutamine 
donor substrates for tTG [18;30]. The 
crosslinking target Q31 in Hsp20 is 
located in an evolutionarily well 
conserved sequence motif 
RLFDQRFEGLL in the N-terminal 
domain (Fig. 4A). Although native αB-
crystallin is not a Q-substrate for tTG 
[28;30], it does harbor a glutamine 
residue in this motif, just as Hsp27 and 
HspB2 (Fig. 4A). We examined whether 
the glutamine residues present in this 
region in Hsp27 and HspB2 (Q31 and 
Q27, respectively) could be labeled with 
the K-probe. Modified peaks, although 
small, corresponding to Hsp27 peptides 
crosslinked at Q31 and Q80 were 
detected (Fig. 4B), and a peak 
corresponding to the labeled 
L24GEQR28 fragment of HspB2 was 
also detected (Fig. 4C). However, we 
found no indication of any deamidation 
in Hsp27 and HspB2 .  
 
 
The TG-reactivity of Q31 is determined by the neighboring arginine residue 
Aligning the conserved RLFDQRFEGLL motif of these four sHsps revealed that 
a basic arginine follows the accessible Q31 and Q27 residues in Hsp20 and HspB2, 
respectively (Fig. 4A). In αB-crystallin, which is not a Q-substrate for tTG [30], a 
hydrophobic phenylalanine residue flanks the glutamine in this region, and in Hsp27, 
which only labels weakly with the K-probe, an alanine neighbors the accessible 
glutamine (Fig. 4A). The TG-reactivity of this particular glutamine could therefore be 
favored by the presence of an arginine.  
Figure 2. Verification of Q31 transamidation by 
MS/MS. A: MS spectrum of Hsp20 cross-linked to 
biotin-GNDPVK probe as described in legend of Fig. 
1. B: The peptide 28LFDQR32 cross-linked to biotin-
GNDPVK with mass of 1628.8 Da was further 
fragmented and subjected to MS/MS peptide 
sequencing to confirm the identity of the cross-linked 
peptide. 
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To test the effect of this arginine 
residue on the substrate accessibility, 
we substituted in αB-crystallin the 
phenylalanine to an arginine (F27R). 
As compared to wild type αB-
crystallin, previously found to 
incorporate the Q-probe but not the K-
probe [28;30], the mutant (F27R) αB-
crystallin clearly showed Q-donor 
reactivity as its monomers were linked 
to the K-probe (Fig. 5 lane 8) and 
crosslinked into labeled dimers (Fig. 5 
lane 4), suggesting the importance of 
the adjacent arginine residue in the 
substrate recognition of the conserved 
glutamine by tTG. 
 
 
Q31 is unique for intramolecular isopeptide-bond formation 
Intermolecular isodipeptide bond formation can commonly take place between 
proteins exposing both donor and acceptor sites for tTG resulting in dimerization 
[2;3;5;7]. However, intramolecular crosslinks may also be formed within the same 
protein [30;39], as shown here for Hsp20 (Fig. 1C). Wild type Hsp20 has two reactive 
glutamines (Q31 and Q66), yet only Q31 was found to be crosslinked to K162. We tested 
the crosslinking of Hsp20 in the absence of Q31 (mutant Hsp20 Q31E). No 
intramolecular crosslink could indeed be seen in the case of mutant Hsp20 (Fig. 6A 
lane 4), but surprisingly, wild type and mutant Hsp20 exhibited similar intermolecular 
crosslinking, as both readily formed homodimers (Fig. 6A even lanes). These results 
could indicate that Q31 is essential for the circularization of wild type Hsp20 by being at 
Figure 3. Transglutaminase deamidates Hsp20 with high efficiency exclusively on Q66. A: MS 
spectra were recorded after Hsp20 was treated with 2.5 × 10-4 U/µL tTG in the presence or absence of 
2 µg biotin-GNDPVK probe. As a control, Hsp20 was incubated in crosslinking buffer containing no 
tTG. The acquired MS spectra show how the mass of the peptide A57PSVALPTAQ66VPTDPGYFS-
VLLDVK81 undergoes a 1-Da shift due to the tTG-catalyzed deamidation (–NH to –O corresponds to a 
1-Da increase), both in the presence and absence of the K-probe. To improve the mass spectrum of 
this lysine-terminated peptide, K81 was converted to homoarginine by O-methylisourea hemisulfate 
treatment, increasing the mass of the peptide (2585.39) with 42 Da to 2627.4. 
B. Peptide A57PSVALPTAE66VPTDPGYFS-VLLDVK81 was further fragmented and subjected to 
MS/MS peptide sequencing to confirm the deamidation of Q66. 
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a crosslinkable distance, i.e. in close proximity, to the C-terminal lysine (K162), while in 
the mutant, another glutamine can still serve as substrate for the intermolecular 
crosslinking.  
The presence of E31 in the 
RLFDQRFEGLL motif could affect 
the conformation of Hsp20. To test 
this possibility, we compared the in 
situ crosslinking of mutant and wild 
type Hsp20 by overexpressing both 
in HeLa cells, where the cellular 
chaperone machinery should help 
the optimal folding of proteins. Wild 
type Hsp20 was crosslinked to 
itself both inter- and 
intramolecularly (Fig. 6B left panel), 
as observed earlier [30], but in the 
case of mutant Hsp20 no 
intramolecular crosslinking and 
only reduced homodimer formation 
was observed upon tTG activation 
(Fig. 6B left panel) . Additional 
cellular proteins were not found 
linked with mutant Hsp20 either 
(Fig. 6B lane 3). All crosslinking was 
completely inhibited in the presence 
of the tTG inhibitor cystamine (Fig. 
6B right panel). These results 
suggest that in the cellular 
environment, Q31 is the major target 
for inter- and intramolecular 
crosslink formation of Hsp20 by tTG.  
 
 
Discussion 
Mammalian small heat shock proteins are substrates for transglutaminase 
[14;18;29;31]. At least five human sHsps (Hsp27, Hsp20, HspB2, HspB8 [30] and 
cvHsp (Boros, S. unpublished observation)) expose glutamine residues for tTG-
Figure 4. The conserved Q31 is also transamidated 
in Hsp27 and HspB2. A: Alignment of the conserved 
RLFDQXGEGLL sequence motif in the N-terminal 
domain of Hsp20, HspB2, αB-crystallin and Hsp27. 
B: MS-spectra of Hsp27 were recorded after 
incubation with tTG and the biotin-GNDPVK probe. 
Inset: Peaks with masses of 2026.0 and 2114.0 Da 
correspond to the Q80LSSGVSEIR89 and the 
L28FDQAFGLPR37 fragments, respectively, 
crosslinked with the K-probe. C: MS spectrum of the 
K-probe labeled HspB2 containing a mass peak 
(1552.7 Da) matching a small fragment of the N-
domain L24GEQR28 crosslinked to the K-donor probe.
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catalyzed crosslinking. We here investigated the substrate site specificity of 
transglutaminase in Hsp20 and found Q31 and K162 as prime targets for tTG-catalyzed 
crosslinking (Fig. 1), of which K162 is in terminal position in the flexing tail of the protein 
[40] (Fig. 4A). Similar to Hsp20, the C-terminal lysine has been shown to be the only 
available lysine for tTG in both αB-crystallin and Hsp27 [28;29]. This clearly suggests 
that these lysines, if present, are commonly accessible for transglutaminase in sHsps.  
Q31, the target glutamine for 
crosslinking in Hsp20 is located in a 
conserved sequence motif 
RLFDQXGEGLL (Fig. 4A). This part of 
the N-terminal domain is evolutionarily 
well conserved throughout the sHsp 
family (Fig. 4A), and harbors a 
reactive Q also in Hsp27 and HspB2 
(Fig. 4B and C). Noteworthy is that a 
glutamine in this region is also 
present in the non glutamine-
substrate αB-crystallin (Figure 4A) 
[15;28;30]. However, the residue 
flanking these homologous 
glutamines varies as basic arginines 
follow the Q in Hsp20 and HspB2, 
and a hydrophobic phenylalanine is 
the adjacent residue in αB-crystallin (Fig. 4A). When the phenylalanine was replaced 
by an arginine (F27→R), αB-crystallin became a Q-donor substrate for tTG (Fig. 5), 
suggesting that the reactivity of Q31 is influenced by its C-terminally neighboring 
residue. Although positively charged residues flanking a given glutamine in unfolded 
proteins have been suggested to diminish the transglutaminase reaction [7], a 
glutamine protruding from a compactly folded domain is more likely to become a 
substrate than others deeply embedded in hidden pockets[7]. The amphipathic 
RLFDQXGEGLL sequence largely determines the structural stability and functionality 
of α-crystallins [41]. It is possible appears that Q31 emerges better from the domain 
structure if followed by an arginine, and the hydrophilic character of this motif becomes 
more dominant, giving tTG better access to the glutamine. 
 
 
Figure 5. The substrate property of Q26 in αB-
crystallin is affected by the C-terminally 
neighboring residue. In αB-crystallin, the 
phenylalanine at position 27 was substituted to an 
arginine (F27R). Wild type and mutant αB-crystallin 
(20 µg) was subjected to tTG-catalyzed labeling
reaction in the presence of 2 µg of biotin-GNDPVK or 
GQDPVR. Each reaction mixture was separated by 
SDS-PAGE and subsequently electroblotted or CBB-
stained. Blots were probed with extravidin-conjugated 
HRP and visualized by ECL reaction. 
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We observed the unique intramolecular crosslinking of Q31 and K162 in Hsp20 
(Fig. 1 and 6). In the Q31-lacking mutant Hsp20 (Q31→E) no intramolecular crosslinks 
could be formed and the homodimer formation was also reduced (Fig. 6A and B). This 
suggests that intramolecular bonds can form solely between Q31 and K162. An acidic 
glutamate in this position could induce conformational changes and therefore a limited 
crosslinking of Hsp20 dimers might still take place through another Q, perhaps Q66. In 
HeLa cells, tTG also could not crosslink the mutant Hsp20 to a small unknown 
endogenous (probably K-donor) protein which is seen with the wild type (Fig. 6B). This 
further supports that Q31 is the primary target glutamine for tTG-catalyzed crosslinking 
in situ. Stress and pathological conditions such as UV irradiation or Alzheimer’s 
disease induce tTG-catalyzed crosslinking of sHsps [18;31]. The in situ tTG-reactivity 
of Hsp20 (Boros et al., submitted for publication), its presence in Alzheimer’s brains 
together with the readiness to crosslink with amyloid-β in vitro [30] all point towards the 
physiological and pathological importance of Hsp20 crosslinking. 
Figure 6. Q31 is a unique site for tTG-catalyzed intramolecular crosslink formation in Hsp20. A:
20 µg of recombinant wild type or mutant (Q31E) Hsp20 was incubated either in the absence or 
presence of 5 µg tTG in crosslinking buffer containing 15 mM DTT. Unmodified monomers are 
indicated with an arrowhead (►), crosslinked homodimers and intramolecular crosslinks are indicated 
with arrows and (♦), respectively. B: HeLa cells were transiently transfected with pIRES-Hsp20-WT or 
pIRES-Hsp20-Q31E. 24 hours after transfection cells were treated with either 2 µM A23187 (Ca2+-
ionophore) to activate tTG or 150 µM cystamine to inhibit tTG. Cell lysates were separated by SDS-
PAGE and subsequently stained with anti-tTG antibody (upper panels) or anti-Hsp20 antibody (lower 
panels). Crosslinked homodimers and intramolecularly crosslinked Hsp20 are indicated by arrow and 
closed diamond (♦), respectively. The open diamond (◊) indicates wild type Hsp20 crosslinked to a 
small unknown endogenous cellular polypeptide with a mass of approximately 5 kDa. 
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A proline residue at position +2 relative to the targeted glutamine has been 
described to positively influence the tTG-catalyzed reactions [37]. Here, under 
crosslinking condition (pH 7.5) and even at a ~10-fold K-probe excess (Table 1), tTG 
deamidated Hsp20 exclusively on Q66, which also is present in a QxP motif (Fig. 3). In 
gliadin, glutamines are also deamidated (and crosslinked) by tTG in the presence of 
primary amines [42;43], but in a rather acidic environment where deamidation is 
preferred over crosslinking [37;38]. It has also been speculated that transamidation and 
deamidation may be effected by distinctly different transglutaminases [38]. However, in 
the case of Hsp20 it appears that the same transglutaminase, tTG, catalyzes the 
transamidation and deamidation of distinct glutamines, Q31 and Q66, respectively. Since 
Hsp20 Q66 lies in a QxP motif, this sequence may be crucial for deamidation also in 
folded proteins.  
The terminal K162 of the highly flexible C-terminal tail [40] and Q31 protruding 
from the N-terminal domain must be in “crosslinkable distance” and thus readily 
crosslink both intra- and inter-molecularly. The structure determined for wheat Hsp16.9 
[44] shows that the C-terminus is indeed in close proximity to the region corresponding 
to Hsp20 Q31.  
The Q and K residues in substrate proteins are thought to approach the tTG 
active site differently, the Q approaching in the direction of the two β -barrels of the 
enzyme, while the K emerges from the active site guided by the His342–Asn343 pair [5]. 
The sole deamidation of Q66 might therefore be due to steric hindrance as Hsp20 
blocks the way of the lysine to the catalytic center after the thiolester bond is formed 
between Q66 and the active site C277. However, further studies are required to 
understand why Q66 can only be deamidated and not transamidated. 
In conclusion, Hsp20 has differential substrate site exposure for crosslinking 
and deamidation catalyzed by tTG, of which K162 and Q31 seem to be conserved in the 
sHsp family and the tTG-reactivity of Q31 is affected by its C-terminal neighbor. The 
exact structural properties of Hsp20 which allow the simultaneous formation of 
intramolecular crosslinks and deamidation are yet to be determined. 
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The small heat shock protein Hsp20 is a novel cellular 
substrate of tissue transglutaminase 
 
 
Introduction 
Transglutaminases (TGs) are Ca2+-dependent enzymes catalyzing the 
formation of isodipeptide bonds between the γ-carboxamide group of polypeptide-
bound glutamines and the ε-amino group of polypeptide-bound lysines [1-4]. The 
ubiquitously expressed tissue type transglutaminase (tTG, TG2 or TGase2) is a 
multifunctional GTP-binding protein which mediates cell signaling, transamidation and 
deamidation [1-3]. The crosslinking (transamidation) activity of tTG has been implicated 
in a variety of cellular processes, including cell adhesion and migration [5;6], wound 
healing, bone ossification and extracellular matrix remodeling, as well as differentiation 
and apoptosis [7-9]. Importantly, aberrant tTG activity is associated with a number of 
protein aggregation disorders including Alzheimer’s disease, Huntington’s disease and 
sporadic inclusion body myositis [1;10-13]. As a result of increased tTG activity, large 
amounts of isopeptide crosslinks have been found in pathological deposits of 
aggregated proteins [11;12]. 
As an interesting pathological overlap, small heat shock proteins (sHsps), 
namely Hsp20 and Hsp27, have also been found in these accumulations [14-16]. 
Moreover, recent evidence suggests the presence of crosslinked Hsp27 in Alzheimer’s 
brain [13]. In human, ten sHsps have been identified [17;18], which generally form 
large and heterogeneous complexes that readily exchange subunits [19;20]. Most 
sHsps are abundantly expressed in contractile tissues and to a lesser extent in the 
nervous system, kidney and skin [17;18]. The best known property of sHsps – as 
Tissue transglutaminase (tTG) is a multifunctional enzyme catalyzing 
Ca2+-dependent crosslink formation between glutamine and lysine residues. 
Hsp20 and other human small heat shock proteins (sHsps) are in vitro
substrates for tTG, and their tTG-mediated crosslinking have been implicated 
in neurodegenerative disorders such as Alzheimer’s disease. In the present 
study, the tTG-reactivity of five sHsps was investigated in transiently 
overexpressing cells. We here report Hsp20 as a novel cellular substrate for 
transglutaminase. The crosslinking of Hsp20 is phosphorylation-dependent 
and was affected by its macromolecular associations with αB-crystallin and 
Hsp27. Moreover, in complex with Hsp20, both αB-crystallin and Hsp27 also 
became prone to tTG-catalyzed crosslinking. These results suggest an 
important role for Hsp20 in the tTG-catalyzed crosslinking of sHsps under 
normal and pathological conditions. 
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components of the cellular chaperone machinery – is their binding to unfolding or 
aggregating proteins to keep those from further aggregation [21;22]. sHsps also hold 
more specific functions, such as the inhibition of apoptosis [23-25], and stabilizing 
associations with different cytoskeletal components during normal as well as stress 
conditions [26;27]. 
 Human Hsp20 (also known as HspB6 [18]) is of special interest because of its 
unique regulatory role in cardiovascular functions, associated with phosphorylation-
dependent changes in its macromolecular assembly [28-32]. Deviating from other 
sHsps, Hsp20 contains a PKA/PKG consensus phosphorylation site RRAS16 [33] and 
an additional phosphorylatable serine has also been identified at position 157 [34;35]. 
cGMP-dependent phosphorylation of Hsp20 as well as transduction of its biologically 
active phosphopeptide analogs both lead to vascular smooth muscle relaxation 
[29;36;37]. In addition, phosphorylation of Hsp20 appears as an important factor in the 
protection from apoptosis induced by ischemia/reperfusion injury in transgenic mice 
with cardiac-specific overexpression of Hsp20 [32;38]. Interestingly, adenoviral gene 
transfer of Hsp20 is associated with significant increases in Ca2+-transient peaks and 
contractility in adult rat cardiomyocytes [31].  
We recently found that Hsp20, as well as four additional members of the small 
heat shock protein family (αB-crystallin, Hsp27, HspB2 and HspB8) can serve as 
lysine- and/or glutamine-donor substrates for tTG in vitro [39]. In the present study we 
identify Hsp20 as a new cellular substrate for tTG-catalyzed reactions. The efficiency of 
Hsp20 crosslinking is influenced by mimicking its phosphorylation and by other sHsps 
associating with Hsp20. The results provide a new perspective for understanding the 
involvement of sHsps and tTG in protein aggregation disorders. 
 
 
Materials & methods 
 
Cells and tissue culture 
HeLa cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM, 
Invitrogen) with penicillin and streptomycin (Roche Applied Science) and supplemented 
with 10% fetal calf serum (PAA Laboratories). 3T3-TG3 cells overexpressing tTG under 
the control of a tetracycline (doxycycline)-regulated promoter (Tet-Off) were grown in 
DMEM supplemented with 15 µg/mL hypoxanthine, 2 µg/mL aminopterin, 10 µg/mL 
thymidine (HAT medium, Sigma Aldrich), 250 µg/mL xanthine (Sigma Aldrich), 10 
µg/mL mycophenolic acid (Gibbco BRL), 400 µg/mL active G418 and 2µg/mL 
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doxycycline [40]. To promote tTG expression, cells were cultured in doxycycline-free 
medium. Where indicated, cells were incubated in culture medium containing 1 µM 
Ca2+-ionophore A23187 (Sigma) or 150 µM cystamine (Sigma). 
 
In vitro transamidation  
Two N-terminally biotinylated hexapeptides, biotin-GQDPVR (Q-donor) and 
biotin-GNDPVK (K-donor) (provided by Dr. J.W. Drijfhout, Leiden), were used as 
probes to detect tTG-catalyzed crosslinking [41]. Purified recombinant Hsp20 and its 
mutant Hsp20S16E were first preincubated in the absence or presence of tTG for 15 
minutes at 37 °C in crosslinking reaction buffer (50 mM Tris HCl pH 7.5, 150 mM NaCl, 
15 mM DTT and 20% glycerol) [39]. The crosslinking reaction was performed in a 
mixture with a final volume of 50 µL containing 20 µg sHsp, 1 µg biotinylated probe and 
either no or 5 µg (2.5 × 10-4 U/µL) guinea pig liver tTG (Sigma), and incubated for 2 
hours at 37 °C after adding CaCl2 to a final concentration of 5 mM. Samples were 
analyzed by SDS-PAGE followed by electro-blotting and stained with Extravidin-
peroxidase conjugate (Sigma) or the appropriate antibodies (see below). 
Immunoreactive bands were visualized as described below (see Electrophoresis and 
Western blot analysis). 
 
Plasmids 
The coding region of wild type αB-crystallin, Hsp27, HspB2, HspB3 and Hsp20 
were cloned separately into the polylinker region of the expression vector pIRES 
(Clontech). Mutations of serine at position 16 in Hsp20 were introduced by site-directed 
mutagenesis according to the manufacturer’s manual (Stratagene). 
 
Transfections 
Approximately 3×105 HeLa cells or 4.5×105 3T3-TG3 cells were plated in 6-well 
plates in DMEM with penicillin, streptomycin, and 10% fetal calf serum, or in DMEM 
supplemented with HAT, xanthine, mycophenolic acid, G418 and 2 µg/mL doxycycline 
[40], respectively. To induce tTG expression, cells were cultured in doxycycline-free 
medium for 24 hours prior to transfection. After 24 hours, HeLa cells were transfected 
with a total of 1 µg of DNA per well (unless indicated otherwise) using FuGENE6TM 
(Roche Molecular Biochemicals), and 3T3-TG3 cells were transfected with 
Lipofectamine PlusTM (Invitrogen) as described by the manufacturers.  
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Detergent solubility 
Cells were harvested by scraping and subsequent centrifugation at 1000 rpm 
for 5 min. After washing once with medium and twice with phosphate-buffered saline, 
cells were resuspended in ice-cold lysis buffer (10 mM Tris pH 7.5, 100 mM KCl, 1 mM 
dithiothreitol, 1 mM EDTA, 5 mM MgCl2, Complete Protease Cocktail (Boehringer) and 
0.5% Nonidet P-40), and lysates were centrifuged at 3000 rpm for 15 min at 4 °C. The 
supernatant containing the detergent-soluble proteins was collected, and the pellet 
containing the detergent-insoluble proteins was obtained after washing once with lysis 
buffer. 
 
Electrophoresis and Western blot analysis 
SDS-PAGE was performed in reducing environment according to standard 
procedures. Proteins were transferred to nitrocellulose membranes (Amersham Biotech 
or Schleicher & Schüll) by electroblotting for Western blot analysis. The membranes 
were incubated successively with primary antibodies (mouse monoclonal anti-αB-
crystallin (Riken Cell Bank), anti-Hsp27 (Stressgen), anti-transglutaminase CUB7402 
(Neomarkers), rabbit polyclonal anti-Hsp20, anti-Hsp25, anti-HspB2 and anti-HspB3) 
and finally with the appropriate horseradish peroxidase-conjugated secondary 
antibodies (Dako Corp.). Immunoreactive bands were visualized by the enhanced 
chemiluminescence (ECL) Western blotting detection kit (Pierce). 
 
 
Results 
Hsp20 is the key substrate of tissue transglutaminase within the sHsp family 
We have recently reported that several sHsps (Hsp20, Hsp27, αB-crystallin and 
HspB2, but not HspB3) are substrates for tTG in vitro [39]. To identify sHsps as cellular 
substrates of tTG, we now transiently overexpressed them in HeLa cells. Crosslinked 
proteins are often observed in insoluble materials; cell extracts were therefore 
separated into detergent-soluble and -insoluble fractions. Hsp27 is the only 
endogenously expressed sHsp in HeLa cells (Fig 1B, lanes 1 and 2). Transiently 
transfected sHsps were highly expressed and equally distributed between the 
detergent-soluble and -insoluble fractions (Fig 1, lanes 3 and 4), apart from HspB3 
which solely localized in the detergent-insoluble fraction (Fig 1E, lane 3).  
Endogenous tTG is abundantly present in the detergent-soluble fraction of 
HeLa cells (Fig 1, lanes 2, 4 and 6), but the intracellular Ca2+ concentration will be too 
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Figure 1. Hsp20 is a cellular substrate for tTG. HeLa cells were transiently transfected with 1 µg of 
DNA encoding either αB-crystallin, Hsp27, Hsp20, HspB2 or HspB3 (A-E, respectively). 24 hours after 
transfection cells were challenged with 1 µM Ca2+-ionophore A23187 for 24 hours and subjected to 
subcellular fractionation (see Material and Methods). The insoluble pellet (p) and soluble fraction (s) 
were separated by SDS-PAGE and subsequently electroblotted and stained with the specific anti-sHsp 
(upper panels) and anti-tTG (lower panels) antibodies. Lanes 1 and 2, untransfected control cells; 
lanes 3 and 4, transfected cells; lanes 5 and 6, transfected cells incubated with ionophore. W, Hsp20 
homodimer; Y larger sHsp oligomers ; intramolecularly crosslinked Hsp20; ¹, monomeric sHsps.  
low to induce the transamidation activity of tTG. We therefore used the Ca2+-ionophore 
A23187 to activate the TG-catalyzed crosslinking of sHsps (Fig 1, lanes 5 and 6). In 
contrast to the in vitro findings [39], out of the five sHsps, only Hsp20 was found to be 
readily crosslinked by tTG (Fig 1C). Surprisingly, the ectopic overexpression of Hsp20 
alone, without incubation with ionophore, already resulted in similar dimerization (Fig 
1C, lanes 3 and 4; black arrowhead) as well as in the formation of high molecular 
weight aggregates. The Hsp20 migrating below the monomer (open diamond) is 
probably intramolecularly crosslinked Hsp20 as determined by previous mass 
spectrometry analysis [42]. These observations suggest that overexpressed Hsp20 is a 
cellular substrate for tTG. 
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Hsp20 stimulates its own crosslinking by tissue transglutaminase  
To confirm the tTG-catalyzed crosslinking of Hsp20, this sHsp was transiently 
transfected into 3T3-TG3 mouse fibroblasts expressing human tTG under an inducible 
promoter [40]. Upon induction, these cells express highly increased amounts of tTG in 
the detergent soluble fraction (Fig 2B, upper panel). In 3T3-TG3 cells no endogenous 
Hsp20 was detected (Fig 2, lower panels, lanes 1 and 2), and after transient 
overexpression we observed Hsp20 in both pellet and soluble fraction (Fig 2A and B, 
lower panels, lanes 3 and 4). In cells induced to express tTG, the intermolecularly and 
intramolecularly crosslinked Hsp20 was detected (Fig 2B, lower panel, lane 4; black 
arrowhead and diamond), but not in the presence of the tTG-inhibitor cystamine (Fig 
2B, lower panel, lanes 5 and 6). This demonstrates that Hsp20 can be crosslinked by 
tTG without artificially increasing the intracellular free Ca2+ concentration. In the 
presence of ionophore the homodimer and intramolecularly crosslinked Hsp20 became 
more prominent (Fig 2A, lanes 7 and 8), which could be significantly inhibited again by 
cystamine (Fig 2B, lanes 9 and 10).  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Hsp20 induces its own crosslinking by tissue transglutaminase. 3T3-TG3 cells were 
transiently transfected with 1 µg of pIRES-Hsp20 DNA either in the presence (A) or absence (B) of 
doxycycline (Dox) to suppress or induce tTG expression, respectively. 24 hours after transfection cells 
were challenged with 1 µM A23187 either in the presence or absence of 150 µgM cystamine for 24 
hours, and subjected to subcellular fractionation. The insoluble pellet (p) and soluble fraction (s) were 
separated by SDS-PAGE and subsequently electroblotted and stained with anti-Hsp20 (lower panels) 
and anti-tTG (upper panels) antibodies. The traces of tTG in the presence of doxycycline (A, upper 
panel) are due to leakage of the Tet-Off system; the parental 3T3 cells express no detectable tTG 
(data not shown). W, Hsp20 homodimers; , intramolecularly crosslinked Hsp20; ¹ Hsp20 monomer. 
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αB-crystallin and Hsp27 associated with Hsp20 become substrates for tTG  
The tTG-catalyzed crosslinking of different sHsps in vitro is facilitated by their 
mixed complex formation [39]. To assess the effects of in situ sHsp interactions, we co-
expressed Hsp20 with αB-crystallin or Hsp27 (0.5 µg DNA each) in HeLa cells. In the 
presence of αB-crystallin, the formation of Hsp20 dimers was much less pronounced 
(Fig 3A, lanes 5 and 6) than in cells only expressing Hsp20 (lanes 3 and 4), and no 
high molecular weight oligomers were detected. Very similar results were obtained 
when Hsp27 was co-transfected with Hsp20 (Fig 3B, lanes 3 - 6). 
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Figure 3. αB-crystallin and Hsp27 diminish the tTG-catalyzed crosslinking of Hsp20. (A) HeLa 
cells were transfected with pIRES-Hsp20 DNA, pIRES-αB-crystallin DNA or equal amounts (0.5 µg 
each) of both. 24 hours after transfection some cell cultures were treated with 2 µM A23187 (Ca2+-
ionophore) or 150 µM cystamine. 48 hours after transfection, cells were subjected to subcellular 
fractionation and the detergent insoluble (p) and soluble (s) fractions were separated on SDS-PAGE 
and subsequently electroblotted and stained with anti-Hsp20 antibody. (B) HeLa cells were transfected 
with pIRES-Hsp20 DNA, pIRES-Hsp27 DNA or equal amounts (0.5 µg each) of both. Further legends 
as for A. (C) HeLa cells were transiently co-transfected with 0.5 µg of pIRES-αB-crystallin DNA and 
increasing concentrations (0 to 2 µg) of pIRES-Hsp20 DNA. 48 hours after transfection cells were lysed 
and 20 µg of total cell extract was subjected to SDS-PAGE and subsequent Western blot analysis with 
anti-Hsp20 and anti-αB-crystallin antibodies. (D) HeLa cells were transiently co-transfected with 0.5 µg 
of pIRES-Hsp20 DNA and increasing concentrations (0 to 2 µg) of pIRES-αB-crystallin DNA. Further 
legends as for C. W, Hsp20 homodimer; W, sHsp heterodimers; Y larger sHsp oligomers; , 
intramolecularly crosslinked Hsp20; ¹, monomeric sHsps.  
Chapter 5 
 112
 The decreased crosslinking when Hsp20 is present together with αB-crystallin 
or Hsp27 indicates that the other sHsps reduce the ability of Hsp20 to be crosslinked 
by tTG. This reduced crosslinking is restored by the addition of Ca2+-ionophore, and 
abolished by cystamine (Figs 3A and B, lanes 9 and 10, and lanes 11 and 12, 
respectively). Although the presence of αB-crystallin or Hsp27 in heteromeric 
associations with Hsp20 reduces the latter’s crosslinking, it does enable the 
crosslinking of αB-crystallin and Hsp27 to Hsp20 (gray arrowheads in Fig 3A and B), 
while αB-crystallin and Hsp27 in their homomeric forms show no crosslinking (Fig 1A 
and B).  
sHsps generally occur as heteromeric and dynamic complexes [20;43]. 
Different sHsp subunit ratios in mixed complexes might modulate the reactivity of 
Hsp20 as a tTG substrate. We therefore transfected αB-crystallin and Hsp20 in 
different ratios into HeLa cells. At constant αB-crystallin and increasing Hsp20 levels a 
corresponding rise of Hsp20 crosslinking was observed, both as homodimers and 
intramolecularly circularized, as well as in Hsp20-αB-crystallin heterodimers. The 
observed increase in homodimer formation was relatively much stronger than the 
increase in heterodimer formation at the highest (2 µg) Hsp20 DNA concentration, 
which might be due to the exceeded heteromerization capacity of αB-crystallin (Fig 3, 
panel C). In the reciprocal experiment, increasing αB-crystallin at a constant Hsp20 
level, we observed a drastic decrease in homodimerization and intramolecular 
crosslinking (Fig 3, panel D). The Hsp20-αB-crystallin heterodimer formation also 
decreased in the presence of increasing amounts of αB-crystallin. These results 
indicate that sHsps that can readily exchange subunits with Hsp20 complexes, strongly 
inhibit the tTG-reactivity of Hsp20 by engaging the Hsp20 subunits in mixed 
associations.  
 
Mimicking phosphorylation reduces the crosslinking of Hsp20 
Since phosphorylation of Ser-16 is an important modulator of the biological 
activity of Hsp20 [28;29;31;32;44], we examined the in situ crosslinkability of the 
unphosphorylatable Hsp20 S16A and the phosphomimicking Hsp20 S16E mutants. The 
mutants showed similar detergent solubility as the wild type Hsp20, but displayed 
striking differences in crosslinkability (Fig 4A and B). Whereas Hsp20 S16E showed no 
detectable crosslinking (Fig 4B, lanes 1 to 4), the unphosphorylatable mutant Hsp20 
S16A had a considerable increase in homodimer and oligomer formation as compared 
to wild type Hsp20 (Fig 4B, lanes 5 and 6). The crosslinking of Hsp20 S16A could not 
be inhibited completely by cystamine (Fig 4A, lanes 7 and 8).  
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The lack of in situ crosslinking of Hsp20 S16E might indicate that the introduced 
negative charge alters the substrate properties of Hsp20. To assess the latter 
possibility, we performed in vitro crosslinking and labeling studies on recombinant 
Hsp20 and Hsp20 S16E. In line with our previous findings [39], both biotinylated Lys- 
and Gln-donor probes labeled the Hsp20 monomers and dimers in the presence of tTG 
(Fig 4C, lanes 2 and 4). Similar to the wild type, a strong labeling and concomitant 
dimer formation was found for 
Hsp20 S16E (Fig 4C, lanes 6 
and 8), demonstrating that the 
substrate properties are 
unaffected. Pseudo-
phosphorylation thus reduces 
the crosslinkability of Hsp20 in 
situ but not in vitro, while 
unphosphorylatability 
increases the crosslinking, 
suggesting that in situ 
phosphorylation of Hsp20 may 
diminish either the activity of 
tTG or the accessibility of 
Hsp20 for tTG. 
Phosphorylation of 
Hsp25 - the Hsp27 ortholog in 
rodents - has been shown to 
inhibit the phosphorylation of 
Hsp20 in vitro [44], and thus 
would be expected to maintain 
the tTG-activating capacity of 
Hsp20. We therefore co-
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Figure 4. Mimicking phosphorylation alters the tTG-catalyzed crosslinking of Hsp20. (A and B) 
HeLa cells were either non-transfected (ctrl) or transiently transfected with wild type Hsp20, Hsp20 
S16E or Hsp20S16A and 24 hours after transfection treated or not with 150 µM cystamine. After 
subcellular fractionation, lysates were separated on SDS-PAGE and subsequently electroblotted and 
stained with anti-Hsp20 antibodies. (C) 20 µg of recombinant wild type Hsp20 and Hsp20S16E were 
incubated with the biotin-GNDPVK and biotin-GQDPVR probes at 2 µM final concentration, in the 
absence or presence of 2.5× 10-4 U tTG/µL. Samples were then analyzed by SDS-PAGE followed by 
biotin blotting. (D) HeLa cells were co-transfected with 0.5 µg of pIRES-Hsp20 and increasing 
concentrations (1, 1.5 and 2 µg) of pIRES-Hsp25EE (pseudophosphorylated Hsp25 S15,90E) or pIRES-
Hsp25AA DNA (unphosphorylatable Hsp25 S15,90A). 48 hours after transfection cells were lysed and 20 
µg of total cell extract was subjected to SDS-PAGE and subsequent Western blot analysis with anti-
Hsp20 and anti-Hsp25 antibodies. W, Hsp20 homodimer; W, sHsp heterodimers; Y, larger sHsp 
oligomers; , intramolecularly crosslinked Hsp20; ¹, monomeric sHsps; open asterisk, monomeric 
recombinant Hsp20.  
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transfected cells with Hsp20 and either pseudo-phosphorylated (S15,90E) or 
unphosphorylatable (S15,90A) Hsp25 (Fig 4C). In agreement with expectation, it 
appeared that in the presence of increasing amounts of pseudophosphorylated Hsp25 
the crosslinking of Hsp20 became more efficient, suggesting that its crosslinkability 
was better maintained, while crosslinking decreased in the presence of the 
unphosphorylatable Hsp25. 
 
 
Discussion 
Among the five studied human sHsps, overexpressed in HeLa cells, Hsp20 is 
the only one that became crosslinked by endogenous transglutaminase (Fig 1). 
Transfected Hsp20 was also found to be crosslinked upon induction of tTG in 3T3-TG3 
mouse fibroblasts (Fig 2). Most interesting, though, is the fact that in both cases 
crosslinking of Hsp20 could already be observed without increasing the intracellular 
calcium concentration with the ionophore A23187 (Fig 1C and Fig 2B). The mechanism 
by which tTG can become active and crosslink Hsp20 remains elusive. Since tTG is a 
Ca2+-dependent enzyme, it is possible that Hsp20 can activate tTG by locally 
increasing the intracellular Ca2+ levels, leading to its own crosslinking. Attempts to 
detect any changes in intracellular Ca2+ levels upon Hsp20 overexpression, by using a 
ratiometric Ca2+-binding fluorescent dye, were unsuccessful (data not shown). This 
may be due to the fact that the cell has a strong capacity to keep the cytoplasmic Ca2+-
concentration at a fixed level. However, adenoviral gene transfer of Hsp20 into rat 
cardiac myocytes is associated with a significant increase in contractility and Ca2+-
transients upon electric stimulation [31], and the N-terminal domain of Hsp20 has been 
speculated to be important in cellular Ca2+-handling [45], which supports the suggestion 
of the Ca2+-mediated activation of tTG by Hsp20. The crosslinking activity of tTG is 
supposed to be latent in the normal intracellular environment, only becoming active 
under terminal conditions such as apoptosis or necrosis [46]. However, cells treated 
with the muscarinic receptor agonist carbachol showed a physiological transient 
increase in intracellular calcium concentrations from ~100 nM to ~450 nM, and 
significant activation of tTG [47]. This indicates that mild physiological stimuli may lead 
to a moderate Ca2+-increase and tTG activation, and may apply for Hsp20 as well. 
However, other mechanisms by which Hsp20 could influence the activity of tTG are 
also possible. 
Oxidative stress and UV irradiation have recently been shown to induce tTG-
catalyzed crosslinking of αB-crystallin [48], and under pathological conditions such as 
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Alzheimer’s disease Hsp27 crosslinked with parkin and ubiquitin has been identified 
[13].  Interestingly, we could not detect any crosslinking of these two sHsps if 
overexpressed alone, i.e. without Hsp20 (Fig 1A and B), but in the presence of Hsp20 
both αB-crystallin and Hsp27 became involved in tTG-mediated crosslinking (Fig 3). 
Thus the crosslinking of Hsp27 under pathological conditions and αB-crystallin by 
stress might be mediated by Hsp20. More importantly, αB-crystallin and Hsp27 
displayed an inhibitory effect on the crosslinking of Hsp20 (Fig 3A and B). These 
results indicate that the substrate properties of both sHsps in homomeric assemblies 
are different from those in mixed complexes with Hsp20. Both αB-crystallin and Hsp27 
can form hetero-oligomeric complexes with Hsp20 if expressed together [33;43]. If 
Hsp20 could indeed interfere with the Ca2+-homeostasis large amounts of Hsp20 in 
homomeric assemblies may be harmful to cells, and thus resemble a stress-like 
condition. Hsp27 and αB-crystallin might moderate this property of Hsp20 by forming 
mixed associations. Northern blot analysis has indeed revealed that tissues expressing 
Hsp20 also express Hsp27 and/or αB-crystallin in higher quantities [49]. 
Phosphorylation is known to affect the properties of Hsp20. Upon 
phosphorylation, macromolecular associations of Hsp20 dissociate into smaller 
complexes which have a different subcellular localization [28]. Such changes might 
affect the TG-substrate property of Hsp20. However, the phosphorylation of Hsp20 
could also have an influence on its Ca2+-handling, altering the activity of tTG. It has 
been shown that phosphorylated Hsp20 protects against apoptosis in situ [38], and a 
phosphopeptide analogue of Hsp20 has been shown to bind the anti-apoptotic 14-3-3 
proteins [50]. 14-3-3 has been shown to prevent dephosphorylation of a number of 
proteins [51;52]. In case of Hsp20, binding to 14-3-3 might thus prolong the 
phosphorylated state of Hsp20 and under certain conditions prevent the activation of 
tTG.  
The current knowledge about the cellular function of Hsp20 is limited, especially 
in relation to tTG. Since Hsp20 has been suggested to play a role in organizing the 
cytoskeleton [28;53;54], the crosslinking is likely to influence its binding capacity to the 
cytoskeleton or preventing stress-induced aggregation of proteins. Crosslinked α-
crystallin has been shown have reduced chaperone-like activity [55], thus similar effect 
of crosslinking in case of Hsp20 can also be expected. Interestingly, crosslinking 
Hsp20 into large oligomers did not change its detergent solubility (Fig 1C and Fig 3A 
and B), suggesting that crosslinking may not stimulate the formation of insoluble 
aggregates. In addition, recent studies have suggested that tTG-catalyzed crosslinking 
decreases the ability of diseases proteins to aggregate [56-58]. Based on these 
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findings, it could be speculated that tTG could catalyze the formation of large but 
soluble complexes by crosslinking Hsp20 to its cellular substrates and prevent the 
formation of insoluble aggregates. This way crosslinking could facilitate the elimination 
of unwanted proteins however, further studies are required to understand the role of 
the tTG-catalyzed crosslinking of Hsp20. 
In summary, Hsp20 is a new cellular substrate for tTG under physiological 
conditions, exposing both lysine and glutamine residues. This property of Hsp20 is 
likely to be influenced by phosphorylation and by interaction with other sHsps. The 
mechanism by which tTG is activated to allow crosslinking of Hsp20 has yet to be 
determined. 
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Tissue transglutaminase (tTG) is a Ca2+-dependent enzyme catalyzing 
the formation of covalent crosslinks between peptide-bound glutamine and 
lysine residues. Lens crystallins, including αB-crystallin and several β-
crystallins, are in vitro substrates for tTG. In both human and bovine fetal lens 
extracts treated with tTG we detected the formation of high molecular weight 
(HMW) aggregates containing crosslinked βB2- and βA3-crystallin. In addition, 
2D-gel electrophoresis combined with mass spectrometry analysis revealed 
that glutamines present in the N-terminal arms of βB2- and βB3-crystallins 
deamidate readily in the presence of tTG. We found that both tTG-catalyzed 
crosslinking and deamidation disrupt the β-crystallin complex, suggesting 
that these tTG-catalyzed modifications can influence the macromolecular 
assembly of lens crystallins. These data together suggest that tTG can 
contribute to the age-related deamidation of glutamine residues of lens 
crystallins. 
Tissue transglutaminase catalyzes the deamidation of 
glutamines in lens βB2- and βB3-crystallins 
 
 
 
Introduction 
 With an aging European population, cataracts are both a major health issue and 
a major health care expense. Untreated cataract is still the world’s leading cause of 
blindness [1]. Due to aging and life long exposure to multiple environmental insults 
such as toxic compounds or UV-light, the eye lens with time looses its transparency 
and refractivity needed to focus light onto the retina, and in turn, cortical cataract may 
develop [2]. The refractivity is provided by its three major structural proteins called α-, 
β-, and γ-crystallins. The six human β-crystallin gene products βA1/βA3, βA2, βA4, βB1, 
βB2 and βB3 [3-5] make up over a third of the proteins in human eye lens [5;6]. Lens 
proteins do not turn over with age and, in time, undergo extensive posttranslational 
modifications such as backbone cleavage, oxidation, deamidation and protein 
crosslinking. Crystallins can be oxidized in a non-enzymatic reaction by UV light 
generated free radicals [7;8], and deamidation of asparagines may also take place in 
spontaneous reactions [9-11]. In contrast to asparagines, glutamines are known to be 
more resistant to spontaneous deamidation [9;11]. However, many crystallin 
deamidation sites have been found at glutamine residues [12-15]. These modifications, 
which may disrupt the native protein structure, cause light scattering and, in turn, 
contribute to age-dependent cataract development [14;16-18]. 
 Tissue transglutaminase (tTG, also known as TGase2) (EC 2.3.2.13) has been 
proposed to contribute to cataractogenesis by aberrant crosslinking of predominantly β-
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crystallin in the outer epithelial layers of the eye lens [19]. The isodipeptide crosslink is 
catalyzed in a two step Ca2+-dependent reaction between the γ-amino group of 
polypeptide-bound lysines and the ε-carboxamide group of polypeptide-bound 
glutamines [20;21]. A thiolester formation between the active site cysteine and the 
target glutamine initiates the reaction, while ammonia is released (the acylation step) 
[22]. In the next and rate-limiting transamidation step, the acyl group is transferred to 
the acyl-acceptor amine (lysine), forming an isopeptide bond (also known as 
deacylation or crosslinking) [22]. However, in the absence of the lysine, in a much 
slower rate, deamidation of the glutamine can also take place [22;23]. The substrate 
preference is not yet fully understood, but a common notion is that tTG is much less 
selective towards lysine than to glutamine residues. 
 The crosslinking activity of tTG has been implicated in several physiological 
processes, including cell motility [24;25], wound healing, extracellular matrix 
remodeling, differentiation and apoptosis [26-28]. As a result of increased tTG activity 
crosslinked proteins have been found in the detergent-insoluble protein particles in 
Alzheimer’s disease and sporadic inclusion body myositis patients [29;30]. 
Interestingly, tTG-mediated deamidation of glutamines in gliadin has been suggested to 
play an important role in celiac disease [31;32], although such deamidation of gliadin 
has not yet been detected in vivo. More importantly, we have recently shown that tTG 
deamidates the small heat shock protein (sHsp) Hsp20 with high efficiency at a 
glutamine site specifically available for deamidation [33]. In lens, β-crystallins together 
with the intermediate filament vimentin are the primary targets for tTG-catalyzed 
crosslinking [34-37]. βB2-, βB3- and βA3-crystallins have been identified as potent 
glutamine substrates for tTG [38-40], but βA3-, together with βB1- and αB-crystallin also 
expose lysine-donor sites for tTG [36;41-43].  
 In this study we examined the transglutaminase reactivity of lens proteins. Our 
findings suggest that tTG could selectively deamidate βB2- and βB3-crystallin in fetal 
lens extract, whereas βA3- and βB1-crystallins are mainly targets for crosslinking. 
Moreover, these modifications result in the disruption of the β-crystallin complex. In line 
with these results, we show that upon aging, β-crystallins undergo similar modifications 
in aging lens. 
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Materials & Methods 
Lens preparation 
 Fetal calf lenses were obtained from slaughterhouse material. Human lenses, 
both fetal and aged, were provided by H.B. Lenses were homogenized in 1-5 mL of 
lysis buffer (50 mM Tris HCl pH 7.5, 150 mM NaCl, 15 mM DTT, Protease Cocktail 
(Boehringer/Ingelheim)) for 3 hr at 4°C. Lens homogenates were clarified by 
centrifugation at 15000 g for 20 min at 4°C. The supernatant was collected and stored 
at -20°C. 
 
Transglutaminase reaction 
 50 µg fetal lens extract with tTG were first preincubated for 15 minutes at 37°C 
in crosslinking reaction buffer (50 mM Tris HCl pH 7.5, 150 mM NaCl, 15 mM DTT and 
20% glycerol). The crosslinking reaction was performed in a mixture with a final volume 
of 125 µL containing 50 µg total lens extract, and either no or 5 µg (2.5 × 10-4 U/µL) 
guinea pig liver tTG (Sigma), and incubated for 2 hours at 37°C after adding CaCl2 to a 
final concentration of 5 mM.  
 
Size exclusion chromatography 
 The water-soluble crystallins were separated into α-, β- and γ-crystallins by size 
exclusion chromatography using a Superose 6 HR gel permeation column (Amersham 
Pharmacia Biotech) and 25 mM bis-Tris, 2 mM EDTA, 150 mM NaCl pH 7.0 elution 
buffer. 
 
2D gel electrophoresis  
 For isoelectric focusing, samples were desalted by using the 2D Clean-up kit 
(Amersham Pharmacia Biotech) according to the manufacturer’s manual. The salt free 
samples were dissolved in 8 M urea and 2% CHAPS, and the protein concentrations 
were determined using the BCA kit (Pierce). For Colloidal Coomassie Blue staining 20 
µg of protein was subjected to isoelectrofocusing on immobilized linear pH gradient 3-
10 gel strips (Amersham Biosciences). For subsequent Western (immuno-) blot 
analysis 4 µg of protein was separated under the same conditions. After isoelectric 
focusing, the strips were placed on conventional 15% SDS-polyacrylamide gels.  
 
Western blot analysis 
 SDS-PAGE was performed according to standard procedures. Proteins were 
transferred to nitrocellulose membranes (Hybond) by electroblotting. The membranes 
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were incubated successively with primary antibodies (mouse monoclonal anti-αB-
crystallin (Riken Cell Bank) or rabbit anti-βA3- (Stressgen) and anti-βB2-crystallin 
antibodies), and with horseradish peroxidase-conjugated secondary antibodies (Dako 
Corp.) 
 
Dot-blot analysis 
After gel permeation chromatography, 25 µL of each fraction was subjected to dot-blot 
analysis. Membranes were successively incubated with rabbit polyclonal anti-αB-
crystallin, anti-βA3-crystallin, anti-βB2-crystallin or anti-γC-crystallin antibodies, and 
finally with alkaline phosphatase-conjugated secondary antibodies (Promega.) 
 
Mass spectrometry 
 Prior to mass spectrometry, proteins were subjected to in-gel digestion (50 µL 
of 10 ng/µL trypsin solution in 100 mM ammonium bicarbonate to rehydrate gel pieces). 
After 30 min on ice, excess solution was removed, 60 µL of 100 mM ammonium 
bicarbonate added to cover gel pieces, and samples incubated overnight at 37°C with 
shaking. Peptides were then collected by removing the supernatant, and 
washing/sonicating the remaining gel pieces, first in 12.5 mM ammonium bicarbonate, 
25% acetonitrile, then in 2.5% formic acid, 25% acetonitrile. The combined 
supernatant/wash solutions were dried in preparation for mass spectrometric analysis. 
Samples were taken up in 5% formic acid prior to reverse phase liquid chromatography 
LC/MS (ThermoFinnigan). 
 Portions of each spot’s digested and extracted peptides were analyzed by 
LC/MS using an Agilent 1100 series capillary LC system (Agilent Technologies) and 
ThermoFinnigan LCQ classic ion trap spectrometer (ThermoFinnigan) using a standard 
electrospray source modified with a 34 G metal needle (ThermoFinnigan,). Samples 
were applied at 5 µL/min to a 3.0 cm x 180 µm trap cartridge containing 5 µm Zorbax 
SB-18 packing material (Agilent) using mobile phase A containing 0.2% acetic acid. 
After application and washing of the sample for 10 min, the flow rate was reduced to 
1.5 µL/min and the trap cartridge switched on-line to a 10 cm by 180 µm column 
containing the same packing material.  Peptides were eluted using a mobile phase B 
containing 75% acetonitrile and 0.2 % acetic acid. The gradient consisted of 2%-10% B 
over 10 min, 10%-35% B over 50 min, and 40%-100% B over 10 min. Profile mode MS 
scans from m/z 400-2000 were acquired, and MS/MS scans were taken when eluting 
peptides were within ±1.5 AMU of an ion list of expected tryptic βB2- and βB3-crystallin 
peptides. 
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 Eluted peptides were identified from the MS/MS spectra using the Sequest 
program (Version 2.7, ThermoFinnigan). The database used was a bovine-species 
subset of the SwissProt protein database. Oxidation of Met and N-terminal acetylation 
were specified as variable modifications. Scan numbers of identified peptides were 
correlated with extracted single ion chromatogram tracings to identify the elution peak 
of the peptides of interest in each LC/MS run. Based on the elution time and profile, an 
appropriate range of retention times was selected for each peptide (and any potentially 
later eluting deamidated form) and a subset of the profile m/z data in a narrow window 
around the isotopic distribution of the peptide’s m/z was generated. The m/z range 
encompassed the entire isotopic envelope and background on either side of the 
isotopic distribution.  
 The percentage of deamidation was determined by comparing the measured 
isotopic distribution of a given peptide to its predicted isotopic distribution. The 
chemical formula of each peptide was determined using the PAWS program (PAWS- 
freeware edition for Windows 95/98/NT/2000, Proteometrics, LLC, 6/8/2000) and the 
theoretical isotopic distribution was calculated. The N, O, and H quantities were 
adjusted to represent the deamidated form and the isotopic distribution of the 
deamidated peptide was calculated. The relative portions of unmodified and 
deamidated peptide Gaussian-folded theoretical isotopic distributions were varied in a 
least squares fitting procedure to best reproduce the measured ion intensities. 
 
 
Results 
 
tTG-catalyzed changes in the human lens proteome 
 To identify the major tTG-catalyzed changes in the lens proteins, human fetal 
lens extract incubated either in the presence or absence of tTG was initially compared 
with the water-soluble fraction of aged (63 yrs) human lens. In fetal lens, all the tTG 
substrate crystallins (αB-, βA3-, βB1-, βB2- and βB3-crystallins) were detected after 
CBB-staining (Fig. 1A and B, thin-lined boxes). Incubating the total lens extract with 
tTG resulted in the formation of a series of crosslinked dimers, all detected in the upper 
part of the gel (thick-lined box in Fig. 1B). Moreover, monomers of βA3-crystallin greatly 
diminished after tTG-treatment, suggesting that in particular this β-crystallin is 
efficiently crosslinked. 
 In the case of βB2- and βB3-crystallin, the treatment with tTG resulted in a 
different kind of modification. After CBB-staining, we observed the appearance of more 
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acidic spots at the height of both monomers (thin-lined boxes in Fig 1A and B), 
suggesting their possible susceptibility to tTG-catalyzed deamidation. Compared to the 
control situation (lens extract incubated in the absence of tTG), other tTG substrates, 
such as βB1- or αB-crystallin did not seem to be strongly affected by tTG. 
 In the water-soluble fraction of the 63-years old lens, comparable changes, 
such as the appearance of multiple spots at the acidic side of βB2- and βB3-crystallins, 
but also a weak dimer formation, could be detected (Fig 1C). 
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Figure 1. tTG-catalyzed changes in the human lens proteome. The water-soluble fraction of total 
lens extract of human fetal lens and 63-year old lens extract was collected. Fetal lens extract (20 µg 
protein) was first incubated in the absence or presence of 2.5× 10-4 U/µL tTG. Samples were then 
separated by 2D-SDS-PAGE followed by CBB-staining (panels A, B and C), or subjected to 
immunoblotting with antibodies against βA3-crystallin (panels D, E and F) or βB2-crystallin (panels G, H 
and I). Thin-lined boxes indicate the major TG-substrate lens crystallins and the thick-lined boxes mark 
the crosslinked dimers; large black arrowheads and small open arrowheads represent the wild type 
and modified (supposedly tTG-deamidated) forms of monomers, respectively; finally, the large open 
arrows indicate the larger crosslinked oligomers.
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βA3- and βB2-crystallins are crosslinking substrates for tTG in the aging lens 
 To learn more about the composition of these HMW dimers, after separating by 
2D-SDS-PAGE, these samples were subjected to anti-crystallin immunoblotting. In the 
untreated control sample, next to the most strongly stained wild type βA3- and βA1-
crystallin monomers (black arrowheads in Fig. 1D), a series of spots was also detected 
at the acidic side of the 26 and 22 kDa monomers, respectively (open arrowheads in 
Fig. 1D). (Apart from the 17 residues N-terminal truncation of βA1-crystallin, βA3- and 
βA1-crystallins are identical and therefore the polyclonal antibody directed against βA3-
crystallin also recognizes βA1-crystallin [44]). An additional anti-βA3-crystallin reactive 
spot at the height of 50 kDa was also detected (boxed area in Fig. 1D). 
 Compared to control, βA3- and βA1-crystallin monomers from the tTG treated 
sample showed a similar staining pattern (Fig. 1E), but a pronounced set of anti-βA3-
crystallin positive spots, probably crosslinked dimers, arranged into a sequential 
pattern appeared around the 50 kDa height (boxed spots in Fig. 1E). Crosslinked HMW 
products larger than 150 kDa were also observed in the upper gel region (Fig. 1E, open 
arrow), corresponding well to the aggregates seen in the aging lens (Fig. 1F). Finally, it 
should be noted that in the 63-years old lens, more modified βA3/βA1-crystallin 
monomers were detected by immuno-staining than by CBB-staining (Fig. 1C versus F), 
which is due to the higher sensitivity of this detection technique.  
 In fetal lens, we found βB2-crystallin mainly in the form of a doublet, one spot 
likely representing the unmodified monomer (Fig. 1G, black arrowhead), and another 
spot on the acidic side of the wild type form (Fig. 1G, open arrowhead). In the tTG-
treated fetal and the 63-years old lens extracts next to these two spots additional acidic 
spots could be detected (Fig. 1H and I, open arrowheads), suggesting their possible 
deamidation. A series of 50- and 150-kDa sized spots, representing the crosslinked 
(and possibly deamidated) βB2-crystallin dimers and oligomers, were also detected 
after tTG treatment (Fig. 1H, boxed area and open arrows, respectively). In the aging 
lens, we also detected two βB2-crystallin-positive spots, in the higher MW region 
corresponding well to the size of the tTG-crosslinked dimers (Fig. 1I, boxed area). This 
may suggest that upon aging, βB2-crystallin may also be prone to tTG-catalyzed 
crosslinking. 
Chapter 6 
 130
 
tTG-catalyzed deamidation in bovine lens 
 The tTG-catalyzed deamidation of β-crystallins was further assessed in bovine 
lenses. Fetal calf lens extracts, incubated in the absence or presence of tTG, and six-
months old bovine lens extracts were subjected to 2D-gelelectrophoresis and 
subsequent colloidal CBB-staining. Similar to the human lenses, we observed three 
major changes in the fetal bovine lens proteome after tTG treatment. First, the 
incubation with tTG resulted in the formation of crosslinked dimers, which were 
detected in the upper part of the gel (Fig 2B versus 2A, boxed area). Second, parallel 
Figure 2. tTG deamidates βB2- and βB3-crystallins in calf lens extract. The water-soluble fractions 
of fetal calf lens was incubated with 5 mM CaCl2 either in the absence (Panel A) or presence of 2.5× 
10-4 U/µL tTG (Panel B) and compared with untreated six months old calf lens (Panel C). Panels D and 
E show the quantification of the spots intensities of the tTG-modified βB2- and βB3-crystallins.  
fetal calf lens extract w/o tTG fetal calf lens extract w/ tTG   calf lens (6 months old)
3 10 3 10 3 10pH pHpH
A B C
D
E
βA3 βB3
βB2
βA3 βB3
βB2
βA3 βB3
βB2
αA
αB
αA
αB
αA
αB
crosslinked
dimers
25
50
20
kDa
6 months
old calf
fetal calf
w/o tTG
fetal calf
w/ tTG
70000
35000
0
70000
140000
0
sp
ot
 in
te
ns
ity
 (a
. u
.) βB2 βB -12
βB3 βB -13
βB -22
βB -23
sp
ot
 in
te
ns
ity
 (a
. u
.)
 131
to the formation of these crosslinked heteromers, the unmodified βA3-crystallin 
monomers disappeared almost completely from the gel (black arrowhead, Fig 2B), 
suggesting their tTG-catalyzed crosslinking into covalent heterodimers. Finally, as was 
the case in the human fetal lens, more pronounced acidic spots were observed next to 
the unmodified monomers of βB2- and βB3-crystallin upon tTG incubation (Fig 2B 
versus 2A). These results were compared to a 6 months old calf lens extract, and we 
found a similar, though less pronounced pattern for βB2- and βB3-crystallin (Fig 2C). 
However, high molecular aggregates, resembling the tTG-crosslinked heteromers 
could not be detected in the 6-months old calf lens extract. 
 
 
 We further analyzed the possible deamidation of the two βB-crystallins by 
comparing the different spot intensities after densitometric quantification. In case of the 
control, approximately 84% of the total amount of βB2-crystallin was found in the main 
spot, which is likely to represent the unmodified protein, and 13% and 3% were present 
Control With tTG 
Peptide fragments 
Main spot (-1) spot (-2) spot Main spot (-1) spot (-2) spot 
A2SDHQAGKPQPLNPK18 100/0/0 86/14/0 97/3/0 90/10/0 40/60/0 48/43/8 
I19IIFEQENFQGHSHELNGPCPNLK42 - 46/54/0 43/57/0 - - - 
A49GSVLVQAGPWVGYEQANCK68 100/0/0 96/4/0 92/8/0 83/17/0 100/0/0 93/0/7 
G69EQFVFEK76 100/0/0 100/0/0 100/0/0 100/0/0 100/0/0 100/0/0 
V102DSQEHK108 - - 100/0/0 92/8/0 98/2/0 100/0/0 
I109LYENPNFTGK120 97/3/0 92/8/0 95/5/0 95/5/0 97/3/0 96/4/0 
M122EVIDDDVPSFHAHGYQEK140 92/8/0 - 94/6/0 100/0/0 - 90/10/0 
V146QSGTWVGYQPGYR160 98/2/0 94/6/0 100/0/0 91/9/0 94/6/0 93/7/0 
G161LQYLLEK168 100/0/0 100/0/0 100/0/0 100/0/0 100/0/0 100/0/0 
D173SGDFGAPQPQVQSVR188 100/0/0 93/7/0 96/4/0 94/6/0 90/10/0 87/13/0 
D192MQWHQR198 100/0/0 95/5/0 99/1/0 - - - 
Table1. Mass spectrometric analysis (MS) of the tTG-ctalayzed deamidation of fetal bovine lens 
βB2-crystallins. Fetal lens extract (40 µg total protein) was incubated with or without the presence of 
tTG and subjected to isoelectrofocusing on immobilized linear pH gradient 3-10 gel strips followed by 
conventional 15% SDS-polyacrylamide gel electrophoresis and Colloidal Coomassie-staining. Prior to 
MS, proteins were subjected to in-gel digestion. Eluting peptides were identified from the MS/MS 
spectra using a bovine-species subset of the SwissProt database. The deamidation values are defined 
as the percentage of the sum (100%) of scores of each peptide form (unmodified, deamidated and 
double deamidated).  
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in the one-negative-charge less (-1) and the two-negative-charge less (-2) spots, 
respectively, suggesting a low rate for deamidation (Fig 2D, left three bars). Treatment 
with tTG resulted in an approximately 17% and 11% increase in the amount of the (-1) 
and (-2) spots, respectively (Fig 2, middle three bars), indicating that βB2-crystallin 
undergoes deamidation in the presence of tTG. Compared to the untreated sample, the 
deamidation rate was also higher in the six months old bovine lens, as 20% and 8% of 
the total βB2-crystallin was present in the (-1) and (-2) deamidated spots, respectively 
(Fig. 2D, right three bars). 
 
 
 Similar to βB2-crystallin, 10% and 2% of the total βB3-crystallin of the fetal lens 
was present in the (-1) and (-2) spots, respectively (Fig 2E, left three bars). However, 
the treatment with tTG resulted in dramatic changes as the intensity of the (-1) spot, 
representing the deamidated βB3-crystallin was almost 6 fold higher compared to the 
control situation (Fig 2E, middle three bars versus left three bars). A similar, 7.5 fold 
increase was observed in the case of the (-2) spot, representing double deamidated 
βB3-crystallin (Fig 2E, middle three bars versus left three bars). Finally, as was in the 
case of βB2-crystallin, the deamidation of βB3-crystallin was also somewhat increased 
in the bovine lens, 18% of the protein was in the more acidic (-1) spot, but only 5% of 
the was found in the (-2) spot (Fig 2E, right three bars) 
Control With tTG 
Peptide fragments 
Main spot (-1) spot (-2) spot Main spot (-1) spot (-2) spot 
A2EQHSTPEQPAAAGK15 100/0/0 100/0/0 100/0/0 86/14/0 32/68/0 17/44/39 
V26IVYEMENFQGK37 100/0/0 97/3/0 90/10/0 91/9/0 93/7/0 92/8/0 
C39ELTAECPNLTESLLEK55 100/0/0 85/15/0 100/0/0 100/0/0 95/5/0 90/10/0 
V56GSIQVESGPWLAFER71 93/7/0 94/6/0 93/7/0 88/12/0 96/4/0 93/7/0 
G76EQYVLEK83 100/0/0 100/0/0 100/0/0 100/0/0 100/0/0 100/0/0 
L116HLFENPAFGGR127 90/10/0 98/2/0 95/5/0 92/8/0 94/6/0 100/0/0 
M129EVIDDDVPSLWAHGFQDR147 - 100/0/0 - 95/5/0 97/3/0 - 
A153INGTWVGYEFPGYR167 100/0/0 14/86/0 13/87/0 18/82/0 13/87/0 13/87/0 
Q170YVFER175 23/77/0 82/18/0 57/43/0 66/34/0 86/14/0 74/26/0 
H180WNEWDANQPQRLQSVR195 100/0/0 97/3/0 100/0/0 100/0/0 100/0/0 100/0/0 
Table 2. Mass spectrometric analysis (MS) of the tTG-ctalayzed deamidation of fetal bovine lens 
βB3-crystallins. Legend as for Table 1.  
 133
αB
βA3
fetal lens w
/ tTG
γC
Elution volume (mL)
10 1612 14 18 2220 248
fetal calf lens
w/o tTG
Ab
so
rb
an
ce
 2
80
 n
m
α βΗ βL γ
B
C
fetal lens w
/o tTG
fetal calf lens
w/ tTG
0
8
16
0
8
16
Elution volume (mL)
10 1612 14 18 2220 24
A
βB2
αB
βA3
γC
βB2
 These findings together suggest that both βB2- and βB3-crystallin could undergo 
tTG-catalyzed deamidation during the aging of the lens. 
 
Deamidation of bovine βB2 and βB3-crystallins 
 Using mass spectrometry, the spots representing the modified calf βB2- and 
βB3-crystallins were analyzed, and deamidation (or double deamidation) of a particular 
peptide and the extent of deamidation were determined (see Materials & Methods).  
 Three spots, one 
representing the major 
gene product, and two 
others with one or two 
negative charge 
differences, were analyzed 
for βB2-crystallin. After tTG 
treatment, the N-terminal 
A2SDHQTQAGKPQPLNK1
8 peptide fragments 
showed high and almost 
identical percentages of 
deamidation when isolated 
from the two more 
negatively charged spots 
compared to control (Table 
1). The 
I18IIFEQENFQGHSHELNG
PCPNLK42 peptide, 
isolated from the two more 
acidic spots in the control 
sample was also found to 
be deamidated, which is 
likely caused by non-
enzymatic deamidation of 
one of the asparagine 
Figure 3. The tTG-catalyzed modifications disrupt the fetal calf βH-crystallin complex. Fetal calf lens 
extracts (200 µg) incubated in the presence or the absence of 2.5× 10-4 U/µL tTG were separated on a 
Superose-6 gel permeation column (Panel A). The fractions were collected and subjected to immuno-dot-
blot analysis by using anti αB-, βB2-, βA3- and γC-antibodies. Panels B and C represent the control 
(absence of tTG) and tTG-incubated fetal calf lens extracts, respectively. 
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residues (Table 1), stimulated by the neighboring glycine residue [45]. The 
corresponding peptide from the tTG-treatedsample unfortunately could not be detected.  
 In the case of βB3-crystallin, the N-terminal peptide A2EQHSTPEQPAAAGK15 
isolated from the (-1) spot was found to be approximately 70% deamidated, whereas 
the deamidation value of the corresponding peptide from the (-2) spot was more than 
120% (Table 2). Since there are two glutamines (Q3 and Q9) in this peptide fragment, 
this data suggests double deamidation for the N-terminal arm of βB3-crystallin. In 
addition, the βB3-crystallin peptide fragment A153INGTWVGYEFPGYR157, with only one 
asparagine but no glutamine residue, is essentially completely deamidated in both the 
absence and the presence of tTG, which could be due to non-enzymatic deamidation 
(Table 2). 
 These results suggest that the tTG-catalyzed deamidation of βB2- and βB3-
crystallin seems to occur predominantly in the more exposed N-terminal arms of the 
proteins.  
 
Disruption of the βH-crystallin complex following tTG treatment 
 Age-related posttranslational modifications might influence the macromolecular 
assembly of the different crystallin complexes. In order to explore whether the tTG-
catalyzed modifications can alter the complex sizes of lens crystallins, fetal calf lens 
extracts were directly subjected to size exclusion chromatography (SEC) after tTG 
treatment and compared with lens extracts incubated in the absence of tTG. The 
elution pattern of the α-crystallin complex showed a slight shift in size in fractions 
between 11 and 13.5 mL, suggesting that in calf lens, tTG may modify the complex 
size of the α-crystallin association (Fig. 3A and top panel in B and C). The smallest 
complex of γ-crystallins did not seem to be influenced by tTG (Fig. 3A and lowest panel 
in B and C). However, major changes were observed as the βH peak disappeared 
almost completely from the fetal calf lens extract after tTG treatment (Fig. 3A). The dot-
blot analysis of the fractions revealed that crystallins such as βB2- and βA3-crystallin, 
both present in the βH- and βL-complexes, elute much earlier from the SEC-column 
(Fig. 3A and middle panels in B and C), suggesting that these proteins occur in larger 
macromolecular associations after treatment with tTG.  
 
Crosslinked and deamidated β-crystallins form different complexes- 
 Since the tTG-catalyzed modifications clearly affected the size of the βH-
crystallin complex, we next examined the modified proteins in the β-crystallin complex. 
Following SEC, fractions from 12.5 to 14 mL, 14.5 to 16 mL, and 17 to 18.5 mL 
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representing the α-crystallin, the altered and the intact βH-complexes, respectively, 
were pooled and separated by 2D-gel electrophoresis. As was expected, the first pool 
of fractions from the untreated lens contained the vast majority of the differentially 
phosphorylated forms of αA- and αB-crystallin, and some high molecular weight 
proteins (Fig. 4A left panel). In addition to these proteins, the corresponding fractions of 
the tTG-treated lens already contain some deamidated as well as unmodified forms of 
βB2- and βB3-crystallin (Fig. 4A right panel, parallel arrowheads). These fractions also 
contained large oligomers crosslinked by tTG (Fig. 4A right panel, boxed area). 
Compared to control, the second pool of tTG-treated proteins was found to be rich in 
the deamidated and double deamidated βB2- and βB3-crystallins, as well as in 
crosslinked material (Fig. 4B). Due to tailing, both αA- and αB-crystallin were also 
present in reasonable amounts in these fractions. In the last pool, representing the βH-
fraction, we mainly detected the deamidated βB2- and βB3-crystallin, whereas βA3-
crystallin was virtually undetectable in the tTG-incubated lens (Fig. 4C). 
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Figure 4. The tTG-
modified fetal calf 
βB2- and βB3-
crystallins associate 
into larger 
macromolecular 
assemblies. After 
incubation in the 
absence (left column) 
or the presence of tTG 
(right column), fetal calf 
lens extracts (200 µg) 
were separated on a 
gel permeation column, 
and fractions 
representing the 
modified α-crystallins 
were pooled and 
subjected to 2D-SDS-
PAGE followed by 
CBB-staining. Panels 
A, B and C represent 
the pooled fractions 
from 12.5 to 14, 14.5 to 
16 and 17 to 18.5 mL, 
respectively. Boxed 
areas show the tTG-
catalyzed crosslinked 
products, large black 
arrowheads and small
open arrowheads 
represent the wild type 
and tTG-deamidated 
forms of monomers, 
respectively.  
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Discussion 
 With aging, crystallins undergo a great variety of posttranslational modifications, 
including deamidation on both asparagine and glutamine residues [12;13;46], as well 
as tTG-catalyzed covalent crosslinking. The latter process has been speculated to play 
a role in cortical cataract formation [35;38-41;47-49]. These publications and our recent 
reports [33;50] on the tTG-catalyzed site-specific crosslinking and deamidation of 
sHsps  have led us to investigate the effect of tTG on the fetal lens proteome. Our most 
important finding is that βB3-crystallin and to a lesser extent βB2-crystallin can undergo 
tTG-catalyzed deamidation in both human and bovine fetal lenses (Fig 1B, Fig 2B, 
Table 1 and 2), while βA3-crystallin is mainly targeted for crosslinking (Fig. 2E). 
Although the exact location of the deamidated target glutamines could not be identified, 
the MS data indicate that the tTG-mediated deamidation of both β-crystallins takes 
place in the exposed N-terminal arm of these crystallins (peptide 
A2SDHQTQAGKPQPLNPK18 in βB2-crystallin and A2EQHSTPEQAAGK15 in βB3-
crystallin) (Table 1 and 2). In support of this, the three N-terminal glutamines (Q5, Q7 
and Q12) in βB2-crystallin have been found to deamidate in human lens [13], although 
the underlying mechanism was not known. It should be noted that other deamidating 
glutamines in βB2-crystallin, such as Q70 and Q162, have also been recently reported in 
cataract [51;52]. Moreover, mimicking deamidation of these glutamines has been 
shown to destabilize βB2-crystallin [18]. 
 The reaction between tTG and a given glutamine in gliadin peptides is 
hampered if proline is flanking the glutamine residue [53]. Being followed by a proline, 
Q12 in βB2-crystallin is thus unlikely to be a target for tTG. Furthermore, Q7 has been 
previously identified as an endogenous substrate for crosslinking [39], which suggests 
that this Q in βB2-crystallin could be the target for tTG-catalyzed deamidation. 
However, Q5 may be also accessible for the enzyme. 
 Deamidation of βB3-crystallin has not been reported earlier. Using 2D-SDS gel 
electrophoresis we could clearly detect the double deamidation of this protein (Fig 2E 
and Fig 4). The subsequent MS analysis suggests that this double deamidation takes 
place on Q3 and Q9 in the N-terminal arm of βB3-crystallin (Table 2). The current 
knowledge about βB3-crystallin and its modifications is very limited. However, it could 
be speculated that the double deamidation of an exposed structure such as the N-
terminal arm and the resulting difference in the net charge of the protein may be an 
important aspect in the assembly or the solubility of βB3-crystallin.  
 tTG treatment resulted in the disruption of the βH-crystallin complex (Fig. 3), the 
deamidated βB3-, and to a lesser extent also βB2-crystallin eluted earlier from the SEC 
column (Fig. 4). These findings may indicate that the modified proteins tend to 
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associate into larger complexes. Deamidating lens crystallins have been suggested to 
undergo conformational changes [16;54] and in turn change their macromolecular 
assemblies [13]. This is in good agreement with our observations about the disrupted 
β-crystallin assembly upon deamidation by tTG.  
 After tTG treatment, we also observed the disappearance of βA3-crystallin, with 
the parallel formation of anti-βA3-crystallin positive crosslinked HMW products (Fig. 1B 
and E), similar to those seen in the case of the aging lens (Fig 1C and F). The 
accessibility of multiple lysine and glutamine sites in βA3-crystallin for tTG [36;39] gives 
an explanation for the readiness to crosslink into HMW aggregates. Other tTG 
substrate crystallins, namely βA1-, βA4- and βB1-crystallins, have also been identified in 
these aggregates [35;47] but not the lysine-donor substrate αB-crystallin [39;43;50] 
The absence of crosslinked αB-crystallin in the HMW aggregates suggests that the in 
vitro and in situ substrate preference of tTG are likely to be different from each other.  
 In summary, we presented evidence that lens β-crystallins can actually undergo 
tissue transglutaminase catalyzed deamidation of glutamine residues. Moreover, tTG 
seems to have differential substrate (protein) preference for crosslinking and 
deamidation, which modifications greatly influence the macromolecular associations of 
the lens proteins and, in turn, may play a not yet defined role in the aging process of 
the lens and in age-related cataract formation. 
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The small heat shock protein HspB2 forms with HspB3 an 
octameric complex that lacks chaperone-like activity 
 
 
Introduction 
Different environmental stresses like increased temperature, pH extreme, 
noxious chemicals or osmotic pressure variation induce the expression of small heat 
shock proteins (sHsps). Organized into a multichaperone network with the large Hsps, 
they help the normal folding process, and under stress-like conditions bind to unfolding 
proteins to keep them in folding competent states [1;2].  
Based on sequence similarities ten human sHsps have been identified and 
designated as HspB1-HspB10 [3;4]. Preceded by a less homologous and in length 
more variable N-terminal domain, a conserved 80–100 amino acid long stretch in the 
C-terminal region called the α-crystallin domain hallmarks the sHsp family [5]. The α-
crystallin domain often has a short flexing C-terminal extension whose length and 
composure are thought to influence the chaperoning capacity [6], whereas the N-
terminal domain can largely determine their association properties [7-9]. sHsps can 
form macromolecular associations up to 800 kDa, which can readily dissociate and 
Mammalian small heat shock proteins (sHsps) are assembled into two 
independent types of complexes in muscle cells. Type-I consists of αB-
crystallin, Hsp27 and Hsp20, and Type-II comprises HspB2 and HspB3. Using 
recombinant proteins we investigated the biochemical properties of this 
complex. Expressed in E. coli HspB2 and HspB3 assemble into a well-defined 
HspB2/B3 complex, while the excess of HspB2 separately forms a more 
heterogeneous complex. Nanoelectrospray ionization mass spectrometry 
established an octameric HspB2/B3 complex comprising six HspB2 and two 
HspB3 subunits. Fluorescent quenching measurements determined that the 
tryptophans are partially exposed in a polar surface environment inside the 
HspB2/B3 complex, suggesting the presence of an isolated water-containing 
hole. HspB2/B3 and type-I sHsps cannot interact in pull-down assays
however, homomeric HspB2 is able to associate with Hsp20, but not with 
Hsp27 or αB-crystallin. Intriguingly, HspB2 displays a moderate chaperone-
like activity, which is clearly diminished in complex with HspB3. Additionally, 
the hydrophobic probe bis-ANS binds poorly to both HspB2/B3 and HspB2, 
but circular dichroism analysis suggests markedly different overall secondary 
structures for the two complexes.. Our results demonstrate that HspB3 may 
function as a modulator of HspB2 by forming a well-defined heteromeric 
complex. 
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exchange subunits [10;11]. In vitro, virtually all sHsps display chaperone-like activities, 
measured by their ability to protect model substrates form thermally or chemically 
induced aggregation [12-15].  
Although both HspB2 and HspB3 have been discovered a while ago, very little 
is known about their functional properties. The expression of HspB2 and HspB3 is most 
prominent in muscle tissues [16] In myotonic dystrophy the diseased muscles increase 
the expression of HspB2 also known as myotonic dystrophy kinase binding protein 
(MKBP), as it has been identified as specific binding partner for myotonic dystrophy 
protein kinase (DMPK), responsible for myotonic dystrophy [17]. Also in neonatal 
myocardium, HspB2 seems to be upregulated together with another sHsp family 
member, Hsp27 [18] and maintains its high levels in the adult heart [19]. Furthermore, 
HspB2 has been found to associate with the Aβ-containing hallmarks of Alzheimer’s 
disease brains [20], but is less active in preventing the biological action of Aβ than 
other tested sHsps [21]. Association with the outer membrane of mitochondria 
suggests a role for HspB2 in stress response [22;23]. Another intriguing aspect of 
HspB2 is that in muscle extracts it co-elutes with HspB3 in an oligomer with an 
apparent molecular mass of 150 kDa that is independent of the oligomers formed by 
Hsp27, αB-crystallin and Hsp20 [16]. 
Even less is known about HspB3. Based on sequence prediction HspB3 has 
been found to be the smallest member of the family with its 17 kDa monomeric sizes 
[24]. One remarkable feature of HspB3 is the lack of the flexing tail of the C-terminal α-
crystallin domain. In skeletal muscle extracts, it exclusively interacts with HspB2 [16], 
and upon proteasomal inhibition, ectopically overexpressed HspB3 can translocate to 
the cytoskeleton in cultured rat cardiac H9C2 cells [25]. HspB3 has only been found 
together with HspB2 in situ, presumably forming a functional assembly with HspB2.  
In this study we describe the biochemical properties of purified recombinant 
HspB2/B3 complex. We show that HspB2 forms an octameric complex with HspB3 with 
a strict 3 to 1 subunit ratio. Furthermore, we show that HspB3 may act as a regulator of 
HspB2 by eliminating the moderate chaperone and thermoprotective activity of HspB2 
and preventing the interaction with Hsp20.  
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Materials and Methods 
Cloning, expression and purification 
The cDNA encoding the rat HspB2 was cloned into pET3a expression vector 
between the NdeI-BamHI sites followed by the appropriate rat HspB3 encoding 
sequence cloned between the BglII-EcoRI sites. Protein expression was induced in the 
BL21 rosetta strain transformed with pET3a-HspB2/B3 by addition of 350 µM isopropyl-
β-D-thiogalactopyranoside and subsequent incubation for three more hours at 37 °C. 
Cells were lyzed by sonication in TEG buffer (25 mM Tris, pH 8.0, 2 mM ethylene-
diaminetetraacetic acid (EDTA), 50 mM glucose) and then centrifuged at 16 000 × g for 
45 min at 4 °C. The obtained supernatants were subjected to 0.12% polyethylene-imine 
precipitation. The sHsps were first fractionated on a DEAE–Sepharose column, using a 
NaCl gradient from 0 to 1000 mM in 2 mM EDTA, 25 mM bis-Tris–HCl, pH 6.5 and 
subsequently purified on a Source 15Q HR 16/10 column. The last purification step 
was done on a prepacked Superose 6 HR gel-permeation column (Pharmacia Biotech) 
using 25 mM bis–Tris, 2 mM EDTA, 150 mM NaCl, pH 7.0. The collected fractions (0.5 
ml) were analyzed by SDS PAGE. The recombinant Hsp27, Hsp20 and αB-crystallin 
were purified in a very similar way using pET3b-human-αB-crystallin, pET3a-human-
Hsp27 and pET8c-rat-Hsp20 (see Boros et al.[26]). 
 
Far-UV circular dichroism spectroscopy 
CD-spectra were recorded on a J-810 spectropolarimeter (Jasco) using 280 
µg/ml of protein in a 1 mm cuvet. Samples were dialyzed against 10 mM potassium 
phosphate buffer pH 7.8 and incubated for 10 min at 37 °C prior to the measurement of 
the spectra. Spectra were recorded between 195 and 250 nm at 20 nm/min with a 
response time of 2 seconds, bandwidth set to 1 nm. 20 spectra were averaged and 
corrected with the average of 5 spectra recorded for the buffer alone.  
 
Mass spectrometry 
Prior to analysis by mass spectrometry (MS), HspB2/B3 (8 mg/mL) was buffer 
exchanged into 200 mM ammonium acetate, pH 7.0, using Micro-BioSpin 6 
chromatography columns (BioRad Laboratories). Satisfactory removal of non-volatile 
buffer salts was achieved after two exchanges of a 25 µL volume of sample. 
Nanoelectrospray ionization MS (nanoESI-MS) measurements were performed on an 
LCT mass spectrometer (Micromass 9UK Ltd). Typically, 2µL of solution were 
electrosprayed from gold-coated glass capillaries prepared in-house. In order to 
preserve noncovalent interactions the following instrument parameters were used: 
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capillary voltage 1.5kV, cone gas 100L/h, sample cone 140V, extractor cone 8V, ion 
transfer stage pressure 8.0 x 10-3 mbar, TOF analyzer pressure 2.0 x 10-6 mbar. The 
pressure in the ion transfer stage was decreased from 8.0 x 10-3 to 5.0 x 10-3 mbar to 
dissociate individual monomers from the HspB2/B3 hetero-oligomers. All spectra were 
calibrated externally using a solution of cesium iodide, and processed with MassLynx 
software (Micromass UK Ltd). 
 
Heat Stability Assay 
To determine the heat stability 250 µg of the protein of interest was gradually 
heated from 22 to 70 °C over a period of approximately 100 minutes in a total volume 
of 1 mL of 10 mM potassium phosphate buffer pH 7.5. As a measure of aggregation 
the absorption at 365 nm was recorded using a Lambda 2 UV/VIS spectrophotometer 
(Perkin-Elmer). 
 
Fluorescence measurements 
The fluorescence spectra were recorded using a Jobin-Yvon Fluorolog 3 
fluorescence spectrometer with excitation and emission band passes set at 2 and 2 
nm. Intrinsic tryptophan fluorescence spectra of HspB2/B3 (0.15 mg/mL) were 
recorded in 10 mM sodium phosphate buffer (pH 7.4) containing 100 mM NaCl with the 
excitation wavelength set at 290 nm. For the fluorescence quenching experiments 
HspB2/B3 was titrated with 2000 mM KI solution containing a trace amount of Na-
Thiosulfate. The results were evaluated by the method described by Lehrer [27]. The 
denaturation of HspB2/B3 was performed by titration with 7.5 M GnHCl. The GnHCl 
concentration was controlled by a refractometer. The denaturation was followed by 
collecting the tryptophan emission spectra. The positions of the maxima were 
determined by the method of Savitzky and Golay [28]. 
To study the binding of the hydrophobic probe bis-ANS, 0.15 mg/mL of each 
sHsp in 10 mM sodium phosphate buffer (pH 7.4) containing 100 mM NaCl were used. 
To each of the 1.2 mL protein samples, 15 µl of 0.8 mM methanolic solution of bis-ANS 
(Molecular Probes) was added and the samples were incubated for 10 min at 37 °C. 
Fluorescence spectra of the samples were recorded from 400 to 580 nm with the 
excitation wavelength set at 390 nm 
 
Chaperone assay 
To measure the chaperoning properties of sHsps we used the insulin protection 
assay described by Farahbakhsh et al [29]. Briefly, proteins were dialyzed overnight at 
4 °C against chaperone buffer (20 mM Pi, 20 mM Na2SO4 pH 6.9). 250 µg sHsp was 
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incubated with 300 µg bovine insulin (Sigma) at 40 °C for 5 minutes. The denaturation 
of insulin was initiated with dithiothreitol (DTT) and the absorbance was measured at 
360 nm for 15 minutes at 40 °C in a Perkin Elmer Lambda2 UV/VIS spectrophotometer. 
 
Colony Survival Assay 
Cells transformed with the appropriate bacterial expression construct were first 
grown overnight, then all cell suspensions were diluted to equal optical density (OD600 = 
0.6) and protein expression was induced for 1 hour by adding 350 µM isopropyl-β-D-
thiogalactopyranoside. After induction cells were heats shocked at 48 °C for 60 minutes 
after which the cell cultures were diluted to OD600 = 0.06. Then the recovery was 
monitored during a 5 hour time course at 37 °C with 30 minute time intervals. 
 
Co-immunoprecipitation assay 
Purified HspB2/B3 (1 µg) and HspB2 (0.5 µg) were incubated either alone 
(negative control) or together with Hsp20, Hsp27 or αB-crystallin (5 µg) or a mixture of 
the three proteins (each 5 µg) in TEN buffer (25 mM Tris pH 8.0, 100 mM NaCl, 2 mM 
EDTA and 0.05% NP-40) for 60 min at room temperature. After the incubation 
antibodies directed to HspB2, Hsp20, Hsp27 or αB-crystallin coupled to protein-A 
beads (Roche) were added to the indicated mixtures and rotated for 60 minutes. 
Thereafter the beads were pelleted and washed 3 times with 1 mL TEN buffer. The 
proteins bound to the beads were by separated by SDS PAGE and analyzed by 
Western blotting.  
 
 
Results 
HspB2 forms a well-defined complex with HspB3 
To learn about the structural and biochemical properties of the HspB2/B3 
assembly this complex was expressed in E. coli and subsequently purified. The two 
proteins were induced together in BL21 rosette cells using a pET3a-HspB2/B3 
construct (see Experimental procedures). The obtained cleared cell lysates were 
separated by DEAE anion exchange chromatography and the fractions containing 
HspB2 and HspB3 were collected, pooled and further fractionated on a Source Q 
column using a NaCl gradient from 0 to 1000 mM NaCl (Fig.1A). At low salt 
concentration HspB2 eluted together with HspB3, but despite its strong interaction with 
HspB3, HspB2 eluted also at higher salt concentrations (Fig. 1A). The fraction 
containing both HspB2 and HspB3 (fraction 2) and the fractions containing only HspB2 
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(fraction 5 till 10) were pooled and used for size determination by size exclusion 
chromatography (SEC). The obtained elution profiles were dependent on HspB3, as 
HspB2 alone eluted in a relatively broad peak, but forms a much sharper peak in 
complex with HspB3 (Fig. 1B). The SDS-PAGE analysis of the fractions shows that the 
ratio between HspB2 and HspB3 in every fraction is constant, indicating that the two 
proteins are in one complex (Fig. 1B inset). With the help of mass standards we 
estimated the molecular mass of the HspB2 complex as 250 kDa and of HspB2/B3 
complex as 150 kDa. The size of the HspB2/B3 complex corresponds well to the 150 
kDa mass for the oligomeric HspB2/B3 subunits found in rat skeletal muscle extract 
[16]. These results show that HspB2 forms a saturable complex with HspB3, likely with 
a well-defined ratio.  
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Purification of HspB2/B3 and HspB2. (A) The HspB2 and HspB3 containing DEAE column 
fraction of a lysate of E.coli cells expressing both proteins was separated on a Source 15Q column with 
a 0 to 1 M NaCl gradient. Samples were collected and separated by SDS-PAGE and stained with 
Coomassie Brilliant Blue (CBB). (B) Analysis of the complex size of HspB2 and HspB2/B3 with 
Superose 12 column. HspB2 eluted in a relatively broad peak with a maximum at 11.0 mL (250 kDa), 
the sharper peak of HspB2/B3 had a maximum at 11.7 mL (155 kDa). (Inset) The HspB2/B3 (upper 
panel) and HspB2 (lower panel) fractions were collected and equal amounts were subjected to SDS-
PAGE and stained with CBB. 
A 
B 
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HspB2 forms with HspB3 an octameric complex 
To determine if the HspB2/B3 assembly indeed has a unique oligomeric state 
the HspB2/B3 complex was subjected to nano-electrospray mass spectrometry (nano-
ESI-MS) under conditions that leaves non-covalent bonds intact [30]. The great 
accuracy of this technique can be used to calculate very precise the subunit 
stoichiometry of hetero-oligomers. Figure 2A shows the mass spectrum acquired under 
conditions favoring the dissociation of monomers from HspB2/B3 oligomers. The 
individual charge states for each peak series were assigned and the mass to charge 
spectrum was transformed to a mass scale (inset). The resultant spectrum shows that 
HspB2/B3 consists of two distinct monomers with the expected masses, one of 17,000 
Da (HspB3) and the other of 20,200 Da (HspB2). By careful control of the instrument 
pressures downstream of the ionization process, we obtained a mass spectrum of 
oligomeric HspB2/B3, showing two distinct charge state series (Fig. 2B). The intense 
series of peaks, m/z 3,500-5,250, were found to arise from tetramers of mass 77.8 kDa 
(inset shows transformed spectrum), which based on the subunit masses must contain 
three HspB2 subunits and one HspB3 subunit. The minor charge state series at m/z 
5600-6600 was found to arise from the association of two identical tetramers into an 
octamer of mass 155.5 kDa (transformed spectrum not shown). Together with the SEC 
data these findings show that the native HspB2/B3 is an octameric complex that 
consists of 6 HspB2 subunits and 2 HspB3 subunits. This complex likely has a two-fold 
symmetry considering its tendency to dissociate into tetramers during nano-ESI-MS. 
  
Figure 2. HspB2/B3 is an octameric complex comprised by six HspB2 and two HspB3 subunits.
(A) NanoESI-MS mass spectrum of HspB2 and HspB3 monomers dissociated from the HspB2/B3 
oligomeric complex at an ion transfer stage pressure of 5.0 x 10-3 mbar (1 mbar = 100 Pa). Charge state 
series arising from HspB2 and HspB3 are labelled in normal and light grey text, respectively. (Inset)
Transformation of the mass to charge spectrum to a mass scale showing the mass of HspB3 (17.0 kDa) 
and HspB2 (20.2 kDa). (B) NanoESI-MS mass spectrum of HspB2/B3 acquired at an ion transfer stage 
pressure of 8.0 x 10-3 mbar. Under these conditions the noncovalent interactions of the assembly were 
preserved, yielding a mass spectrum containing ions arising from higher order oligomers of HspB2/B3. 
The major charge state series was attributed to a tetramer of mass 77.75 kDa (inset), consistent with a 
tetramer containing three HspB2 subunits and one HspB3 subunit. The minor charge state series around 
m/z 6000 was assigned to an HspB2/B3 octamer, equivalent to the association of two tetramers. 
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The microenvironment of the tryptophans present in HspB2/B3 
The fluorescence from tryptophan contains valuable information about the local 
environment of the residues. By measuring the fluorescence emission maximum it can 
be determined if the tryptophans are completely covered (~330 nm) or exposed at the 
polar surface (~350 nm) [31]. Both HspB2 and HspB3 harbor one Trp in the α-crystallin 
domain at position 130 and 95, respectively. HspB2/B3 showed maximal fluorescence 
at 341nm (Fig. 3A). Denaturation of HspB2/B3 by guanidine-HCL, forcing full solvent 
exposure of the tryptophans, only shifted the emission maximum towards a longer 
wavelength by 4 nm (Fig. 3A, inset). These results show that the tryptophans in 
HspB2/B3 are in a polar environment and are likely exposed to the solvent. It is thus 
plausible to assume that the tryptophans are localized at the surface of the HspB2/B3 
complex. To analyze this we performed a fluorescence quenching experiment. We 
used iodine ions as a quencher, which due to the relatively big hydrate shell do not 
penetrate into the protein interior and therefore cannot quench the tryptophan residues 
located in the interior of the protein. The reciprocal of the relative reduction of the 
fluorescence intensity (I0/µL) was plotted versus 1/[KI] (Fig. 3B). From the intercept of 
the straight line ([KI] = ∞) it was calculated that only 35 ± 6% of the fluorescence 
intensity can be quenched. These data show that some of the tryptophans are not 
accessible at the exterior of the complex.  
 
 
Figure 3. The tryptophans of HspB2/B3 are in a polar environment, but not well accessible by 
the fluorescence quencher iodine. (A) The intrinsic tryptophan fluorescence spectrum of HspB2/B3
(0.15 mg/mL) in 10 mM sodium phosphate buffer (pH 7.4) containing 100 mM NaCl was recorded by 
exciting the sample with 290 nm of light. (Inset) The maximum fluorescence spectrum shift of 
HspB2/B3 upon denaturation with GnHCl is 4 nm. All fluorescence spectra were recorded with 
excitation and emission band passes set at 5 and 3 nm, respectively. (B) Quenching of tryptophan 
fluorescence of HspB2/B3 with iodine ions. The initial fluorescence intensity (I0) divided by the 
fluorescence intensity change (µL) was plotted as a function of the reciprocal of the KI concentration. 
The proportion of the fluorescence that can be quenched was calculated from the intercept of the fitted 
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HspB3 inhibits the interaction of HspB2 with Hsp20 
The HspB2/B3 complex in muscle cell lysates has been suggested to act mainly 
as an independent sHsp system as it does not associate with Hsp20, Hsp27 and αB-
crystallin, although a weak interaction between Hsp20 and HspB2 was detected [16]. 
To analyze if the recombinant HspB2 and HspB2/B3 complex exhibit similar 
associating properties, a mixture containing equal amounts of purified Hsp20, Hsp27 
and αB-crystallin was allowed to exchange subunits with HspB2 or HspB2/B3. After 60 
min of incubation at room temperature HspB2 was immuno-precipitated with HspB2 
antiserum followed by a Western blot analysis to detect the interacting proteins (Fig. 
4A). As expected, HspB3 was efficiently co-precipitated with HspB2. Interestingly, 
Hsp20 could not co-precipitate with HspB2/B3, but was efficiently pulled down with the 
homomeric form of HspB2,suggesting that HspB3 blocks the Hsp20 binding site of 
HspB2. Furthermore, αB-crystallin and Hsp27 did not co-precipitate with HspB2, 
although Hsp20 was present (Fig. 4A). Since Hsp20 can interact with both αB-crystallin 
and Hsp27 [32], these results implicate that the binding of HspB2 to Hsp20 prevents 
the interaction with αB-crystallin and Hsp27. To confirm this we also performed the 
reciprocal pull down experiment using specific antibodies directed to Hsp20, Hsp27 
and αB-crystallin. The three recombinant sHsps were incubated with HspB2 or 
HspB2/B3 either individually (Fig. 3B lanes 2-4) or as a mixture (Fig. 4B lanes 5-6). 
Figure 4. HspB2, but not the HspB2/B3
complex interacts with Hsp20. (A) Purified 
HspB2/B3 (1 µg) and HspB2 (0.5 µg) were 
incubated alone (lane 3-4) or with a mixture of 
Hsp20, Hsp27 and αB-crystallin (each 5 µg) 
(lane 5-6) for 60 min at room temperature and 
subsequently immunoprecipitated (IP) using 
antibodies directed to HspB2. As negative 
control no proteins were added (lane 2). The 
precipitated proteins were analyzed by 
Western blotting using antibodies directed to 
the indicated proteins. Lane 1 shows 5% of 
the input of HspB2/B3 with Hsp20, Hsp27 and 
αB-crystallin. (B) Purified HspB2/B3 (1 µg) 
and HspB2 (0.5 µg) were incubated with 5 µg 
Hsp20 (upper panel), 5 µg Hsp27 (middle 
panel) or 5 µg αB-crystallin (lower panel) 
(lane 3-4) or with a mixture of the three 
proteins (each 5 µg) (lane 5-6) for 60 min at 
room temperature and subsequently 
immunoprecipitated (IP) using the indicated 
antibodies. As negative control HspB2/B3 
was incubated with buffer alone (lane 2). The 
precipitated proteins were analyzed by 
Western blotting with anti-HspB2 serum. Lane 
1 shows 5% of the HspB2/B3 input. 
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After immunoprecipitation the co-precipitated HspB2 was detected by Western blotting. 
Again Hsp20 showed a clear interaction with HspB2, but not with HspB2/B3. No 
qualitative or quantitative influence on the co-precipitating HspB2 were observed in the 
presence of Hsp27 or αB-crystallin, indicating that the interaction between Hsp20 and 
HspB2 is not affected by these two sHsps. Finally, smilar to the reciprocal experiment, 
in neither the presence nor the absence of Hsp20 could we detect interactions between 
the type-I Hsp27 and αB-crystallin and the type-II HspB2/B3 
or HspB2. These data suggest that only Hsp20 on its own can form a specific complex 
with HspB2, but not with HspB2/B3. 
 
HspB3 inhibits the moderate chaperone-like and thermoprotective activity of 
HspB2 
A general activity of sHsps is to prevent aggregation of unfolding proteins. To 
study this chaperone-like activity of HspB2 and HspB2/B3 we measured the ability of 
these two complexes to prevent aggregation of dithiothreitol denaturated insulin [29]. In 
line with previous reports, at a 1-to-1 mass ratio, recombinant αB-crystallin fully 
inhibited the DTT-induced 
aggregation of insulin (Fig. 5A). 
In similar ratio, HspB2 also 
partially (approximately 50 %) 
protected insulin from 
aggregation, indicating HspB2 
as a moderate chaperone. On 
Figure 5. HspB2 exhibits 
moderate chaperone-like and 
thermoprotective activity, which 
is negated by HspB3. (A). 
Chaperone activity of 250 µg 
HspB2/B3 (), HspB2 (S) or αB-
crystallin (¡) determined by 
measuring the ability to prevent 
DDT-induced precipitation of 250 
µg insulin at 40 °C. Insulin alone is 
indicated with closed circle (z). 
(B) Thermoprotective activity of 
HspB2/B3, HspB2 or αB-crystallin 
determined by measuring the 
growth of E. coli cells expressing 
HspB2/B3 (), HspB2 (S) or αB-
crystallin (¡) after a heat shock at 
48 °C for 60 minutes 
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the contrary, practically no prevention of the insulin aggregation was observed in the 
presence of HspB2/B3, clearly indicating that HspB2 has moderate chaperone-like 
activity, which is clearly inhibited by HspB3. 
To further investigate the effect of HspB3, we tested whether HspB2 and 
HspB2/B3 could confer thermotolerance to E. coli cells (Fig. 5B). After heat shock (60 
min at 48 °C at OD580= 0.6), cells were diluted and cell recovery was monitored for 5 
hours by measuring the cell density (OD580) at 30 minutes intervals. Already after three 
hours we observed an increase in cell growth of cells expressing αB-crystallin (positive 
control). However, cells expressing either HspB2 or HspB2/B3 showed no significant 
increase in cell growth recovery after 3 hours, indicating that HspB2 has no 
thermoprotective activity compared to αB-crystallin. 
 
HspB3 does not affect the thermostability or surface hydrophobicity, but 
changes the overall secondary structure of the HspB2/B3 complex 
To investigate why HspB2/B3 has no detectable chaperone-like activity and 
HspB2 only moderate, we analyzed several biochemical properties important for the 
chaperone-like activity. The thermostability of HspB2 and HspB2/B3 was assessed by 
gradual heating up to 70 °C. The absorption measured at 360 nm indicated the 
temperature-induced precipitation. As shown in Fig. 6A, solutions of both HspB2 and its 
complex with HspB3 remained clear even after heating up to 70 °C, similar to αB-
crystallin, indicating that both the homomeric and the heteromeric forms of HspB2 are 
resistant to heat-induced aggregation, whereas recombinant Hsp20 started to 
precipitate already around 50 °C.  
To determine whether HspB3 diminishes the chaperoning capacity of HspB2 by 
reducing its hydrophobic surface, we assessed the binding ability of the fluorescence 
probe bis-ANS to homomeric HsppB2 as well as to the HspB2/B3 complex (Fig. 6B). 
For both HspB2 and HspB2/B3 we recorded practically identical signal intensities with 
maxima at 484 nm, indicating that there is no difference in surface hydrophobicity 
between the two forms. However in comparison with αB-crystallin, HspB2 and the 
HspB2/B3 complex exhibited significantly lower capacity to bind bis-ANS. 
 
Next we analyzed the secondary structure of HspB2 and HspB2/B3 by far-UV 
circular dichroism (Fig. 6C). The spectrum recorded for recombinant αB-crystallin 
showed negative ellipticity with a minimum at approximately 211 – 215 nm, reflecting 
its high β-sheet content. A very similar spectrum but with a more negative amplitude 
was also observed for HspB2. Interestingly, the minimum negative ellipticity for the 
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HspB2/B3 complex was found at higher wavelength (218 nm), indicating that the 
complex contains relatively more α-helices. These observations show that HspB3 
affects the overall secondary structure of the HspB2/B3 complex. 
 
 
 
Discussion 
In this study, we investigated the HspB2/B3 small heat shock protein system. 
NanoESI-MS analysis of the HspB2/B3 complex revealed the presence of two kinds of 
heteromeric building blocks, tetramers with a mass of 77.8 kDa and octamers with a 
mass of 155.5 kDa (Figure 2). Because both heteromers have well defined masses, the 
HspB2/B3 complex is unlikely to be polydisperse, a feature often observed with 
additional sHsps [11]. The size of the octamer (155.5 kDa) is in good agreement with 
the complex size of HspB2/B3 association identified by SEC (Figure 1B), and is 
therefore the native form of the HspB2/B3 complex. Moreover, the HspB2/B3 complex 
isolated form muscle tissue extracts has the same size [16;17;33], indicating that the 
purified recombinant complex has the natural configuration. Based on the monomeric 
Figure 6. (A) The heat stability of 250 µg 
HspB2/B3 (), HspB2 (S), αB-crystallin (¡) 
or Hsp20 ({) determined by measuring the 
aggregation during gradually heating from 22 
to 70 °C. (B) The bis ANS binding ability of
HspB2/B3 (), HspB2 (S) or αB-crystallin 
(¡) (each 0.15 mg/mL) in the presence of 10 
mM bis-ANS determined by measuring the 
fluorescence spectra at the excitation 
wavelength set at 390 nm. (C) Far-UV circular 
dichroism spectra of HspB2/B3 (), HspB2 
(S) or αB-crystallin (¡) HspB2 and 
HspB2/B3. Protein concentration was 280 
µg/mL 10 mM potassium phosphate buffer pH 
7.8. 
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size of HspB2 (20.2 kDa) and HspB3 (17 kDa) it appears that the octamer comprises 
six HspB2 and two HspB3 monomers. The dissociation of the octamer into two 
tetramers with identical masses indicates that the octameric complex has a two-fold 
symmetry. Based on this symmetry and the fact that in the yeast two-hybrid system 
HspB3 not but HspB2 does show homophilic interaction [16], we postulate that the 
octameric complex consists of a dimer of HspB2 trimers facing each other with the two 
HspB3 subunits binding in the middle of the HspB2 trimers (Figure 7). The tryptophans 
of HspB2 and HspB3 are exposed to a relatively polar environment indicating that they 
are localized in a water-containing area. Some of the tryptophan residues are not 
accessible form the outside as determined by fluorescence quenching experiments 
(Figure 3B) which suggests a water-containing hole in the interior of the complex, a 
structural feature often observed for sHsps [34]. Up to now three crystal structures of 
sHsps have been solved. MjHsp16.5 consists of twenty-four monomers forming a 
hollow spherical complex [35], Hsp16.9 consists of twelve subunits forming two disks of 
each 6 subunits [34] and Tsp36 forms a tetrameric structure [36]. The quaternary 
structures of these sHsps are all very different from the octameric structure of the 
HspB2/B3 complex, which shows the great flexibility of the subunit assembly between 
the different sHsp family members. Unfortunately attempts to crystallize the HspB2/B3 
complex failed, which might be due to the difficulty in removing a contamination of 
homomeric HspB2 (Figure 1B).  
Unlike the HspB2/B3 complex, pure HspB2 elutes in a broad peak from both the 
Source-Q and the size exclusion column (Figure 1), suggesting that homomeric HspB2 
likely forms polydisperse associations. HspB2 binds relatively well to Hsp20 but not to 
αB-crystallin and Hsp27 (Figure 4). These findings are in good agreement with yeast 
two-hybrid studies, showing that only Hsp20 is able to interact with the HspB2 [16]. 
With the help of several different protein-protein interaction assays HspB2 has been 
shown to interact with HspB8 [33]. In rat skeletal muscle extract the concentration of 
HspB2 and HspB3 is 0.30 and 0.09 µg/mg of total protein, respectively [16]. Thus the 
ratio between these two proteins is almost 3:1, indicating that in muscle tissue most 
HspB2 is in complex with HspB3 [16]. The slight excess of HspB2 is likely bound by 
Hsp20 or HspB8 (Fig. 4 and [16;33]). 
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Compared to the good chaperone αB-crystallin, HspB2 exhibits moderate 
chaperone-like activity in the insulin assay, whereas the HspB2/B3 complex showed no 
prevention of DTT-induced insulin aggregation (Fig. 5A), suggesting that HspB3 
reduces the chaperone-like function of HspB2. Neither HspB2/B3 nor the HspB2 
complex could bind efficiently to bis-ANS (Fig. 6B), indicating that the surface of both 
macromolecular associations is not very hydrophobic. This very low surface 
hydrophobicity certainly contributes to the moderate or the absent of chaperone-like 
capacity of HspB2 and the HspB2/B3 complex, respectively. By CD analysis we 
showed that HspB2/B3 has different secondary structure content than HspB2 (Fig. 6C). 
HspB2/B3 has a relatively high α-helix content compared to the more β-sheet 
containing HspB2 (Fig. 6C). Thus, the binding of HspB3 induces an overall change in 
the secondary structure of HspB2, which is likely to relate to the inhibitory effect of 
HspB3. Furthermore, HspB3 lacks the flexing tail at the C-terminus [24], which is a 
crucial factor for the chaperone-like activity of sHsps [6]. The absence of the C-terminal 
tail is probably another additional factor 
responsible for the lack of chaperone- 
like activity of the HspB2/B3 complex. In 
line with this it was found that the 
expression of both HspB2 and HspB3 
are not induced by heat stress in C2C12 
myoblast cells [22]. The absence of 
chaperone-like activity and stress 
inducibility suggests that HspB2/B3 
might rather be a storage complex in 
muscle cells that needs to dissociate to 
become active. Suzuki et al. have shown 
that homomeric HspB2 interacts with 
myotonic dystrophy protein kinase 
(DMPK) and in this way can protect the 
activity of the kinase under normal and 
stress conditions [17]. In order to fulfill 
this chaperoning activity HspB3 likely 
dissociates from HspB2. Taken 
together, our results suggest that HspB3 
has a role in regulating the moderate 
Figure 7. Schematic model of the HspB2/B3 
complex. HspB2 and HspB3 form an octameric 
complex with a 2-fold symmetry in which the 
subunits have a 3 : 1 ratio. Only HspB2 has 
homophilic interactions. 
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and highly specific chaperoning capacity of HspB2 by forming a well-defined octameric 
complex with HspB2. 
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General Discussion 
 
Tissue transglutaminase (tTG) is a multifunctional participant in various cellular 
processes, ranging from intracellular signaling to apoptosis, which also include certain 
pathological conditions like the autoimmune celiac disease or the neurodegenerative 
inclusion body diseases [1-6]. The Ca2+-dependent transamidating core activity of tTG 
has attracted probably the greatest interest so far, since this protein crosslinking 
reaction enables the enzyme to partake in many different processes by generating 
protein-protein complexes held together by proteolysis-resistant covalent isodipeptide 
crosslinks between peptide bound glutamine and lysine residues [6]. Over the past 
years, extensive research has identified a variety of structural proteins as substrates for 
tTG, including many of the cytoskeletal [7-12] and extracellular matrix proteins [13-17], 
but also enzymes [14;18-20] as well as several hormones [21-24] have been found to 
be engaged in the crosslinking reaction (for details see Table 1 in Chapter 1). Proteins 
related to neurodegenerative diseases, like the amyloid-β precursor protein 
(Alzheimer’s disease) [25;26], hyperphosphorylated tau [27-29] (Alzheimer’s disease), 
parkin and α-synuclein (Parkinson’s disease) [30;31], and many of the polyQ-proteins 
(Huntington’s disease and many ataxias) [32;33], are also reported as particularly good 
substrates for the increasingly active tTG. A disrupted Ca2+-homeostasis has been 
implicated in several neurodegenerative disorders [34-37] and is thus likely to 
accompany the higher transglutaminase activity, which altogether could perhaps 
effectively contribute to the accumulation of perturbed proteins in the form of inclusions. 
Members of the chaperone network, including the Hsp70/Hsp40 system, but 
also the tTG substrate small heat shock proteins (sHsp) αB-crystallin and Hsp27, are 
frequently found to associate tightly with certain forms of the insoluble inclusion bodies 
such as the neurofibrillary tangles and amyloid plaques in AD brains [31;38;39], but not 
the polyQ-aggregates [40]. In addition, by binding to several (also tTG substrate) 
cytoskeletal proteins, sHsps such as αB-crystallin, Hsp27 and Hsp20 are also 
important regulatory elements of the cytoskeletal architecture. 
The research presented in this thesis was carried out to better understand the 
interactions of tissue transglutaminase and its substrates, in particular the mammalian 
sHsps, as well as the role of their delicate relation in the formation of protein 
aggregates and in turn their possible contribution to inclusion body diseases. 
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The sHsp family: a pool of tTG substrates 
Most of the ten members of the human sHsps are expressed throughout the 
body [41;42]. The expression of three sHsps, αA-crystallin (HspB4) and HspB9 
together with HspB10, shows high tissue specificity as their expression is restricted 
only to the lens and the testis [42-47], respectively. Others like HspB2, HspB3 and 
cvHsp (HspB7) are mainly expressed in various muscle tissues [48;49], whereas the 
previously characterized lysine-donor substrates Hsp27 (HspB1) [50] and αB-crystallin 
(HspB5) [51;52], together with Hsp20 (HspB6) and HspB8, are rather ubiquitous [47-
49;53]. The in vitro screening for additional substrates in the small heat shock protein 
family showed that at least five family members Hsp27, Hsp20, HspB8 (Chapters 2, 3 
and 4), cvHsp and HspB9 (unpublished observations) expose glutamine and lysine 
residues for tTG; HspB8 even has multiple sites accessible for crosslinking (Chapter 2). 
On the other hand, αB-crystallin and HspB2 expose only a sole crosslinkable lysine or 
glutamine residue, respectively (Chapter 2 and 3). Identifying the actual positions of the 
target residues in the primary sequence of sHsps revealed that the tTG-reactive lysine 
and glutamine sites are generally well conserved amongst the small heat shock 
proteins. The lysine in terminal position in the flexing C-terminal tail of several sHsps is 
available for tTG, whereas the most conserved part of the N-terminal domain contains 
the glutamine residue accessible for crosslinking (Chapter 4). The accessibility of this 
glutamine for tTG might relate to the quaternary structure and the chaperone function 
of sHsps since amongst those that tend to assemble into large multimers and exhibit 
good chaperone-like properties (α-crystallins and Hsp27), none can present this 
particular glutamine residue for tTG-catalyzed crosslinking (Chapter 4) whereas the 
poor chaperones Hsp20 and HspB2 do.  
The formation of large dynamic assemblies is a common characteristic of 
sHsps, both in vitro and in vivo. In human muscles, small heat shock proteins are 
organized into two heteromeric non-covalent complexes, one comprising Hsp27, αB-
crystallin and Hsp20, and the other HspB2 and HspB3 [49]. Apart from Hsp20, which 
can interact weakly with HspB2 (Chapter 8 and [49]), members of one complex do not 
associate with those from the other complex [49]. In these dynamic associations of 
sHsps, the lysine and glutamine residues that are available for tTG can be engaged in 
a variety of crosslinking reactions. In the presence of tTG, sHsps exposing both 
reactive residues and present within the same complex (Hsp20 and Hsp27) can form 
covalently linked homo-oligomers, but both sHsps can also readily crosslink into 
hetero-oligomers with αB-crystallin (Chapter 2). Between the other complex members, 
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covalent crosslink formation can only take place between HspB2 and Hsp20 (Chapter 
2).  
In additional disease simulating experimental conditions, where sHsps can also 
associate with aggregating proteins such as amyloid-β [54], sHsps clearly interfere with 
the amyloid polymerization process (Chapter 2), and crosslinked heteromers of sHsps 
and amyloid-β are also readily formed in the presence of tTG (Chapter 2). Despite the 
lack of unequivocal in situ evidence, these observations may still point out that non-
covalent, thus reversible protein associations such as the sHsp multimers and the 
chaperone–aggregating-protein complexes can facilitate their own crosslinking by tTG. 
Under pathologic conditions, these assemblies might also become prone to be fixed by 
the enzymatic spotwelding (crosslinking) activity of transglutaminase (Chapter 2). This 
assumption is in good agreement with the fibrin crosslinking by Factor-XIII-A, as during 
blood coagulation the haemostasis requires the production of a more stable structure 
than the self-assembly of the thrombin-fragmented fibrin into a clot network. The 
introduction of a few, strategically located crosslink bridges into the fibrin polymer 
greatly increases the rigidity and the proteolytic resistance of the clot [55;56]. 
Therefore, if protein complexes with important physiologic functions can become 
stabilized by such crosslinks, then the occurrence and importance of this crosslinking 
under pathologic circumstances can also be envisaged. 
Analyzing the substrate properties of Hsp20 by thorough peptide mass 
fingerprinting revealed that this particular small heat shock protein has the ability to 
present sites for transglutaminase for a unique intramolecular crosslinking (Chapter 4). 
Although Hsp20 has two glutamines (Q31 and Q66) and one lysine (K162) available for 
tTG, the isopeptide crosslink bridge within an Hsp20 molecule can only be formed 
between Q31 and K162 (Chapter 4). This internal, thus intramolecular crosslink formation 
occurs rarely among transglutaminase substrates, and therefore the present 
knowledge about the physiological and/or pathological importance of such crosslinking 
is very limited. However, the high efficiency of the intramolecular crosslinking of Hsp20 
in vitro, and also the presence of such intramolecular crosslinking in cells transfected 
with Hsp20, clearly underlines the biological significance of the internal crosslink 
formation. Such an intramolecular loop formation with a proteolysis-resistant covalent 
bond could likely change both the structural and functional properties of a protein. 
Though transglutaminase cannot form such intramolecular crosslinks in αB-crystallin, it 
is known from the literature that once crosslinked, αB-crystallin has a decreased 
chaperone-like capacity [57]. On the other hand, an increase in the activity of 
phospholipase-δA2 has been reported upon its intramolecular crosslinking by tTG [18]. 
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Required for both oligomerization and chaperone-substrate interaction, the C-terminal 
extension is one of the major structural elements of sHsps [58]. Once transglutaminase 
forms such an internal covalent loop between the C-terminal tail and the conserved N-
terminal domain motif of Hsp20, this new circular conformation and the reduced C-
terminal tail flexibility are expected to alter important structural and functional 
characteristics, such as the protein stability and the capacity to bind other proteins. 
Taken together, it is appealing to suggest that the family of small heat shock proteins, 
in particular Hsp20, could serve as an easily accessible pool of substrates for tissue 
transglutaminase. 
 
 
Hsp20 – A key player in the sHsp–tTG interaction 
Although most members of the small heat shock protein family can be generally 
engaged in tTG-catalyzed crosslinking reactions in cell free conditions, their behavior 
as a tTG substrate is markedly different in the cellular environment. In the cell, sHsps 
except Hsp20 are usually unavailable for crosslinking, unless they are associated with 
Hsp20 (Chapter 5). The association of Hsp20 with other sHsps, such as αB-crystallin 
and Hsp27, is a commonly accepted notion [49;59;60]. In fact, Hsp20 has never been 
found to be expressed without the presence of either or both of these two sHsps. The 
exposure of the easily accessible lysine and glutamine target residues in Hsp20 on one 
hand, and the readiness to form heteromeric associations with other stress proteins 
and presenting those to transglutaminase on the other hand, may already give ample 
indications that Hsp20 is in a key position in the enzyme-substrate relationship of 
sHsps and tTG. 
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+
Figure 1. Schematic overview of the cellular “defense” mechanisms against unwanted accumulation of 
unfolded protein aggregates.  
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But Hsp20 seems to possess another peculiar characteristic, namely a 
phosphorylation-dependent activating effect on tissue transglutaminase (Chapter 5). To 
adopt the catalytically active conformation for protein crosslinking, tTG requires only 
Ca2+ [2]. Therefore, a logical assumption would be that the presence of Hsp20 
(especially in its unphosphorylated form) somehow provides the enzyme with an 
adequate amount of free Ca2+ required for activation. The molecular mechanism by 
which the cell can utilize Hsp20 to increase the free cytoplasmic Ca2+ concentration is 
yet elusive. However, an effect of Hsp20 on the cellular Ca2+-homeostasis in different 
models of the cardiovascular system has also been seen in other studies [61-66]. 
Given the fact that Hsp20 has virtually no affinity for free Ca2+ (Boros et al, unpublished 
observations), the possibility of Hsp20 itself acting as a Ca2+-binding protein or an ion 
channel/pore is not very likely. The fact that Hsp20 does not co-precipitate with tTG 
(Boros et al, unpublished observations), also rules out the possibility that Hsp20 – 
through a specific or nonspecific binding to tTG – would desensitize the enzyme 
towards Ca2+-ions by covering the Ca2+-binding pockets of tTG. Yet, the binding of 
Hsp20 to Ca2+-channel, Ca2+-pump or cytoplasmic Ca2+-binding proteins, which could 
result in a modest change of the local Ca2+-homeostasis and the localized activation of 
tTG, may be considered. 
This hypothesis, however, needs supporting experimental data since it conflicts 
with the old dogma of transglutaminase activation, which suggests higher enzyme 
activity only during extreme situations, when the cellular Ca2+-homeostasis is usually 
overwhelmed [2;6;67]. The last decade of transglutaminase research has nevertheless 
presented tangible evidence that the amount of Ca2+ needed for its activation can vary 
in a wide range, from physiological [68;69] to supraphysiological/lethal concentrations 
[70]. Thus transient or localized activation of transglutaminase might be simply part of 
the proper cellular repertoire. These findings may also underpin the hypothesis about 
the Hsp20-related activation of transglutaminase. Since sHsps have been implicated in 
an astonishing array of cellular functions, such as the inhibition of apoptotic processes, 
conferring thermotolerance, organizing the cytoskeletal architecture, altering the 
functionality of the musculature, as well as the cardiovascular system [71-75], perhaps 
the (direct or indirect) participation in the regulation of Ca2+-homeostasis and/or the 
activating effect on transglutaminase could also be just another property of Hsp20 that 
is yet to be understood. 
 
Protein Deamidation By Tissue Transglutaminase 
The other intrinsic activity of tissue transglutaminase is catalyzing the 
deamidation of proteins by converting a given peptide-bound glutamine into a 
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glutamate residue [6;76;77]. In contrast to the great diversity of crosslinking susceptible 
substrates, only a meager repertoire of proteins, mainly the plant-originated gluten 
peptides (gliadin) and fragments of other gluten-like proteins, has been found to 
undergo tTG-catalyzed deamidation [78-84]. Having been characterized as potential 
targets of transglutaminase-catalyzed deamidation, two family members of the small 
heat shock proteins (HspB2 and Hsp20) and two of the β-crystallins (βB2- and βB3-
crystallin) (Chapters 4 and 6) expand the narrow array of proteins sensitive for 
deamidation. These sHsps and lens β-crystallins, however, both exhibited a profoundly 
different behavior from the other known deamidation substrates as their extensive 
deamidation by tissue transglutaminase was catalyzed together with their crosslinking 
in the abundant presence of lysine donor substrates. If tTG requires distinct 
glutamines, perhaps located in discrete motifs, for simultaneous deamidation and 
transamidation it may be possible that full-length proteins exposing the given 
glutamines in these motifs, readily undergo both types of modifications at the same 
time. This would also imply that in the absence of accessible lysine-donor substrates 
transglutaminase only catalyzes the deamidation of the conventional crosslinking-
sensitive glutamine residues in a slow and pH-dependent manner.  
The biological importance of tTG-catalyzed deamidation is not yet fully 
understood. Transglutaminase modified peptide fragments of gluten may be important 
in autoimmune processes of celiac disease as they are much stronger antigens than 
the unmodified ones [5;84]. The functional complexes of β-crystallins fall apart upon 
their deamidation and re-associate into larger size aggregates, which could be 
stabilized by the tTG-catalyzed crosslinks seen in the aggregates (Chapter 6). 
Alterations in the macromolecular assemblies of β-crystallins following their 
conformational changes upon aging also have been reported previously [85-87]. 
Moreover, the activity of transglutaminase has been reported to be higher than normal 
in certain cases of cataract [5;88;89]. Thus, regarding the lens, transglutaminase could 
also contribute to its age-dependent processes such as the formation of cataract. 
Though functional studies have not yet been carried out in case of Hsp20, one 
may speculate that its efficient deamidation by transglutaminase in vitro could also take 
place in the cell as well, and result in changes of the macromolecular organization of 
this sHsp. 
 
Models For The sHsp-tTG Interaction In The Cell 
The findings presented in this thesis provide tangible evidence to demonstrate 
the multilateral relationship between tissue transglutaminase and small heat shock 
proteins, as the enzyme can catalyze both the crosslinking and deamidation of small 
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heat shock proteins, while sHsps, Hsp20 in particular, can influence the activity of tTG. 
The fact that these proteins can actually be involved in a myriad of interactions rather 
than just the ordinary protein-crosslinking reaction, tentatively points toward their 
(patho)physiologic relevance. However, it also raises important issues, such as why 
sHsps would behave as tTG-substrates and why tTG or other TGases would need 
sHsps as substrates in such redundancy. 
Unfortunately, the currently available experimental data cannot yet answer 
these questions with certainty, nevertheless it may allow some speculations. The 
accumulation of unfolded proteins can be detrimental to cells as it may induce 
additional aggregation of still functional proteins and may eventually lead to cell death 
[90;91]. Under normal conditions, cells have two major toolsets to counteract the 
accumulation of unwanted proteins (Figure 1). One is the proteasomal degradation 
pathway and the other is the chaperone machinery. The proteasomal degradation 
pathway is a powerfool tool in the elimination of unrepairable and aggregating proteins 
[92;93]. Unwanted proteins first become tagged with ubiquitin moieties, which is the 
signal for targeted proteasomal degradation, and these labeled proteins are recruited to 
the proteasome [94;95]. 
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Figure2. Theoretical model of the sHsp function in aggregate formation. Upon protein unfolding (1), sHsps can bind 
the unfolded proteins and keep them in folding-competent state (2). At low rate of unfolding, sHsps can help additional 
members (large Hsps) of the chaperone machinery to refold the non-native proteins (route 1-2-3A-3B-4). When the 
chaperoning capacity may become exceeded (high unfolding rate), bound to the unfolded proteins, sHsps could play an 
important role in stabilizing the aggregates. Their accessible tTG-substrate lysine and glutamine residues could be 
utilized by tTG to introduce extra crosslinks (3C), providing greater stability for the aggregates. These isopeptide 
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(marked in purple) and between sHsps and their unfolded substrate proteins (represented in orange. In the absence of 
sHsps crosslinks can only be formed between the aggregating proteins (2). 
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The chaperone machinery is a repair mechanism for damaged and unfolding 
proteins. In this network, sHsps have been suggested to function as interfaces as they 
first bind to the non-native proteins, keep them in folding competent state and later 
present them to the large chaperones (Hsp40/70 complex) with refoldase activity [96-
98]. However, due to the limited capacity or the malfunction of these systems, not all 
unfolding proteins might be rescued from aggregation by the chaperones, nor can they 
be eliminated by the exceeded capacity of the proteasome. In such cases, stabilizing 
the inclusions by transglutaminase-catalyzed crosslinks could perhaps mean an 
additional solution for the stressed cell to neutralize the harmful presence of 
accumulating unfolding proteins, especially once they are bound to small heat shock 
proteins (Figure 2, route 1-2-3A-3C). In vitro data suggest that the conformation of the 
unfolding protein appears to determine with which region the sHsps bind to their 
substrates [96;99;100]. Moreover, the crosslinking sites of sHsps are located in 
structures important for the chaperone-substrate binding (Chapters 2, 4 and 
[50;51;101]). It could be speculated that one or more of the multiple crosslinking sites 
of sHsps could be utilized by transglutaminase to introduce extra crosslinks to further 
stabilize the aggregates (Figure 2, route 1, 2 and 4B). In addition, bound to sHsps, 
aggregates could obtain a structurally more organized state, which may also be in favor 
of crosslinking. sHsps therefore can be speculated to have a complex function as 
strategic bridges and spacers between the accumulating damaged proteins, which is of 
importance in the reinforcement of the inclusion stability by introducing strategically 
located crosslinks catalyzed by transglutaminase. 
Noteworthy is that recent findings point towards the significance of crosslinked 
sHsps in the pathology of the inclusion body disorders. In Alzheimer’s disease and 
sporadic inclusion body myositis, sHsps are frequently found to co-localize with the 
abnormal accumulations of amyloid deposits and neurofibrillary tangles 
[38;39;102;103], and can associate with Aβ and interfere with the polymerization 
process of Aβ (Chapter 2). The diseased tissues regularly exhibit several-fold higher 
transglutaminase activity and a concomitant strong increase in the isopeptide crosslink 
content, up to 30- to 50-fold [104;105]. But more importantly, Hsp27 crosslinked with 
ubiquitin moieties in neurofibrillary tangles has been indirectly detected recently [31]. In 
addition, stress conditions such as UV irradiation and oxidative stress, both known 
activators of sHsps [106-108] and contributing factors to the etiology of cortical cataract 
and AD, respectively [5], can disrupt the Ca2+-homeostasis [109;110] and therefore 
increase the activity of transglutaminase [111;112]. In fact, UV irradiation provokes the 
tTG-catalyzed crosslinking of αB-crystallin in vitro [112], which might suggest similar 
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underlying cellular mechanisms between the two stressful situations. Although clear-cut 
evidence that the interaction between sHsps and tissue transglutaminase contributes to 
the pathologic inclusion body formation is still lacking, the currently available indirect 
evidences might provide a rudimentary working hypothesis of this interaction and its 
implications in the aggregate formation.  
 
 In the different types of tissues, including muscle and brain, sHsps contribute to 
the proper cellular functioning by organizing the cytoskeletal architecture [72;113;114], 
modulating the muscular tonicity [113;115] and regulating the apoptotic processes 
[73;74]. Upon stress, when cellular injury and protein unfolding commonly occur, the 
unfolding proteins may trigger the dissociation of the multi-assemblies of sHsps. This 
may be the first line of defense against aggregate formation, as they function as a 
standby reservoir of chaperones for several non-native proteins binding easily to an 
oligomeric complex of sHsps [96;116;117]. After a partial dissociation, sHsps 
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possessing chaperone-like activity such as αB-crystallin and Hsp27 could bind to the 
proteins in need of repair, yet some may remain in complex with Hsp20 (Figure 3, step 
2 and 3B). Next, in cooperation with the large Hsps (Hsp40/Hsp70) proteins may be 
refolded (Figure 3, step 3A), and with the re-association of the sHsp assemblies at the 
end of the cycle the status quo is reset (Figure 3, route 1, 2 and 3).  
For example, the presence of αB-crystallin decreases the number of inclusions 
found after GFAP overexpression, and restores the normal filamentous organization 
[118]. However, a shifting equilibrium towards protein unfolding could lead to eventual 
aggregate formation, and it is also likely to require further chaperoning capacity. The 
triggered dissociation of αB-crystallin and Hsp27 could result in the domination of 
Hsp20 in the remaining complex, which then might subsequently promote a raise in the 
local Ca2+-concentration by a not yet known mechanism (Figure 3, step 4B). This most 
likely mild alteration in the Ca2+-homeostasis, perhaps together with additional stress 
related Ca2+-transients, could lead to the activation of transglutaminase. This way the 
aggregates – in at least some forms of neuromuscular disorders – could become 
(further) stabilized by crosslinking and sequestered into the non-aqueous phase 
(Figure 2 and Figure 3). At first, this stabilizing process may be protective, but a 
disrupting Ca2+-homeostasis resulting from prolonged stress could lead to irreversible 
activation of transglutaminase and subsequent uncontrolled crosslinking, which later 
may be detrimental to the cell.  
 
Concluding remarks and Future Directions 
It is not always easy to predict in which future direction research is heading. 
Nevertheless, the studies about sHsps and tTG presented here in this thesis allow one 
to venture some reasonable guesses. Tissue transglutaminase is a highly regulated 
Ca2+-dependent enzyme with the ability to deamidate proteins and to covalently 
crosslink them at certain lysine and glutamine residues. The above presented work 
brings evidence that the substrate site exposure of the small heat shock proteins is not 
restricted to the two previously described prominent members (αB-crystallin and 
Hsp27) [50-52], but is a rather general feature as more than half of human sHsps (αB-
crystallin, Hsp27, Hsp20, HspB2, HspB8, cvHsp and HspB9) have this property. Our 
data also give indications that these crosslinkings may occur under physiological and 
pathological conditions. However, direct evidence of the presence of tTG- modified 
sHsps in situ could not be obtained. Therefore a line of further research should be 
heading in this direction. Careful and thorough analysis of the presence of crosslinked 
sHsps in patient materials such as autopsy specimens from Alzheimer’s disease brains 
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and biopsy material form sporadic inclusion body myositis would greatly contribute to 
the understanding of what role sHsps and tTG play in such pathologic conditions. 
There are also indications that sHsps, notably Hsp20, can actually influence the 
activity of transglutaminase, depending on the phosphorylation state and the 
composition of their macromolecular assemblies. On its own, the discovery of the 
substrate and activator relationship between Hsp20 and tTG (Chapter 5) opens up a 
new avenue for future research. Hsp20 has been investigated mainly within the 
cardiovascular system, where Ca2+ homeostasis is the essence of proper function. In 
each tTG-related inclusion body disease the disturbance of Ca2+ homeostasis plays a 
central role in the uncontrolled activation of tTG; the issue how Hsp20 can actually 
raise the Ca2+ levels in the cell is thus of importance, and needs to be addressed. The 
fact that this effect of Hsp20 seems to be regulated by phosphorylation and interaction 
with additional sHsps is an important point even for further therapeutic considerations.  
The intramolecular crosslink formation is another interesting aspect of Hsp20, 
as similar modification of PLA2 causes a large increase in the enzyme activity [18]. 
However, the function of the crosslinks in Hsp20 is largely elusive. The possibility that 
these loop-like formations in Hsp20 could be utilized as an anchoring point for proteins 
interacting with Hsp20 is appealing, and could be considered for further studies. 
There is also compelling evidence that next to the crosslinking reaction, tTG 
can simultaneously catalyze the efficient deamidation of sHsps (Hsp20 and HspB2) as 
well as lens β-crystallins. These posttranslational modifications clearly disrupt the 
macromolecular organization of the lens proteome, suggesting that the enzyme may 
contribute to the age-related changes of the lens proteome, important in cataract 
formation. However, these are indirect evidences and the actual in situ confirmation of 
these modifications is yet to be obtained.  
Taken all together, instead of the conventional enzyme-substrate relationship, 
the presented data suggest multilateral interactions between tissue transglutaminase 
and small heat shock proteins, which might be one of the relevant factors in the 
pathologic formation of inclusion bodies. 
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Summary 
 
Cortical cataracts, Alzheimer’s disease, sporadic inclusion body myositis or 
Parkinson’s disease are all progressive disorders hallmarked by the formation of 
inclusion bodies and with an aging population they are major concerns in many 
Western countries (Chapter 1). The research devoted to the design of new therapies 
and more importantly, to the prevention of these diseases is therefore of great interest. 
The success of these approaches is essentially dependent on the good understanding 
of the basic molecular and cellular mechanisms that can be associated with the 
pathologic changes. In relation to each above mentioned disease, in the past years, 
extensive but mainly separate research had been conducted on the field of 
transglutaminases and small heat shock proteins. The principal goal of the work 
presented in this thesis was to investigate the enzyme-substrate interaction of tissue 
transglutaminase and small heat shock proteins and if there are, present clues that 
could point towards the possible contribution of these interactions to the pathology of 
progressive inclusion body diseases. 
There are ten small heat shock proteins (sHsps) expressed in human. In the 
initial steps, we investigated the tTG substrate capacity within the most prominent 
members of the sHsp family by using by using recombinant technology and 
biochemical tools. In these experiments, several sHsps (Hsp27, Hsp20, HspB8 
(Chapter 2) as well as cvHsp and HspB9 (unpublished data)) were found to expose 
both the lysine and glutamine residues for tTG. Although αB-crystallin was occasionally 
reported as a glutamine substrate for tTG, our results, however, are in agreement with 
those reporting αB-crystallin only as an exclusive lysine-donor for tTG (Chapter 2 and 
3). Single site exposure is also characteristic to HspB2 but in case of this sHsp, the 
available crosslinking site was found to be a glutamine residue (Chapter 2, 3 and 4). 
Given the fact that the crystal structure of the human small heat shock proteins 
is unknown, it is of importance to know the exact location of the TG-reactive sites as it 
may reflect to structural and also functional properties of sHsps. Combining the 
utilization of hexapeptides as tTG substrate probes and peptide mass fingerprinting 
(Chapter 3), the sites engaged in crosslinking reactions were identified as evolutionary 
well conserved residues in Hsp20, HspB2 and Hsp27. These sites are located in 
regions which have been suggested as crucial structural elements for protein stability, 
macromolecular associations as well as the chaperoning function of sHsps (Chapter 3 
and 4) and can be utilized by the enzyme to stabilize large protein assemblies (Chapter 
2). Another important finding of these studies was the identification of site specific 
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deamidation of glutamine residues in Hsp20 and HspB2 different from those engaged 
by the enzyme in crosslinking reaction (Chapter 3 and 4). The evidence of such 
efficient deamidation clearly indicates that the deamidating capacity of the enzyme is 
far greater than previously speculated.   
In vitro studies are crucial elements in the understanding of an enzyme-
substrate relation however, to speculate about the biological (physiologic/pathologic) 
importance of these exquisite posttranslational modifications, they must take place in 
the living cell as well. In cultured cells, sHsps, if present in large excess, can also serve 
as accessible substrates for the enzyme, but the crosslinking of sHsps, other than 
Hsp20, seems to be coordinated by their macromolecular associating property with 
Hsp20.  
This places Hsp20 into a key position amongst the mammalian sHsps (Chapter 
5). The importance of Hsp20 is further substantiated by its ability to act as a potent 
activator of tTG by likely enhancing the free Ca2+ concentration and by its unique ability 
to readily form intermolecular crosslinks in the presence of tTG. 
The biological assignment of the eye lens is focusing light on the retina. 
Plasticity, transparency and refractivity are properties essential for this process.  
Responsible for these are the lens crystallins, these proteins with high water-solubility 
and concentrations, but no protein turnover have to withstand the life long exposure to 
multiple environmental stresses. With aging however, crystallins loose their solubility 
and start to aggregate due to severe chemical and possibly enzymatic modifications, 
the transparency deteriorates and cataract develops. Crosslinking of lens crystallins 
have been previously speculated as one of the modifications that contributes to 
cataract. In Chapter 6 we propose that lens crystallins that are especially resistant to 
most age-related modifications can actually undergo enzymatic deamidation by tTG 
and this alteration may lead to the aggregation of other lens proteins.  
 Although HspB2 and HspB3 have been discovered a while ago only a limited 
knowledge is available about these proteins. In skeletal muscle, these two sHsps 
exclusively associate with each other in a defined ratio moreover, as described in 
Chapters 2, 3 and 4, HspB2 exposes glutamine-donor substrate sites for 
transglutaminase. In Chapter 7 we investigated the biochemical properties of the 
HspB2/B3 complex and suggest that HspB3 may regulate the moderate chaperone-like 
activity of HspB2. 
 The main goal of the above summarized experiments was to better 
understand the enzyme-substrate interaction of small heat shock proteins and tissue 
transglutaminase and to find clues pointing towards the contribution of these 
interactions to the pathology inclusion body diseases. In Chapter 8, the findings of this 
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thesis are briefly discussed and a tentative model of the pathological involvement of 
these interactions between sHsps and tTG is introduced.  
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Samenvatting 
 
De ziekte van Alzheimer, de ziekte van Parkinson en sporadische inclusie body 
myositis zijn allemaal progressieve afwijkingen met een karakteristieke eiwit aggregatie 
in de cel. Als gevolg van een ouder wordende populatie zijn deze ziekten in vele 
westerse landen een belangrijke reden tot bezorgheid (Hoofdstuk 1). Er is daarom veel 
interesse voor de ontwikkeling van nieuwe therapieen en de voorkoming van deze 
ziektes. Het succes van deze aanpak is voornamelijk afhankelijk van een goed begrip 
van de onderliggende cellulaire- en moleculaire mechanismen die geassocieerd 
kunnen worden met pathologische veranderingen. 
In de afgelopen jaren is er uitgebreid onderzoek gedaan naar de boven 
genoemde ziekten en transglutaminases (tTG) of kleine hitte schok eiwitten (sHsps) 
afzonderlijk. De primaire doelen van het werk beschreven in dit proefschrift zijn: ten 
eerste een enzym-substraat verband te leggen tussen tTG en sHsps en ten tweede 
aantonen dat deze interacties bijdragen aan de pathologie van bovengenoemde 
ziekten. 
In de mens zijn er tien verschillende sHsps. In de eerste stappen van dit 
onderzoek is er met behulp van recombinante eiwit expressie en biochemische 
technieken gekeken of deze sHsps een substraat kunnen zijn voor tTG. Hieruit is 
gebleken dat Hsp27, Hsp20, HspB8 (hoofdstuk 2), cvHsp en HspB9 (ongepubliceerde 
data) zowel lysine als glutamine residuen exposeren die een substraat kunnen zijn 
voor tTG. Hoewel alfaB crystalline soms gerapporteerd wordt als een glutamine 
substraat voor tTG zijn onze resultaten in overeenstemming met andere gepubliceerde 
artikelen die alfaB alleen omschrijven als  lysine donor voor tTG (Hoofdstuk 2 en 3). 
Ook HspB2 heeft slechts 1 substraat voor tTG, maar in dit geval is het substraat een 
glutamine residu (Hoofdstuk 2, 3 en 4). 
Omdat de kristal structuur van de humane sHsps niet bekend is, is het van 
belang om de exacte locatie van de TG-reactieve plaatsen te weten. Dit zou bij kunnen 
dragen aan structurele en functionele eigenschappen van sHsps. Met behulp van 
Hexapeptides als substraat voor tTG en peptide massa vingerprint zijn er in Hsp20, 
HspB2 en Hsp27 evolutionair gezien goed geconserveerde plaatsen gevonden die 
betrokken zijn bij crosslinking (Hoofdstuk 3). Deze geconserveerde sites zijn 
gelocaliseerd in regio’s die worden gezien als cruciaal voor de stabiliteit, voor 
macromoleculaire associaties en voor de chaperone functie van sHsps (Hoofdstuk 3 en 
4) en kunnen  worden gebruikt door tTG om grote eiwit complexen te stabiliseren 
(Hoofdstuk 2). Tevens is er met behulp van deze studies gevonden dat er plaats-
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specifieke deamidatie van glutamine residuen plaats vindt in Hsp20 en HspB2. Deze 
glutamine residuen verschillen van de residuen die betrokken zijn bij de cross-linken 
door tTG (Hoofdstuk 3 en 4). De efficientie van deze deamidatie wijst erop dat de 
deamidatie capaciteit van tTG veel groter is dan eerder is aangenomen . 
In vitro studies zijn cruciaal voor het begrip van een enzym-substraat relatie, 
maar om te kunnen speculeren over het biologische (physiologische/pathologische) 
belang van deze posttranslationele modificaties moeten deze ook plaatsvinden in de 
levende cell. In gekweekte cellen kunnen sHsps, wanneer zij in grote hoeveelheden 
aanwezig zijn, ook functioneren als substraat voor tTG. Crosslinking van sHsps 
(behalve Hsp20) lijkt echter gecoordineerd te worden door middel van associatie met 
Hsp20. 
Dit geeft Hsp20 een sleutel rol in de zoogdier sHsps (Hoofdstuk 5). Het belang 
van Hsp20 wordt tevens onderstreept door dat het kan functioneren als een potente 
activator van tTG. Waarschijnlijk activeert het tTG door middel van het verhogen van 
de vrije Ca2+ concentratie in de cel en door de unieke eigenschap van Hsp20 dat het 
in aanwezigheid van tTG makkelijk intermoleculaire crosslinks vormt. 
De ooglens moet het licht op de retina focussen, daarom is het van belang dat 
de lens transparant, plastisch en refractief is, hiervoor zijn de lens crystallines 
verantwoordelijk. Deze crystallines zijn eiwitten die goed in water oplosbaar zijn en in 
hoge mate tot expressie komen. Omdat deze eiwitten niet worden afgebroken 
gedurende het leven, moeten zij een levenslange blootstelling aan verschillende 
stressen uit de omgeving doorstaan. Met het ouder worden, verliezen crystallines hun 
oplosbaarheid en gaan door chemische en waarschijnlijk ook door enzymatische 
modificaties samen klonteren. Hierdoor wordt de lens minder transparant en ontstaat er 
staar. In eerdere studies werd er gesuggereerd dat het crosslinken van crystallines een 
van de modificaties is die bijdraagt aan de vorming van staar. In hoofdstuk 6 wordt de 
mogelijkheid beschreven dat lens crystallines, die zeer resistent zijn tegen de meeste 
ouderdoms-gerelateerde modificaties, enzymatische deamidatie kunnen ondergaan 
door tTG. Deze deamidatie zou dan kunnen zorgen voor de aggregatie van andere 
lens eiwitten. 
Hoewel HspB2 en HspB3 een tijd geleden al ontdekt zijn, is er nog maar weinig 
bekend over deze eiwitten. In skelet spieren gaan deze twee sHsps een exclusieve 
associatie met elkaar aan in een goed gedefinieerde verhouding. Bovendien heeft 
HspB2 glutamine substraat sites voor transglutaminase (Hoofdstuk 2, 3 en 4). In 
hoofdstuk 7 is er onderzoek gedaan aan de biochemische eigenschappen van het 
HspB2/HspB3 complex. Hieruit is gebleken dat HspB3 de chaperone-achtige activiteit 
van HspB2 zou kunnen reguleren. 
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Het belangrijkste doel van de bovengenoemde experimenten was om een beter 
inzicht te krijgen in de enzym-substraat interactie van sHsps en tTG en om 
aanwijzingen te vinden die duiden op een bijdrage van deze interacties in de 
pathologie van de eiwit aggregatie ziekten. In Hoofdstuk 8 tenslotte worden de 
resultaten die beschreven zijn in dit proefschrift kort bediscussieerd en er wordt een 
model geintroduceerd van de pathologische effecten van deze interacties tussen 
sHsps en tTG.  
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Osszefoglalas 
 
A szurkehalyog, az Alzheimer- vagy a Parkinson kor, de az inkluzios testes 
izomgyulladas is azon idoskori progressziv betegsegek koze tartozik melyek maig meg 
nem oldott problemat jelentenek Europa folyamatosan oregedo tarsadalmai szamara 
(Elso fejezet). Eppen ezert az uj terapias lehetosegeket de meginkabb a betegsegek 
megelozeset celzo kutatasokra a tudomany egyre fokozodo hangsulyt fektet. Az erre 
iranyulo kiserletek sikerenek egyik meghatarozo alapfeltetele a pathologias 
elvaltozasok hattereben allo alapveto sejtes es molekularis mechanizmusok pontos, 
reszletekig kiterjedo ismerete. Az elmult evekben valemennyi fennt emlitett progressziv 
elvaltozas kapcsan szeleskoru, de egymastol fuggetlen kutatasokat vegeztek a szoveti 
transzglutaminazt (tissue transglutaminase, roviden tTG) es a kis hosokk feherjeket 
(small heat shock protein (roviden sHsp)) illetoen. E doktori dolgozat elsodleges 
celkituzese volt, hogy tanulmanyozza a tTG enzim es a sHsp feherjek kozotti enzim-
szubsztrat kolcsonhatast, valamint ennek meglete eseten, bizonyitekokat mutasson be 
a ket feherje kozti kolcsonhatas progressziv inkluzios testes (denaturalt feherjeket 
felhalmozo) betegsegek kialakulasaban betoltott szerepere. 
Az emberi szervezetben tíz különbözo kis hosokk feherje fordul elo. Elso 
lepeskent biokemiai modszereket es rekombinans gentechnologiat alkalmazva 
megvizsgaltuk valamennyi jelentosebb sHsp feherje transzglutaminaz-szubszratkent 
valo viselkedeset. Megallapitottuk, hogy szamos sHsp, tobbek kozott a Hsp27, Hsp20, 
HspB8 (Masodik fejezet), eppugy mint a cvHsp es a HspB9 (nem kozolt adatok) 
rendelkeznek a transzglutaminaz enzmim szamara hozzaferheto lizin es glutamin 
aminosav oldallancokkal. Annak ellenere, hogy egyes irodalmi adatok az αB-crystallin 
kis hosokk feherjet a tTG enzim glutamin-szubsztratjakent jellemzik, a jelen munka 
kiserleti eredemenyei, – egyetertesben szamos, masok altal is kozolt megfigyelessel –, 
az αB-crystallint csak lizin-donor szubsztratkent azonositjak (Masodik es harmadik 
fejezet). Megallapitottuk, hogy hasonloan az αB-crystallinhoz, a HspB2, – a sHsp 
feherje-csalad egy masik tagja –, szinten egyetlen az enzim szamara hozzaferheto 
oldallancot hordoz, ami azonban nem lizin hanem glutamin tipusu szubsztratja a 
szoveti transzglutaminaznak (Masodik, harmadik es negyedik fejezet). 
Az emberi (emlos) kis hosokk feherjek kristalyszerkezete ismeretenek 
hianyaban, a transzglutaminazzal reagalo glutamin es lizin oldallancok helyenek 
pontos ismerete a polipeptidelancban fontos es uj informaciokkal szolgalhat a sHsp 
feherjek szerkezeti es mukodesi sajatossagiarol. A tTG enzimmel reakcioba lepo 
szubsztrat oldallancok helyzetenek azonositasara kidolgoztunk egy a specialisan 
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megjelolt glutamin- vagy lizin-szubsztrakent viselkedo hexapeptideken es a peptid 
tomegspektroszkopian alapulo modszert (Harmadik fejezet). Megallapitottuk, hogy az 
enzim altal katalizalt keresztkotesekben a Hsp20, a HspB2 as a Hsp27 feherjeknek 
specialis, a torzsfejlodes soran konzervalodott lizin illteve glutamin oldallancai vesznek 
reszt (Harmadik es negyedik fejezet). Ezek az aminosav oldallancok a feherjelanc 
olyan regioiban talalhatoak amelyek kulcsfontossaguak a kis hosokk feherjek 
szerkezeti stabilitasa, makromolekularis szervezodedese es a gardedam (feherje vedo) 
funkcioja szempontjabol (Harmadik es negyedik fejezet). Ezen tulmenoen, a szoveti 
transzglutaminaz kepes stabilizalni a nagy meretu koros feherje aggregatumokat 
(inkluzios testeket) azaltal, hogy kovalens keresztkotest letesit a sHsp feherjek 
oldallancai es a veluk kozvetlen kolcsonhatasban levo, – adott esetben –, 
nemkivanatos feherjek glutamin es lizin oldalcsoportjai kozott (Masodik fejezet). A 
tomegspektroszkopos kiserletek masik lenyeges eredmenyekent elsokent mutattuk ki a 
kizarolagosan az enzim altal katalizalt deamidaciora (a glutamin glutaminsavva torteno 
atalakitasa) erzekeny glutamin oldallancok jelenletet a Hsp20 es a HspB2 kis hosokk 
feherjekben (Harmadik es negyedik fejezet). Ezek a megfigyeleseink egyertelmuen 
bizonyitjak, hogy a tTG enzim lenyegesen hatekonyabban kepes a glutamin 
glutaminsavva torteno atalakitasara mint ahogy az a korabbiakban javasoltak. 
Az in vitro kemcso-kiserletek nelkulozhetetlen elemei barmilyen enzim-
szubsztrat kapcsolat megismeresenek, azonban biologiai (elettani vagy adott esetben 
a korelettani) jelentoseget ezeknek a kulonleges poszttranszlacios modositasoknak 
(ertsd a tTG altali modositasoknak) csak akkor jelenthetjuk ki, ha ezek az elo sejtben is 
elofordulnak. Tenyesztett sejtekben a nagy mennyisegben jelen levo ki hosokk feherjek 
szinten szubsztratjai a tTG enzimnek (Otodik fejezet). Kiserleti adataink arra engednek 
kovetkeztetni, hogy a Hsp20-tol eltero, egyeb kis hosokk feherjek transzglutaminaz 
altali keresztkoteset nagymertekben befolyasolja az ezen sHsp-k Hsp20-szal valo 
asszociacios kepessege (Otodik fejezet). Sejtes kiserletinkben megfigyeltuk, hogy a 
Hsp20 kepes a szoveti transzglutaminaz aktivalasara, feltehetoen a sejt szabad 
kalciumion koncentraciojanak megnovelesevel (Otodik fejezet). A fenti tulajdonsagok 
alapjan megallapithato, hogy a Hsp20-nak kulcsfontossagu szerepe van az emberi 
(emlos) kis hosokk feherjek kozott.  
A szemlencse legfontosabb szerepe, hogy a kulvilagbol raeso fenyt a retinara 
fokuszalja. A feladat ellatasahoz a szemlencsenek nagyfoku rugalmassaggal es 
fenyatereresztessel (transzparencia) valamint fenytoro kepesseggel (refraktivitas) kell 
rendelkezie. A fenti tulajdonsagokert a szemlencse krisztallin feherjei a felelosek. Ezek 
a lencseben magas koncentracioban elofordulo es nagymertekben vizoldekony 
feherjek az elet soran nem tudnak ujra termelodni, es eppen ezert a kulonfele 
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behatasokkal es kornyezeti valtozasokkal (pl.: UV sugarzas) szemben kevesbe 
erzekenyek. Mindezek ellenere az oregedes soran a lencsefeherjek veszitenek 
vizoldekonysagukbol, a kulonbozo kemiai es enzimatikus (poszttranszlacios) 
modosulasok kovetkezteben fokozatosan denaturalodnak / aggregalodnak amelynek 
vegeredemenyekent a szemlencse fenyatareszto kepessege lecsokken es kialakul a 
szurkehalyog. A szurkehalyog kilalkulasanak egyik molekularis mechanizmusa a 
lencsefeherjek tTG enzim altal katalizalt kereszkotese. A hatodik fejezet kiserletei 
bizonyitekokat szolgaltatnak arra nezve, hogy az oregedesi folyamatok soran fellepo 
legtobb modifikacioval szemben kulonosen ellenallo lencsefeherjeket a szoveti 
transzglutaminaz enzim nagymertekben kepes deamidalni ami a lencsefeherjek 
aggregalodasahoz vezet. 
Bar a HspB2 es HspB3 feherjek felfedezese nem uj keletu, megis igen keves 
ismert e ket kis hosokk feherjerol. A vazizmokban ez a ket sHsp egy specialis jol 
definalt komplexet alkot es ahogy azt tobb fejezet is emliti (masodik, harmadik es 
negyedik fejezet) a HspB2 feherje glutamin-donor szubsztratja a tTG enzimnek. A 
hetedik fejezetben megvizsgaltuk a HspB2/B3 komplex biokemiai tulajdonsagait es 
eredemenyeink szerint a HspB3 feherjenek a HspB2 mukodeset szabalyozo szerepe 
van a HspB2/B3 komplexben. 
A fentiekben osszefoglalt kiserletek elsodleges celja volt az enzim-szubsztrat 
kolcsonhatas tanulmanyozasa a szoveti transzglutaminaz es a kis hosokk feherjek 
kozott, valamint olyan bizonyitekok bemutatasa amely utalhat e kolcsonhatas 
progressziv inkluzios testes (denaturalt feherjeket felhalmozo) betegsegek 
kialakulasaban betoltott szerepere. A dolgozat nyolcadik fejezete roviden osszefoglalja 
es ertelmezi a bemutatott eredmenyeket, valamint modellezi a kis hosokk feherjek es a 
szoveti transzglutaminaz kozti kolcsonhatas korfolyamatokban betoltott lehetseges 
szerepet. 
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